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ABSTRACT 
Current thinking suggests that preeclampsia is associated with activation of the 
maternal vascular endothelium in response to factors released from the placenta due to 
placental hypoxia. Failure of physiological modification of spiral arteries due to 
impaired trophoblast invasion results in a several-fold increase in the risk of 
developing pre-eclampsia and/or (IUGR). The defect behind impaired trophoblast 
invasion is not fully explained and the aetiological factor(s) linked with the 
development of pre-eclampsia, compared to normotensive IUGR, is not known. In 
this thesis, I examined placental and serum levels of fms-like tyrosine kinase I (sFltl) 
and placental growth factor (PIGF), as mediators of angiogenesis, and Fas and FasL, 
as mediators of apoptosis, in three groups; preeclampsia, normotensive IUGR and 
controls who had abnormal mid-trimester uterine artery Doppler. 
Uterine artery Doppler flows were examined in 553 women at 24 weeks. 97 of them 
had abnormal uterine artery Doppler flow and were enrolled in this study. 86 women 
were followed up; among them eight women developed preeclampsia and seven 
developed normotensive IUGR. Umbilical artery Doppler examination 24 hours 
before delivery in both groups, showed significantly lowered resistance indices in the 
preeclampsia compared to the normotensive IUGR group. 
I examined placental and serum levels of fms-like tyrosine kinase I (FIt I) and 
Placental Growth Factor (PIGF) in three groups. Soluble FItI acts as an antagonist for 
both Vascular Endothelial Growth Factor (VEGF) and PIGF. Placental FIt 1 and serum 
sFlt 1 were higher and serum PIGF was lower in the preeclampsia group compared to 
the other two groups. This could be responsible for the systemic manifestations of 
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preeclampsia. This dysregulation in serum sFltl and PIGF was found as early as 24 
weeks in pregnancies with abnormal uterine artery Doppler examination. The 
normotensive IUGR group had significantly elevated serum sFlU compared to 
controls. This could be due to an element of placental hypoxia in the IUGR group. 
To investigate the in-vivo effect of sFltl on impaired placental angiogenesis and 
trophoblast invasion, I examined the correlations between uterine artery Doppler 
resistance indices and serum sFIU and PIGF at 24 weeks. Significant correlations 
were found between these markers and uterine artery Doppler pulsatility index (pn 
and resistance index (Rn on both the placental and non-placental sides at 24 weeks. 
Fas and Fas ligand (FasL) are membrane proteins that mediate cellular apoptosis, and 
recently were related to cellular growth and migration. Using western blotting and 
immunohistochemistry, placental expression of Fas (western blotting) and (FasL) 
(immunohistochemistry) was assessed in the three study groups. No differences in 
placental Fas or Fas ligand were found between the groups. In addition, serum levels 
of Fas and FasL were measured at 24 weeks and within 24 hours of delivery in the 
same groups. Serum Fas was not different between the three study groups at 24 weeks 
and within 24 hours of delivery. Serum FasL was below the kit's detection threshold 
in the samples studied. 
In conclusion, placental FlU and its soluble form sFltl seem to play an important role 
in the pathophysiology of preeclampsia. In addition, sFltl correlated positively with 
the severity of impaired trophoblast invasion and could playa central role in blocking 
placental angiogenesis in these pregnancies. This needs further evaluation. Fas and 
3 
FasL do not seem to have a role In impaired placentation and development of 
preeclampsia and IUGR. 
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INTRODUCTION 
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1.1 Definition of Preeclampsia 
Preeclampsia is a serious disorder of human pregnancy, which because of a lack of 
complete understanding of aetiology and pathophysiology, is defined by the 
presenting symptoms and signs. In this thesis, the definition of preeclampsia made by 
other authors has been taken to imply significant hypertension and proteinurea, 
although different thresholds have been used in many of the studies cited. Patients 
recruited into the present study have preeclampsia as defined according to the 
guidelines of the International Society for the Study of Hypertension in Pregnancy 
(ISSHP). This defines preeclampsia as hypertension of at least 140/90 (diastolic blood 
pressure recorded at Korotkoff 5) on two separate occasions at least four hours apart 
and in the presence of at least 300mg protein in a twenty-four hour collection of urine, 
arising de novo after the 20th week of gestation in a previously normotensive woman 
and resolving completely by the 6th post partum week (Davey et aI., 1988). 
1.2 Incidence of Preeclampsia 
Preeclampsia complicates 2-5% of pregnancies in the United Kingdom. It is a leading 
cause of maternal mortality and is responsible for considerable perinatal mortality and 
morbidity (HMSO). Furthermore, preeclampsia carries health care implications in 
adult life. Infants born of pregnancies complicated by preeclampsia are at an increased 
risk of hypertension, heart disease and diabetes (Barker, 1992). Therapy of 
preeclampsia is now, as it has been for the last 100 years, delivery of the fetus and 
placenta. Consequently, part of the increased perinatal mortality is due to iatrogenic 
prematurity. It is estimated that 15% of pre-term births are secondary to delivery for 
preeclampsia (Meis et al., 1995). An appropriate therapeutic strategy based upon the 
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underlying cause of the disease is clearly required to reduce the impact of this 
condition. However, the precise aetiology of preeclampsia is poorly defined. 
1.3 Aetiology of Preeclampsia 
The precise aetiology of preeclampsia, which has been tenned the 'disease of 
theories' (Zwiefel, 1916), has eluded physicians since the time of Hippocrates. At the 
turn of the last century, the presence of a circulating toxin of fetal origin was 
postulated as the cause of eclampsia, and hence the disease became known as 
'toxaemia of pregnancy'. More than a century later, the toxaemic theory remains the 
favoured hypothesis although the focus is now on the placenta rather than the fetus. It 
is now widely accepted that preeclampsia is associated with abnormal placental 
implantation, which is believed to result in relative placental ischaemia. Furthermore, 
as yet unidentified maternal or fetal genes may confer susceptibility. The syndrome of 
preeclampsia, which normally presents in the third trimester, possibly results from an 
immunologically based maternal response to the faulty placental implantation 
occurring earlier in pregnancy. This response, which can involve almost every major 
system of the body, reflects the involvement of the maternal vascular endothelium, 
now widely regarded as the target cell of the disease process. These observations have 
led to the development of an aetiological model of preeclampsia (see Figure 1.1). 
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Figure 1.1 The proposed pathogenesis of preeclampsia. 
GENETIC PREDISPOSITION 
ABNORMAL MATERNAL 
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SMALL HYPOPERFUSED PLACENTA 
RELEASE OF 
CIRCULATING FACTORS 
ENDOTHELIAL DYSFUNCTION 
20 
1.3.1 The Genetics of Preeclampsia 
A familial factor has been recognised in the pathogenesis of preeclampsia for many 
years. Epidemiological studies have demonstrated a 3-4-fold increase in the incidence 
of preeclampsia in first-degree relatives of affected women (Chesley et aI., 1986; 
Arngrimsson et aI., 1990). Family genetic studies have previously been reported to 
support models of maternal inheritance due to a recessive gene with a population 
frequency of 0.16 to 0.31 (Chesley et aI., 1986; Amgrimsson et aI., 1990), or a 
dominant gene with a population frequency of 0.14 and 48% penetrance 
(Arngrimsson et ai., 1990). However, data on the incidence of preeclampsia in 
identical twin sisters, although limited, indicates that discordance is more common 
than concordance, implicating factors other than the maternal genotype (Thornton et 
aI., 1999). 
One possible factor is the contribution of the fetal genotype. Epidemiological data 
have been reported, consistent with fetal recessive inheritance (Cooper et aI., 1979) 
or, maternal-fetal sharing of a recessive gene (Liston et ai., 1991). Genetic studies of 
preeclampsia are beset by difficulties. Extended pedigrees are relatively uncommon. 
In part this is due to the fact that males cannot be tested for susceptibility and that 
females can only be tested if they become pregnant. Furthermore, preeclampsia is 
predominantly a disease of first pregnancy and therefore the interaction between 
maternal and fetal genotypes can only be tested once. Finally, the definition and 
diagnosis of preeclampsia, in even the recent past, has been variable and imprecise. 
Hence, retrospective analysis of hospital records, when they are available, is often 
frustrating and unreliable. There are presently several studies in progress that are 
attempting to address the complex issues surrounding genetic studies in preeclampsia. 
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One such study, the Genetics of Preeclampsia Collaborative Study (GOPEC) is a 
multi-centre UK project. The aim is to utilise transmission disequilibrium testing 
(TDT) , in order to examine distortions in the transmission of marker alleles from 
heterozygous (informative) parents to affected individuals. In the first instance, the 
GOPEC study will investigate various candidate genes, which have been implicated 
by previous studies. 
The genetic inheritance of preeclampsia is undoubtedly complex. However it is highly 
likely that the advent of complete disclosure of the human genome and rapidly 
evolving genotyping technology will make genome wide screening by TDT a realistic 
possibility within the next few years. 
1.3.2 Immunological Aspects 
The underlying reason for the failure of trophoblast invasion In preeclampsia is 
unknown. It has been suggested that abnormal placentation reflects an abnormal 
maternal immunological response to fetal antigens derived from the father. The 
increased prevalence of preeclampsia in mUltiple pregnancies, molar pregnancies and 
those associated with increased placental mass suggests that fetal antigen load and 
trophoblast volume have a pathological role in this disorder (Taylor, 1997). 
There is extensive epidemiological evidence to implicate immunological factors in the 
aetiology of preeclampsia. These data suggest that prior exposure to paternal antigen 
is protective against preeclampsia (Taylor, 1997). Preeclampsia is largely a disease of 
the first pregnancies (Misra et al., 1997). It is proposed that the normal fetal maternal 
transfusion that occurs during pregnancy and particularly during delivery exposes the 
mother to products of fetal (and hence paternal) genome, protecting her in subsequent 
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pregnancIes. In keeping with this concept, the protective effect of first pregnancy is 
partially lost if a women has a child with a new father (Trupin et al., 1996). 
Li and Wi (2000) conducted a cohort study based on 140,147 women with two 
consecutive births during 1989-1991 identified through linking of annual California 
birth certificate data. Among women without preeclampsia in the fust birth, changing 
partners resulted in a 30% increase in the risk of preeclampsia in the subsequent 
pregnancy compared with those who did not change partners. However, among 
women with preeclampsia in the first birth, changing partners resulted in a 30% 
reduction in the risk of preeclampsia in the subsequent pregnancy. These findings 
demonstrate that preeclampsia is a disease of primipaternity rather than primigravidity 
and are consistent with the hypothesis that normal pregnancy reflects a state of 
tolerance to the foreign paternally derived antigens of the fetus, whereas in women 
with preeclampsia this immunological tolerance is impaired. 
In line with this hypothesis, several studies have demonstrated that the incidence of 
preeclampsia may be related to the duration of prior exposure to paternal antigens in 
sperm. During a protracted sexual relationship women develop an immune response 
against paternal antigens expressed on spermatozoa or in seminal fluid (Robillard et 
al., 1996), which is possibly impaired in women using barrier methods of 
contraception (Klonoff-Cohen et al., 1989), and enhanced by oral exposure (Koelman 
et al., 2000). As would be predicted, women inseminated with sperm that are not 
from their husband have an increased risk of preeclampsia (Smith et al., 1997). 
Furthermore, women conceiving with donated embryos have an even greater risk of 
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developing preeclampsia presumably because the entire fetal genome is allogenic in 
these pregnancies (Salha et aI., 1999). 
1.3.3 The Role of the Placenta 
The pivotal role of the placenta In the pathogenesis of preeclampsia has been 
established by several clinical observations. Firstly, It has long been recognised that 
removal of the placenta leads to resolution of the disease and indeed this remains the 
mainstay of current clinical management. Secondly, preeclampsia can occur in the 
absence of a fetus. Indeed hydatiform moles are associated with an increased 
incidence of preeclampsia (Scott et aI., 1976). Finally, the incidence of preeclampsia 
is increased in pregnancies associated with hyperplacentosis such as multiple 
pregnancy and diabetes (Szulman et aI., 1982; Coonrod et aI., 1995; Sibai et ai., 
2000). 
Thirty years ago, morphological examination of placental bed biopsies from women 
with preeclampsia demonstrated shallow invasion of trophoblasts and failure of 
vascular remodelling (Brosens et at., 1972). Applications of contemporary 
bioscientific approaches have provided detailed insight into deficient mechanisms in 
this process. 
Within the placenta in early gestation, trophoblasts differentiate and give rise to sub-
populations of cell. One subpopulation, the extravillous trophoblast, invades the 
uterine wall (interstitial invasion) and its blood vessels (endovascular invasion). 
During normal pregnancy, the trophoblasts destined to be endovascular, adopt a more 
endothelial cell-like phenotype and invade the uterine spiral arteries progressing back 
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as far as the myometrial segments. Immuohistochemical studies of placental bed 
biopsies suggest that trophoblast cells and endothelial cells transiently coexist on 
walls of partially modified spiral arteries (Pijnenborg et ai., 1983; Zhou et ai., 1997b). 
Trophoblast cells migrate along the luminal surfaces of vessels, invading them and 
partially replacing the endothelial cells and most of the musculoelastic tissue in the 
vessel walls (Pijnenborg et ai., 1980; Enders et ai., 1991; Blankenship et ai., 1993; 
Meekins et ai., 1997). The vessels are subsequently restructured such that they have 
little smooth muscle and become larger in diameter. This creates a high flow, low 
resistance circulation that maximises maternal blood flow to the placental villi at the 
maternal-fetal interface. There is contrasting evidence as to whether trophoblasts 
themselves are important in arterial remodelling. Although it has been suggested that 
some changes in the decidual vessels occur independently, as part of the maternal 
response to pregnancy, there is also strong evidence that invasive interstitial 
trophoblasts prepare the decidual spiral arteries for endovascular trophoblast 
migration (Pijnenborg et ai., 1983; Blankenship et ai., 1997). The invasive trophoblast 
may play an important role in inducing further changes either by interactions or 
factors produced by the interstitial trophoblast or by direct cellular interactions of the 
endovascular trophoblast with the cells of the vessel that they subsequently replace. 
The pathogenesis of preeclampsia and intrauterine growth restriction is associated 
with trophoblasts failing to adopt an endothelial cell-like phenotype and endovascular 
invasion failing to proceed beyond the superficial portions of the spiral arteries in 
early pregnancy (Lim et ai., 1997; Meekins et ai., 1994; Zhou et ai., 1997a). The 
cause of this impaired placentation is not fully understood but may in part be due to 
poor invasive properties of the trophoblastic cells or changes in the maternal decidual 
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tissues, which regulate trophoblast behaviour, perhaps mediated via multifunctional 
cytokine pathways. The cytotrophoblastic expression of adhesion molecules, which 
influence invasion, is altered in women with preeclampsia (Pijnenborg et al., 1996). 
In vitro studies have shown lower attachment of trophoblasts from pre-eclamptic 
placentas on fibronectin and vitronectin compared to normotensive controls, which 
may reflect differences in expression of matrix receptors (Pijnenborg et al., 1996). 
Maternal factors leading to inhibition of trophoblast invasion include reduced 
expression of the histocompatibility antigen HLA-G (Colbern et al., 1994), local 
inflammatory cell behaviour (Butterworth et al., 1991) and cytokine regulation of 
integrin expression (Vinatier et al., 1995). 
The end result of altered differentiation is inadequate trophoblast invasion. The 
incomplete remodelling of the maternal vasculature results in inadequate 
uteroplacental perfusion, particularly later in pregnancy. The subsequent 
hypoxia/ischaemia is presumed to trigger the release of a circulating factor(s) into the 
maternal circulation. 
1.3.4 The Link Between Reduced Placental Perfusion and Maternal Systemic 
Disease 
The link between deficient trophoblastic invasion early in pregnancy and the 
widespread endothelial dysfunction manifesting much later has eluded researchers for 
many years. The observation that terminating the pregnancy, and more specifically, 
that delivery of the placenta results in resolution of the disease suggest that the 
placenta is the focus of production of the putative factor(s) that influences the 
endothelial cell. This hypothesis, and the nature of the circulating factor(s), has been 
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investigated in a wide variety of both in vivo and ex vivo studies. One of the frrst 
studies to investigate the potential of circulating factors was reported over a decade 
ago and is widely credited with reviving the concept of toxaemia (Rodgers et ai., 
1988). This much cited study demonstrated that serum from women with 
preeclampsia was cytotoxic to cultured human umbilical vein endothelial cells 
(HUVECS) when compared with control sera from normal pregnant women. The 
cytotoxic effect of serum of preeclamptic women was reduced after 24 to 48 hours 
post partum. This rapid disappearance of cytotoxic activity suggested that the putative 
factor(s) had a short half-life and provided evidence that it was related to the products 
of conception. Interestingly, the cytotoxic effect persisted when a combination of 
antenatal sera from normal pregnant women and women with preeclampsia was 
utilised, providing further evidence of an active circulating factor as opposed to a 
relative deficiency of a protective factor. This landmark study has subsequently been 
extended by other investigators in a wide variety of cultured cell types. It now appears 
that the circulating factor(s) induce an alteration in endothelial function (Tsukimori et 
ai., 1992; Roberts et ai., 1992) rather than gross morphological injury and cell death 
as was initially suggested (Rodgers et aI., 1988). This contention is supported by the 
observation that when seeded in the presence of sera from women with preeclampsia, 
endothelial cells proliferate, attach and spread in a manner similar to those seeded in 
sera from normal pregnant women. Moreover, endothelial cells continue to grow well 
during incubation with serum from women with preeclampsia, and any metabolic 
changes can be reversed by replacing the serum from women with preeclampsia with 
standard culture medium (Lorentzen et ai., 1991). 
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Several investigators have used the technique of small vessel myography to study 
endothelial function in isolated vessels. Using an isometric technique, Ashworth et al. 
(1998) observed that incubation of vessels isolated from normal pregnant women with 
plasma from women with preeclampsia induced an alteration in endothelium-
dependent responses, such that the response to bradykinin was markedly impaired. 
Under these conditions vessels from normal pregnant women mimicked the behaviour 
of vessels isolated from women with preeclampsia (Ashworth et ai., 1998). Further 
investigation of this phenomenon has revealed that the effect was independent of the 
parity of the patient from whom the vessel was isolated, but was specific to vessels 
from pregnant women (Hayman et ai., 2001). 
In summary, there is an abundance of evidence to implicate the presence of a 
placentally derived circulating factor that targets the endothelial cell in preeclampsia 
and induces widespread alterations in function. Evidence suggests that there are a 
number of characteristics any putative factor must possess. These include the ability 
to pass freely into the maternal circulation and to produce functional alterations 
including an increase in cellular permeability and possibly cell turnover, an alteration 
in prostacyclin and nitric oxide production and subsequent functional change in the 
response to endothelium-dependent vasodilators. Although definitive identification of 
one single factor has not been made, a number of factors have been advanced as 
potential candidates for this role. 
1.3.4.1 Vascular Endothelial Growth Factor (VEGF) 
Vascular endothelial growth factor (VEGF) is a potent stimulator of angiogenesis (1, 
3), and promotes endothelial cell proliferation and migration (Clark et ai., 1998). 
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VEGF was shown to be essential for embryonic development in mice (Ferrarea et al., 
1996; Carmeliet et al., 1996) and its action cannot be compensated for by other 
closely related factors (Joukov et al., 1996; Olofsson et al., 1996; Counetal et al., 
1990). The receptors for VEGF-the fins-like tyrosine kinase, Flt-1 (Shibuya et al., 
1990), and the kinase domain receptor, KDR are present in endothelial cells present in 
many tissues (Peters et al., 1993; Millauer et al., 1993; Olander et al., 1991). Flt-l but 
not KDR, on the other hand is highly expressed by trophoblast cells (Charnock-Jones 
et al., 1994; Clark et al., 1996). 
Angiogenesis is a complex process necessitating the interaction of numerous cell 
types that leads to the coordinated development of a complex three-dimensional 
vascular structure. Many factors are involved in angiogeneis, and it is the balance of 
stimulators such as VEGF and inhibitors that determines the net result (O'Reilly et al., 
1994; Hanahan & Folkman, 1996). In the placenta, there is profound angiogeneis as 
high-capacity transport develops between the maternal and fetal circulation (Clark et 
al., 1996) (see above). In human placentation, while there is profound angiogenesis 
within the placental villi, there is little angiogenesis in maternal tissue. This suggests 
that there are locally acting factors that regulate vascular growth. 
VEGF has been implicated to act as an endothelial survival factor by promoting 
scaffold formation and cell attachment in microvascular endothelial cells (Ahmed et 
al., 2000; Watanabe & Dvorak, 1997). Withdrawal of VEGF from xenografted c6 
gliomas resulted in blood vessel regression and endothelial cell death (Benjamin & 
Keshet, 1997). As VEGF declines throughout gestation, these data suggest a possible 
mechanism for the regression of the capillary nets during stem villous formation (see 
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above) (Ahmed et aI., 2000). Five genes for VEGF have so far been identified and 
these are designated as VEGF-A (Leung et aI., 1989), -B (Paavonen et al., 1996), -C 
(Joukov et al., 1996), -D (Yamada et al., 1997) and the virally encoded -E (Lyttle et 
ai., 1994). There are three receptors for VEGF-A; VEGFR-1, VEGFR-2 and VEGFR-
3. VEGF-A is highly expressed in the placenta and previous studies showed strong 
expression of its antagonist, Fit -1, in both villous and extravillous trophoblast (EVT) 
cells (Charnock-Jones et aI., 1994; Clark et aI., 1996). Expression of VEGF-A in 
different placental cell types has been shown to increase under hypoxic conditions 
(Wheeler et al., 1995). 
In preeclampsia, there is circumstantial evidence that antagonism of VEGF may have 
a role in hypertension and proteinurea. VEGF is a well-known promoter of 
angiogenesis; it also induces nitric oxide and vasodilatory prostacyclins in endothelial 
cells, suggesting a role in decreasing vascular tone and blood pressure (Morbidelli et 
aI., 1996; He et aI., 1999). VEGF has been implicated in glomerular healing, and anti-
VEGF compounds have been found to increase apoptosis, impair glomerular capillary 
repair, and increase proteinurea in a rat model of mesangioproliferative nephritis 
(Ostendorf et aI., 1999). Furthermore, exogenous VEGF was found to accelerate renal 
recovery in rat models of glomerulonephritis and experimental thrombotic 
microangiopathy (Masuda et aI., 2001; Kim et aI., 2000). More recently, exogenous 
VEGF was shown to ameliorate post-cyclosporin-mediated hypertension, endothelial 
dysfunction, and nephropathy (Kang et aI., 2001). In recent antiangiogenic clinical 
trials, VEGF signalling inhibitors have resulted in hypertension and proteinurea 
(Maynard et aI., 2003). The study by Clark et al (1998) showed that the placenta 
secretes a soluble form of VEGF antagonist, namely sFIt-l, which naturally regulates 
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the potent angiogenic action of VEGF. sFlt-1 is believed to playa role in regulating 
placental and decidual angiogenesis. 
Collectively these data suggest that VEGF is important not only in blood vessel 
regulation but also in maintaining the glomerular filtration barrier. A recent study 
describing new knockout mice, reduction of VEGF production by podocytes alone led 
to massive proteinurea and glomerular endotheliosis (Eremina et aI., 2002). 
Additionally, VEGF-neutralising antibodies in clinical cancer trials have resulted in 
proteinurea (Yang et aI., 2000). These reports support the hypothesis that VEGF 
deficiency in the glomerulus may produce proteinurea. 
The role of VEGF in preeclampsia has received substantial attention. Several authors 
have reported increased systemic VEGF levels in women with preeclampsia (Baker et 
aI., 1995; Bosio et aI., 2001; Hunter et aI., 2000; Sharkey et aI., 1996). Other authors 
have reported reduced levels (Lyall et aI., 1997; Reuvekamp et aI., 1999; Livingston 
et aI., 2000). In reviewing the methodology of these studies carefully, all the studies 
reporting decreased levels used a commercially available ELISA kit (R&D Systems), 
which measures free (unbound) VEGF as previously shown by others (Hornig et aI., 
2000; Banks et aI., 1998; Anthony et aI., 1997). On the other hand, all studies 
reporting increased VEGF in preeclampsia used either radioimmunoassay or a non-
R&D ELISA system, measuring total (bound and unbound) VEGF (Baker et aI., 
1995; Bosio et aI., 2001; Hunter et al., 2000; Sharkey et aI., 1996). Under many 
circumstances, these two entities would be intererchangeable. However, in pregnancy, 
circulating sFlt 1 is present at very high levels (the mean sFlt 1 level in nonnal-tenn 
pregnancy was 0.5+/- 0.2 ng/ml), compared with the nonpregnant state, in which sFlt 1 
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levels are relatively low (the mean sFltl level in healthy female volunteers was 0.15 
+/- 0.04 nglml (Maynard et aI., 2003). Therefore, in normal pregnancy, and especially 
in preeclampsia where circulating levels of sFltl are extremely high, most VEGF is 
bound to circulating sFltl (Jelkmann et aI., 2001). Free VEGF levels, which more 
accurately reflect effective, circulating VEGF, will thus be substantially lower than 
total VEGF levels. Seen in this light, the previously confusing and contradictory 
literature on VEGF supports the hypothesis that preeclampsia is characterised by 
normal to high total VEGF levels.(perhaps induced by placental hypoxia) but low free 
VEGF and PIGF levels, owing to a great excess of sFltl. 
1.3.4.2 Placental Growth Factor (PIGF) 
Placental growth factor is a secreted dimeric glycoprotein that shares significant 
homology with VEGF, hence its role in angiogenesis. Like VEGF, PIGF is a potent 
angiogenic growth factor capable of inducing proliferation, migration, and activation 
of endothelial cells (Ziche et aI., 1997). Unlike the case of VEGF, abundant 
expression of PIGF is restricted to the placenta (Maglione et aI., 1991; Maglione et 
al., 1993), with the primary site of synthesis being the trophoblast (Khaliq et aI., 
1996; Vourela et aI., 1997; Shore et aI., 1997). Also in contrast VEGF, low oxygen 
tension results in downward regulation of PIGF expression in primary cultures of 
human trophoblasts (Shore et aI., 1997). 
The high basal expression of PIGF in trophoblasts and decreased expression during 
hypoxia in vitro suggest that PIGF may be altered in preeclampsia. Cross-sectional 
studies in normal pregnancy show that PIGF levels rise during the second trimester 
and peak at the early third trimester before falling to low levels by delivery. 
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Decreasing PIGF levels near term may be the result of acute hypoxia, because labour 
was associated with significantly reduced serum levels of PIGF. 
In healthy pregnant women, the serum levels of PIGF increased by approximately four 
times from the late first trimester to the late second trimester (Torry et aI., 1998). This 
increase may reflect growth of the placenta, which is concomitant with the need to 
recruit and maintain an adequate placental circulation. Low levels of PIGF during the 
first trimester may reflect the paucity of maternal blood flow into the intervillous 
spaces at this time (Jaffe et aI., 1997). Serum PIGF levels declined steadily from peak 
levels at approximately 28 to 30 weeks' gestation to term but remained slightly higher 
than levels found during the first trimester. 
PIGF mRNA expression has been found exclusively in villous trophoblasts, whereas 
protein localization was also noted in the fetal stem vessels, implying that trophoblast-
derived PIGF may act in a paracrine fashion to influence placental blood vessels 
(Vourela et aI., 1997). A study by Shore et al showed that hypoxia severely inhibited 
PIGF mRNA expression in normal trophoblasts (Shore et aI., 1997). Torry et al. 
(1998) showed that serum PIGF levels were significantly lower in preeclampsia 
compared with gestational-age matched controls, and that although PIGF levels 
decreased gradually with gestational age in healthy pregnancies, the levels in 
preeclampsia showed no significant changes with gestational age, as they were almost 
one fifth the normal range. Importantly, the low levels of PIGF noted in patients with 
preeclampsia were not due to a decrease in placental size, and most probably 
represent trophoblast response to hypoxia. There was significant drop of the level of 
PIGF at term, and during labour due to the hypoxic effect on the placenta by the 
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increasing myometrial tone in the third trimester and uterine contractions in labour. In 
cases of preeclampsia, however, there was no correlation between mode of delivery 
and the level of PIGF in the serum or cord blood, suggesting that low expression of 
PIGF in preeclampsia preclude additional perturbations in placental perfusion from 
having a significant effect (Torry et aI., 1998). 
1.3.4.3 Placental soluble fms-like tyrosine kinase 1 (sFltl) 
Placental soluble fms-like tyrosine kinase 1 (sFlt1), a splice variant of the VEGF 
receptor (Flt1) lacking the transmembrane and cytoplasm domains, acts as a potent 
VEGF and PIGF antagonist (Kendall et aI., 1996; Shibuya et ai., 2001). It is produced 
by a number of tissues, including the placenta (He et aI., 1999). Its physiologic role is 
unclear. Recently, both placental sFlt1 expression and sFltl levels in the amniotic 
fluid have been noted to be elevated in preeclampsia (Zhou et aI., 2002; Vuorela et 
aI., 2000). 
A recent study by Maynard et al. (2003) demonstrated excess serum sFltl levels in 
preeclampsia. In their study, excess sFltl production most likely originated in the 
placenta as its mRNA was upregulated in the placentas and the serum levels fell 
within 48 hours after delivery. They also demonstrated that administration of sFlt1 to 
pregnant rats induces hypertension, proteinurea and glomerular endotheliosis, the 
classic lesions of preeclampsia. The systemic effects of sFltl do not require the 
presence of pregnancy or the placenta, as hypertension and glomerular changes 
occurred in both non-pregnant and pregnant rats when infused with sFlt 1. This 
suggests a direct effect of sFlt 1 on the maternal endothelium. Their work suggested 
that sFlt1 acts through its antagonism of both VEGF and PIGF, since the sole VEGF 
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antagonist, sFlkI, did not produce the preeclampsia phenotype in pregnant rats. The 
preeclampsia phenotype that developed in rats was associated with decreased 
circulating levels of free VEGF and PIGF, resulting in endothelial dysfunction in vitro 
and was rescued by exogenous VEGF and PIGF. This suggests that, although the 
primary trigger for abnormal placental development and excess sFlti production in 
preeclampsia remains speculative, excess sFlti alone may be sufficient to produce 
generalised endothelial dysfunction and some of the clinical phenotype noted in 
preeclampsia. Interestingly, the pathologic effects of sFlti were dose dependent in the 
animal model; rats treated with low-dose sFltl, with plasma levels similar to those 
seen in preeclamptic women, generally showed milder renal pathology as compared 
with rats treated with higher dose of sFltl. A possible explanation is that sFltl may be 
one of several factors elaborated by the placenta that influence the severity of 
preeclampsia. It is also possible that the recombinant adenoviral-linked sFltl, which 
was used to induce preeclampsia in these animals, has a less potent in vivo activity 
than endogenous sFltl present in human serum. Alternatively more prolonged, 
sustained levels of sFlt I are required to produce severe disease. Furthermore, none of 
the treated animals in this study, developed thrombocytopenia, which is present in 
humans with the condition of haemolysis, elevated liver function tests, and low 
platelets (HELLP) syndrome, a variant of preeclampsia. In view of the above and 
because patients with mild preeclampsia had only slightly elevated sFltl levels, they 
concluded that sFlti may be causative in most but not all cases of preeclampsia in 
humans and that additional factors might be involved in HELLP syndrome. 
The above study, however, did not distinguish whether sFltl production by the 
placenta is a primary or secondary event. Hypoxia has been shown to increase sFlt 1 
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production by placental cytotrophoblasts (Hornig et at., 2000). If placental hypoxia is 
an early event in preeclampsia, sPltl release may occur as a secondary phenomenon. 
It has been proposed that placental angiogenesis is defective in preeclampsia, as 
evidenced by failure of the cytotrophoblasts to convert from an epithelial to an 
endothelial phenotype (referred to as pseudovasculogenesis) and invade maternal 
spiral arteries (Zhou et at., 1997). It seems plausible that angiogenic molecules such 
as VEGF, PIGF, and sFltl may be important regulators of early placental 
development and pseudovasculogenesis. In fact, it has recently been shown that 
exogenous sFltl inhibits placental cytotrophoblast invasion in vitro (Zhou et at., 
2002). Thus excess placental sFlt1, in addition to its direct effect on the maternal 
endothelium in the third trimester, may also play a more primary role in deranged 
placental development in preeclampsia. In the study by Maynard et at. (2003), the 
sFltl treated-rats did not develop the placental pathological changes typical of 
preeclampsia, such as infarcts and shallow spiral invasion. However, this may reflect 
the fact that sFltl protein was administered in the early second trimester, after spiral 
artery invasion had already been established. 
In vitro studies on the chorioallantoic membrane of the chicken have demonstrated 
that VEGF binding to both Flt-1 and KDR mediates branching angiogenesis, while 
PIGF binding to Flt-l alone results in non-branching angiogenesis (see above) 
(Wilting et at., 1996; Kurz et at., 1998). In the human placenta; VEGF, PIGF and the 
two receptors are differentially expressed throughout gestation: VEGF and KDR are 
most intense during early gestation and decline as pregnancy advances (Vuckovic et 
at.. 1996) while PIGF and Flt-l increase towards term (Clark et at., 1996). 
Correlations of these growth factors effects and their expression patterns throughout 
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gestation with the development of the villous angioarchitecture (Kaufmann et aI., 
1985) suggest that VEGF and KDR are involved in the first two trimesters of 
pregnancy in the establishment of the richly branched capillary beds of the 
mesenchymal and immature intermediate villi, while PIGF and Flt-l are more likely 
to be involved in the formation of the long, poorly branched, terminal capillary loops 
in the last trimester (Ahmed et ai., 2000). 
1.3.4.4 Neurokinin B 
Neurokinin B is a neuropeptide and one of three known mammalian tachykinins; the 
others being substance P and neurokinin A. The tachykinins are normally restricted to 
the nervous tissue and exert their effects peripherally by release from nerve endings 
and activation of the neurokinin receptors, NK1, NK2 and NK3. Neurokinin B 
preferentially binds to the NK3 receptor, activation of which has been demonstrated to 
induce hypertension by contraction of the rat portal vein and mesenteric vasculature 
(D'Orleans-Juste et aI., 1991) and increase canine heart rate (Thompson et aI., 1998). 
Neurokinin B was previously thought to be restricted to the brain. However, Page et 
al. (2000) have recently reported that the syncytiotrophoblast of the human placenta 
expresses neurokinin B mRNA. Moreover they found that plasma levels of the peptide 
were significantly elevated in women with preeclampsia, as compared with normal 
pregnant women. They speculated that, in response to placental ischaemia consequent 
upon defective trophoblastic invasion, placental production of neurokinin B increases, 
in order to increase blood pressure and correct the hypoperfusion of the feto-placental 
unit. The subsequent stimulation of the neurokinin B receptors is hypothesised to 
cause constriction of the mesenteric vascular bed and the portal veins, leading to an 
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increase in blood pressure, damage to the liver and kidneys and the symptoms of 
abdominal pain. Reduction in blood flow to the liver is speculated to lead to an 
accumulation of undetoxified metabolites, such as lipid peroxides, which may 
contribute to endothelial cell damage and dysfunction. The authors also suggest that in 
severe cases of preeclampsia, concentrations of neurokinin B may be sufficient to 
stimulate peripheral NK 1 receptors on platelets and neutrophils and hence contribute 
to the other symptoms of preeclampsia associated with activation of these cells. 
Finally, the authors suggest that increased secretion of neurokinin B may pre-date the 
development of clinical signs and symptoms of preeclampsia and therefore increased 
levels of neurokinin B in early pregnancy may identify pregnancies destined to 
develop preeclampsia. The neurokinin B hypothesis is attractive, particularly as there 
are several potent and commercially available selective antagonists for NK receptors, 
allowing for the implementation of a much-needed pharmacological intervention early 
in the disease process. However, the findings of this small study await confirmation. 
In particular, the localisation of NK receptors in the human vasculature and the effect 
of neurokinin B on human vascular tone await elucidation. Quantitative analysis of 
the placental production of neurokinin B in normal and compromised human 
pregnancy and circulating maternal plasma levels in all three trimesters of pregnancy 
await clarification in a longitudinal study. Undoubtedly this area will be the focus of 
intense research in the immediate future. 
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1.3.4.5 Syncytiotrophoblast microvillous membranes (STBM) 
STBM have been proposed to be the factor linking the defective placentation to the 
endothelial dysfunction (Smarason et ai., 1993). Morphological evaluation of 
placentas from women with preeclampsia shows abnormally shaped 
syncytiotrophoblast microvilli and areas of focal necrosis, associated with a reduced 
number of microvilli. These changes are similar to those seen in placental villi, 
cultured under hypoxic conditions. In vitro experiments have demonstrated that 
STBM can interfere with endothelial cell growth in cultured endothelial cells by 
suppressing proliferation and disrupting the cell monolayer (Smarason et ai., 1993). 
Furthermore, perfusion of isolated subcutaneous arteries with a high concentration of 
STBM abolishes acetylcholine-induced vasodilatation (Cockell et ai., 1997). 
STBM prepared from placentas of normal women and women with preeclampsia had 
similar effects on endothelial cells, indicating the effect of STBM in preeclampsia to 
be quantitative rather than qualitative (Smarason et ai., 1993). Knight et ai. (1998) 
studied the presence of STBM in pregnant women and reported the concentrations of 
STBM to be significantly increased in the maternal circulation of women with 
preeclampsia, with concentrations in the uterine vein exceeding that in peripheral 
venous circulation, indicating the placental origin of the STBM. The mechanism by 
which STBM exerts effects on endothelial cells is unclear. However recent evidence 
has emerged linking STBM with oxidative stress. It has been reported that incubation 
of cultured endothelial cells with STBM produced a substance that activates 
peripheral leukocytes and primes peripheral monocytes to give greater responses after 
activation (von Dadelszen et aI., 1999). 
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1.3.4.6 The role of oxidative stress 
More recently, evidence has emerged to support a role for oxidative stress in linking 
reduced placental perfusion with systemic maternal pathophysiology (Hubel, 1999). 
Oxidative stress is a pathological state, implicated in the aetiology of many disorders 
including atherosclerosis, in which pro-oxidants dominate over antioxidants. The 
resultant increase in the formation of reactive oxygen species can damage cell 
membranes, proteins and DNA. Epidemiological studies have revealed that many of 
the risk factors associated with the development of preeclampsia such as obesity, 
black race, lipid abnormalities, insulin resistance and raised serum homocysteine are 
also associated with the risk of developing atherosclerosis in later life. These 
observations have led to the emerging hypothesis that suggests reduced placental 
perfusion generates oxidative stress and leads to widespread endothelial dysfunction 
in preeclampsia. The hypothesis proposes that reduced placental perfusion results in 
the generation of reactive oxygen species (Hubel et al., 1997; Roberts et aI., 1999). 
Placental blood flow is known to be reduced by posture, activity and uterine 
contractions and to rapidly return to normal with the termination of these stimuli. In 
normal pregnancy it is suggested that adaptive mechanisms prevent this from resulting 
in hypoperfusion-reperfusion oxidative stress. Evidence for this concept is the 
presence of stable metabolites generated by oxidative stress in the placentas of women 
with preeclampsia (Wang et aI., 1992). Furthermore, enzyme activities and mRNA 
expression of the placental antioxidant enzymes superoxide dismutase and glutathione 
peroxidase have been found to be significantly decreased in placentae from women 
with pregnancies complicated by preeclampsia as compared to those from normal 
pregnant women (Wang et al., 1996). This is thought to lead to an abnormal increase 
in placental production of lipid peroxides in preeclampsia. In addition, markers of 
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lipid peroxidation, including malondialdehyde (Hubel et aI., 1996) and 8-
epiprostaglandin-F2a (Barden et ai., 1996) are increased in the plasma of women with 
preeclampsia. Furthermore, it has been reported that both the water-soluble 
antioxidant, ascorbic acid and the lipid-soluble antioxidants alpha-tocopherol and 
beta-carotene levels are decreased in the plasma of women with preeclampsia 
compared with normal pregnant women, suggesting that antioxidant nutrients may be 
utilized to a greater extent to counteract free radical-mediated cell disturbances, 
resulting in a reduction in antioxidant plasma levels in this disease (Mikhail et al., 
1994). The increase in lipid peroxide formation by the placenta in preeclampsia may 
account for many of the pathological changes seen in this disease. With half-lives 
extending up to minutes, lipid peroxides formed at a primary site may accumulate in 
lipoproteins and be transferred throughout the circulation. Elevated lipid peroxide 
levels in plasma inhibit the enzyme prostaglandin synthase, with a consequent fall in 
the production of prostacylin. However, platelet thromboxane A2 synthesis is 
unaffected by such compounds. This could potentially lead to an alteration in the ratio 
of prostacylin to thromboxane production, comparable to that observed in 
preeclampsia (Wang et aI., 1991). Lipid peroxides have also been noted to induce 
smooth muscle contractions in a variety of isolated arterial preparations. Furthermore, 
elevation of circulating levels of lipid peroxide products induced by deprivation of 
vitamin E in rats produced an increased pressor responsiveness to angiotensin IT and a 
decreased isolated mesenteric artery relaxation to acetylcholine (Hubel et aI., 1989). 
Recently, the results of a prospective randomised placebo controlled trial suggested 
that supplementation with vitamins C and E in women at increased risk of 
preeclampsia was associated with a significant decrease in plasma markers of vascular 
endothelial cell activation and placental insufficiency (Chappell et al., 1999). This 
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study also demonstrated a significant reduction in the occurrence of preeclampsia in 
the treated group. Confirmation of the clinical usefulness of this therapy by a larger 
trial is awaited, but the findings do support the involvement of oxidative stress in the 
genesis of endothelial dysfunction in preeclampsia. 
1.4 Endothelial dysfunction in preeclampsia 
The vascular endothelium is no longer thought to be simply an inert lining of the 
vasculature but is now recognised as a highly specialised, metabolically interactive 
interface between blood and the underlying tissues. Furchgott and Zawadzki (1980) 
first demonstrated the obligatory role of the endothelium in mediating acety1choline-
induced relaxation in isolated arterial strips or rings. In addition to modulating 
vascular tone, the endothelium is now known to play a role in maintaining 
thromboresistance, as well as participating in the inflammatory response. 
As our understanding of the role of the endothelium has evolved, a concept has 
formed that the endothelial cell is the target of the disease process in preeclampsia. 
This hypothesis is attractive as the ubiquitous nature and diverse functions of the 
vascular endothelium could account for the complex multisystem nature of the clinical 
manifestations of the disease process. 
The concept of endothelial cell involvement in preeclampsia is by no means novel. A 
textbook in use over 70 years ago stated that; 
"One of the few points to emerge clearly from the study of the pathology of eclampsia 
is that the toxin acts as an endothelial poison, particularly affecting the walls of 
capillary vessels" (Johnstone, 1939). 
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However the significance of this hypothesis was largely ignored for over sixty years, 
until a series of publications from Roberts and co-workers revived this concept 
(Roberts et aI., 1993; Roberts et aI., 1989; Rodgers et aI., 1988). With an increased 
awareness of the physiological significance of vascular endothelial cell function, the 
seemingly unrelated SIgns of hypertension, prtoeinurea, oedema, and 
hypercoagulability converged to provide clinical evidence of a unifying 
pathophysiological mechanism: systemic, maternal endothelial cell dysfunction. 
There is extensive evidence for endothelial involvement in preeclampsia. The best-
characterised morphological abnormality of this syndrome, once assumed to be 
pathognomonic of the condition, involves endothelial cells (Spargo et aI., 1959). This 
distinctive renal lesion, glomerular endotheliosis, is found in up to 80% of women 
with preeclampsia and consists of glomerular capillary cells engorged with 
intracellular inclusions. The absence of this lesion in any other form of hypertension 
and that fact that it disappears completely after delivery, suggest that it is unlikely to 
be secondary to hypertension or hypoperfusion. Campbell and Campbell (1983) 
described direct evidence of a loss of endothelial cell integrity with a resulting 
increase in vascular permeability when they found that an albumin-bound dye, Evan's 
blue, disappeared from the intravascular compartment of women with preeclampsia at 
an increased rate compared with normal pregnant women. 
There is a substantial body of supporting evidence from studies of circulating 
endothelial cell markers in preeclampsia. Levels of fibronectin, factor VIII antigen, 
von Willebrand factor, tissue plasminogen activator and plasminogen activator 
inhibitor-1 have been found to be elevated in the circulation of women with 
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preeclampsia (Roberts et ai., 1989; Friedman et ai., 1995). Although these substances 
are synthesised by several different cell types, the only common source of production 
is the vascular endothelium. Several studies have reported increased levels of 
circulating endothelin-l in preeclampsia (Taylor et ai., 1990; Mastrogiannis et al., 
1991) that may reflect an increased synthesis by activated endothelial cells 
(MacCumber et ai., 1989; Yoshimoto et ai., 1990). It is recognised that an intact 
endothelium is a vital component of the coagulation system (Roberts et ai., 1993). 
Widespread deposition of fibrin, associated with diffuse vascular damage suggesting 
activation of the coagulation system is a recognised pathological feature of 
preeclampsia. However, unless preeclampsia is complicated by disseminated 
intravascular coagulation, routine coagulation tests are normal. More sensitive 
indicators of coagulation abnormalities have been reported in a high proportion of 
women with preeclampsia including an altered ratio of factor VIII related antigen to 
coagulation activity (Redman et ai., 1977), a reduction in the platelet count (Redman 
et ai., 1978) and an increase in the levels of plasma ~-thromboglobulin (Ayhan et al., 
1990). Significantly, these changes antedate the onset of clinical manifestations of the 
disease by several weeks. 
One of the most striking and consistent pathophysiological abnormalities of women 
with preeclampsia is an increased sensitivity to pressor agents such as angiotensin II 
(Gant et ai., 1973; Gant et ai., 1987) and noradrenaline (Magness et ai., 1994). Gant 
et al. (1973) performed a longitudinal study throughout pregnancy and reported that 
whereas normal pregnancy was associated with a relative refractoriness to angiotensin 
II, women destined to develop preeclampsia exhibited increased sensitivity to infused 
angiotensin II from as early as 18 weeks. This finding has been confirmed by an in 
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vitro study by Aalkjaer et al. (1985) who used the technique of wire myography to 
investigate the functional characteristics of isolated omental resistance vessels from 
women with preeclampsia, normal pregnant women and non-pregnant women. The 
vessels from the women with preeclampsia had an increased responsiveness to 
angiotensin II compared with the vessels from the normotensive pregnant women 
whereas the angiotensin II responsiveness of the vessels from the women with 
preeclampsia and from the non-pregnant women were similar. However, no difference 
in responsiveness to norepinephrine was found between any of the groups. Pascoal et 
al. (1998) evaluated the responses of omental arteries from normal pregnant women 
and women with preeclampsia to either KCI or vasopressin. They reported that 
maximal contraction due to either agent was significantly augmented in vessels from 
women with preeclampsia. 
The suppressed response to pressor agents in normal pregnancy and the increased 
sensitivity observed in preeclampsia is yet to be fully elucidated. Data from animal 
studies supports a role for the sympathetic nervous system in modulating vascular 
tone in pregnancy. Parent et al. (1990) compared the sensitivity of pregnant and non-
pregnant rat mesenteric arteries to noradrenaline and phenylephrine. They reported a 
significant decrease in sensitivity to these pressor agents in vessels isolated from 
pregnant animals compared to those isolated from non-pregnant animals. They further 
demonstrated that removal of the endothelium had no significant influence on this 
alteration leading to the suggestion that the changes observed in pregnancy were 
neurologically mediated. Davidge et al. (1992) also examined rat mesenteric arteries 
from pregnant and non-pregnant animals and reported that arteries from pregnant 
animals were less sensitive to phenylephrine than arteries from non-pregnant animals. 
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Furthermore, cyclo-oxygenase inhibition had no effect on the vasoconstrictor 
response in arteries from either group. Inhibition of nitric oxide and endothelial cell 
removal had a similar twofold increase in phenylephrine sensitivity in arteries from 
both the pregnant and non-pregnant rats suggesting that the decreased sensitivity to 
phenylephrine during pregnancy was not modulated acutely by nitric oxide or by 
prostaglandin products of the cyclo-oxygenase pathway. 
Nelson et al. (1998) examined responses to electrical field stimulation (EFS) of 
perivascular nerves in human uterine arteries removed from pregnant and non-
pregnant patients undergoing hysterectomy. EFS induced-constrictions were 
significantly lower in uterine arteries from pregnant than from non-pregnant patients. 
When arterial rings were precontracted, the response to EFS was biphasic, consisting 
of an initial constriction followed by a postconstriction relaxation. The EFS-induced 
relaxation was endothelium independent and was greater in uterine arteries from 
pregnant than from non-pregnant patients. The relaxation was enhanced by 
guanethidine and superoxide dismutase, inhibited by nitric oxide synthase inhibitors, 
blocked by tetrodotoxin, and unaffected by atropine, propranolol, or indomethacin. 
The results demonstrated that human uterine arteries respond to EFS with contraction 
and relaxation and that these responses may be mediated, respectively, by 
norepinephrine and, in part, by nitric oxide released from periarterial nerves. 
McCarthy et al. (1994); Knock et al. (1996) and Ogoghoi et al. (1996) studied the 
effects of preeclampsia on endothelium-dependent relaxation of subcutaneous 
resistance arteries. McCarthy et al. used acetylcholine; Knock et al. used bradykinin 
and Oguogho et al. used acetylcholine and histamine to investigate endothelium-
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dependent responses in isometrically mounted arteries isolated from normal pregnant 
women and women with preeclampsia. In all of these studies an impairment of 
endothelium-dependent relaxation in arteries from women with preeclampsia was 
observed. No difference to relaxation to sodium nitroprusside was observed between 
the groups in any of the studies indicating that differences in vascular smooth muscle 
behavior did not underlie the difference in vasorelaxation. 
Pascoal et al. (1998) reported a similar impairment to acetylcholine in isometrically 
mounted omental arteries from women with preeclampsia when compared to vessels 
isolated from normal pregnant women. Ashworth et al. (1997) compared 
endothelium-dependent responses in isometrically mounted small myometrial arteries 
isolated from normal pregnant women and women with preeclampsia. They reported 
significantly impaired responses to bradykinin in vessels from women with 
preeclampsia as compared with responses in vessels from normal pregnant women. 
There are at least three endothelium-derived agents responsible for mediating 
endothelium-dependent relaxation in resistance arteries, nitric oxide, prostacyclin and 
endothelium-derived hyperpolarizing factor (EDHF). Among these, the one most 
extensively studied is nitric oxide. 
Nitric oxide in normal pregnancy and in preeclampsia 
Nitric oxide is synthesised from L-arginine in a reaction catalysed by the enzyme 
nitric oxide synthase (NOS). The production of nitric oxide requires molecular 
oxygen, and the presence of at least four cofactors, with the concomitant production 
of citrulline. NOS is present in at least three isoforms: of these the endothelial (eNOS) 
and neuronal (nNOS) isoforms are constitutive. These isoforms of NOS are activated 
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by an influx of calcium into cells. The third isoform, inducible NOS (iNOS) is 
different from the constitutive forms in that it is functionally independent of calcium. 
iNOS is expressed in a wide variety of cells, including macrophages, neutrophils and 
mast cells and is produced in response to immunological stimuli (Michel et aI., 1993). 
The role of nitric oxide in activated immune cells is to inflict lethal oxidative injury 
on pathogens. 
Mammalian adaptation to normal pregnancy involves profound alterations in the 
cardiovascular system, resulting in a decrease in total peripheral resistance. This is a 
reflection of widespread maternal vasodilatation. Data from animal studies suggests 
that this is in part mediated by increased biosynthesis of nitric oxide in pregnancy 
(Weiner et aI., 1994; Yang et aI., 1996). However, caution should be employed when 
extrapolating the results of animal studies to the human state, as it is recognised that 
there is intra- and inter-species variation in the contribution of nitric oxide to 
vasorelaxation. Indeed, the balance of evidence supporting a role for increased nitric 
oxide generation in human pregnancy is far less convincing. Many studies 
investigating nitric oxide generation in human pregnancy rely on the measurement of 
nitrite and nitrate, two stable end products of nitric oxide metabolism. Increased 
serum concentrations of nitrite in the plasma of normotensive pregnant women 
compared to non-pregnant women have been reported (Seligman et aI., 1994). In 
contrast however, other investigators have failed to observe any difference in plasma 
concentration or urinary excretion of nitrate or in exhaled nitric oxide in normal 
pregnancy (Cameron et al., 1993; Brown et aI., 1995; Morris et aI., 1995). There are 
similarly conflicting results regarding nitric oxide production in pregnancies 
complicated by preeclampsia with some studies reporting increased levels (Nobunaga 
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et aI., 1996; Smarason et aI., 1997; Lyall et aI., 1995), others finding decreased levels 
(Seligman et aI., 1994) and some reporting no difference (Cameron et aI., 1993). 
The conflicting results of these studies may be explained in part by differences in the 
methodology. However, studies of this nature are intrinsically difficult as it is 
recognised that dietary intake of nitrate is known to affect plasma levels and urinary 
excretion. The dietary intake of the patients in the studies cited was not controlled 
since measurements were often made in women presenting with severe preeclampsia. 
Furthermore, urinary excretion of any substance is dependent upon the glomerular 
filtration rate, which is commonly reduced in preeclampsia. Although some 
investigators attempt to control for this by analysing urinary nitrate/nitrate against 
creatinine clearance, this has been done on random spot collections instead of the 
more accurate 24-hour urine collection. To address these problems, large cohorts of 
women undergoing strict dietary control need to be studied with longitudinal analysis 
of 24-hour urine collections. Conrad et al. (1999) performed such a study and they 
demonstrated that plasma levels and urinary excretion of nitrate and nitrite does not 
increase in normal pregnancy, but that the urinary excretion of these metabolites is 
modestly reduced in preeclampsia. 
One final caveat that applies to all studies of nitric oxide biosynthesis is that it is 
possible that the local production of nitric oxide increases or decreases by small but 
biologically significant amounts and only in certain vascular beds. Such changes 
would therefore be obscured by analysis of whole body synthesis. 
There is now increasing evidence that nitric oxide synthesis may be regulated via the 
production of endogenous inhibitors of nitric oxide synthesis. Holden et aI., 1998 
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measured the circulating concentration of one of these inhibitors, asymmetric 
dimethyl arginine (ADMA), throughout normal pregnancy, in preeclampsia and in 
normal non-pregnant women. They reported that the early fall in blood pressure in 
normal pregnancy was accompanied by a significant fall in the plasma ADMA 
concentration and as pregnancy progresses the concentration increases again. 
Furthermore, when pregnancy was complicated by preeclampsia, concentrations of 
ADMA were found to be significantly higher than in the non-pregnant or normal 
pregnant state. The role of ADMA in nitric oxide regulation in both normal pregnancy 
and preeclampsia requires clarification. It is possible that enhanced production of 
ADMA may be of pathophysiological importance in preeclampsia and lead to 
decreased synthesis of nitric oxide. Alternatively, increased circulating concentrations 
of ADMA may represent a feedback response to enhanced nitric oxide production in 
preeclampsia. 
Normal pregnancy is associated with profound changes in the cardiovascular system. 
In particular, normal pregnancy is characterised by an attenuated response to 
vasoactive agonists, such as angiotensin II, the net effect being vasodilatation. The 
technique of myography has allowed the isolation and study of small resistance 
arteries from various maternal vascular beds. The study of these small calibre arteries 
is particularly pertinent as vessels of this size contribute most to precapillary 
resistance. Myography studies provide evidence that the vascular changes of normal 
pregnancy are not entirely mediated via nitric oxide. 
McCarthy et al. (1994) used a small vessel WIre myograph to examIne the 
endothelium-dependent relaxation of subcutaneous arteries in normal pregnant and 
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non-pregnant women. They found no significant difference in the degree of 
acetylcholine-mediated relaxation between vessels from the two groups. This would 
argue against a universal increase in receptor mediated nitric oxide production in the 
human myometrial vasculature in pregnancy. However, they also reported that the 
inhibition of both cyclooxygenase and NOS only modestly attenuated the relaxation to 
acetylcholine in vessels from normal pregnant and non-pregnant women, suggesting 
the presence of an additional vasoactive mediator such as endothelium derived 
hyperpolarizing factor (EDHF). 
Pascoal and Umans (1996) studied small arteries from the omentum of women with 
preeclampsia and normal pregnant women. They demonstrated that the vessels from 
normal pregnant women completely relaxed to acetylcholine and bradykinin in an 
endothelium-dependent but nitric oxide-independent manner, again suggesting the 
presence of EDHF. They also found that the vessels from women with preeclampsia 
exhibited impaired responses to acetylcholine compared with vessels from normal 
pregnant women. 
Ashworth et al. (1997) studied endothelium-dependent relaxation in the resistance 
arteries of the myometrial vascular bed. They also reported a marked reduction in 
endothelium-dependent relaxation in vessels from women with preeclampsia and a 
significant nitric oxide-independent component to bradykinin induced relaxation in 
the vessels of normal pregnant women. 
In summary, endothelium-dependent, nitric oxide independent vasorelaxation has 
been described by a number of groups in resistance arteries from a wide variety of 
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vascular beds in normal pregnancy, suggesting that the role of nitric oxide in normal 
pregnancy may be limited. Furthermore, impaired endothelium-dependent relaxation 
has been observed in vessels from women with preeclampsia. 
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1.5 Role of trophoblast apoptosis in preeclampsia 
1.5.1 Trophoblasts and immune tolerance 
Different mechanisms, either alone or in combination, play a role in conferring 
maternal immune tolerance against the semi-allogeinc fetal allograft. The 
proliferation, invasion, and differentiation of trophoblast cells during implantation is a 
tightly controlled process of intracellular signalling that is mediated by cytokines, 
growth factors, and hormones (Norwitz et aI., 2001; Wegmann & Guilbert, 1992; 
Mellor & Munn, 2000; McMaster et aI., 1994). An extensive array of cytokines is 
produced at the trophoblast-maternal interface that contributes to the well being of the 
fetoplacental unit. These cytokines help to regulate the maternal immune response and 
so maintain a successful pregnancy (Athnassakis et aI., 2000). Trophoblasts 
themselves possess certain properties that could promote tolerance. These include a 
lack of MHC antigen expression (Bulmer et aI., 1992), the presence of 
immunosuppressive substances such as transforming growth factor-B (Kauma et aI., 
1990), and the expression of CD59, an inhibitor of compliment cascade (Tedesco et 
aI., 1993). In addition, Fas and FasL interaction seem important in conferring immune 
privilege to the invading trophoblasts (see below). 
Normal pregnancy is characterised by a lack of maternal cell-mediated immune 
response against the implanting embryo. Instead, humoral immunity predominates 
during pregnancy (Wegmann & Guilbert, 1992; Wegmann et aI., 1993). This switch, 
from cytolytic to humoral immunity, is the result of maternal changes in the cytokine 
profile (Wegmann et aI., 1993). The balance between T helper (Th)-l, or 
proinflammatory cytokines and Th-2, or anti-inflammatory cytokines is thought to be 
crucial for determining the success or failure of pregnancy. It is currently believed 
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that production of pro inflammatory cytokines such as interleukin 2 (IL-2), tumour 
necrosis factor (TNF) , and interferon is suppressed in normal pregnancy, whereas 
production of Th-2 cytokines, such as IL-4, -6, and -10, is enhanced (Mellor & Munn, 
2000; Roth & Fisher, 1999). 
Placental and decidual tissues isolated from normal pregnancy, however, have been 
shown to produce both Th-1 and Th-2 cytokines (Tranchot-Diallo et aI., 1997; 
Bennett et aI., 1998). The type of cytokines thought to be potentially harmful to 
pregnancy in humans as well as in mice are those classified as pro-inflammatory 
cytokines. For example excess production of TNF and gamma interferon is involved 
in preterm delivery (Casey et aI., 1989; Casey et aI., 1990). Besides influencing the 
maternal immune response, many of these cytokines have been shown to affect 
trophoblast physiology, specifically the proliferation and apoptosis of trophoblast 
cells (Hunt, 1989; Yai et aI., 1994). 
1.5.2 Definition of apoptosis 
Apoptosis was first described as a morphologic pattern of cell death characterised by 
cell shrinkage, membrane blebbing, and chromatin condensation culminating in cell 
fragmentation. The terminal deoxynucleotidyl transferase deoxy-UTP-nick end 
labelling (TUNEL) method may identify apoptosis before the characteristic 
morphologic changes become apparent (Ishihara et aI., 2002). Although TUNEL 
labelling is correlated with apoptosis, it has been suggested that this method might 
also detect fragmented DNA in necrotic cells within a tissue. Therefore, study of 
cellular ultrastructural changes in apoptosis, combined with TUNEL labelling permit 
a reliable differentiation between apoptosis and cell necrosis (Gold et ai., 1994). 
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1.5.3 Death receptors 
Integral to many forms of apoptosis is a family of at least 14 different cyteine 
proteases called caspases. Caspases are synthesised as inactive precursors called 
procaspases. Cleavage and activation of procaspases can occur following a variety of 
stimuli including DNA damage and death receptor activation (Joza et ai., 2002; Herr 
& Debatin, 2001). Death receptors belong to a superfamily of receptors involved in 
proliferation, differentiation and apoptosis called the Tumour Necrosis Factor (TNF) 
superfamily (Krammer, 1999). Death receptors are type I integral receptors with a 
conserved extracellular domain containing two to four cytoseine rich pseudo-repeats, 
a single transmembrane region and a conserved intracellular death domain about 80 
amino acids in length that binds to adaptor proteins and initiates apoptosis (Golstein, 
1997; Griffith & Lynch, 1998; Schulze-Osthoff et ai., 1998; Idriss et ai., 2000). Each 
receptor can bind with one or more than one type of ligand expressed on adjacent 
cells. Binding of ligand to receptor induces receptor trimerisation and clustering on 
the plasma membrane is required to initiate apoptosis in cells. Among the different 
death receptors, Fas (CD95/Apo1) and Fas ligand (FasL) will be discussed here. 
Fas receptor 
Fas mediated apoptosis can be regulated by a variety of signalling pathways in cells 
and is required for normal cell function (6). One of the principal roles of Fas receptor 
is regulating the immune response and this is the most clearly characterised function 
of Fas receptor. However, Fas receptor is expressed on most tissues and also plays an 
important role in regulating the function of many tissues (Curtin & Cotter, 2003). 
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FasL Receptor 
In contrast to Fas receptor, expression of FasL (CD95L), a type II transmembrane 
molecule belonging to the tumour necrosis factor receptor superfamily, is limited to 
certain leukocytes and tissues with immune privilege (Griffith et al., 1995). Fas-FasL 
interactions leading to clonal deletion of antigen presenting cells have been implicated 
in the establishment of graft tolerance (Kabelitz, 1998), and provide one explanation 
for the immune privilege status of certain tissues, including the placenta, cornea and 
testis (Griffith et al., 1995). Fas-mediated apoptosis regulates other cells involved in 
adaptive and is a principal mechanism by which cytotoxic T lymphocytes (CTL) 
induce apoptosis in cells expressing foreign antigens (Medema et al., 1997). 
Progression and metastasis of tumours is associated with resistance to Fas-receptor 
mediated apoptosis (French & Tschopp, 2002). In addition, upregulation of Fas ligand 
often occurs in tumour cells following chemotherapy and may play a key role in 
immune evasion by eliminating infiltrating lymphocytes (Strand et al., 1996; Pinko ski 
& Green, 2000). 
Fas-FasL interaction 
Activation of Fas receptor by the Fas ligand initiates a caspase cascade culminating in 
apoptosis in sensitive cells. Effective formation of a protease complex called Death 
inducing signalling complex (DISC) is required in Fas-mediated apoptosis (Curtin & 
Cotter, 2003). Immediately following Fas receptor ligation with Fas ligand, 
microaggregates of Fas receptor form on the cell surface independent of caspase 
activity (Algeciras-Schimnich et al., 2002). Trimerisation of Fas receptor is the 
minimal event required for effective DISC formation (Schneider et al., 1998). 
Activation of caspase 8 occurs following DISC formation and directly regulates the 
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formation of large Fas receptor aggregates on the plasma membrane of cells and 
increased DISC activity. These large clusters of Fas receptor are endocytosed and 
recycled (Algeciras-Schimnich et al., 2002). Caspase 8 activation appears to be the 
principal initiator during apoptosis (Curtin & Cotter, 2003). 
Although Fas is viewed as the prototypical death receptor in susceptible cells, Fas 
may mediate apoptosis-independent processes such as proliferation, angiogenesis, 
fibrosis, and inflammation (Hohlbaum et al., 2002). The most striking example of 
apoptosis-independent Fas function is derived from transgenic mice and pancreatic 
islet cell transplantation studies in which beta cells were genetically engineered to 
express Fas ligand in an effort to confer immune privilege through apoptotic deletion 
of invading, Fas-expressing T-cells (Chervonsky et ai., 1997; Allison et al., 1997; 
Kang et ai., 1997). These studies surprisingly revealed extensive neutrophil 
infiltration and islet cell destruction, rather than preserved pancreatic morphology. 
In non-immune tissues, the expression of Fas and FasL correlates with the presence of 
tissue-specific micro-environment factors and cytokines, which are known to locally 
modulate immune reactions (Chen et ai., 1998). Therefore, changes in Fas and FasL 
expression reflect not only a shift in the cytokine profile (Garcia-Velasco et ai., 1998) 
but also alterations in the hormonal environment of these tissues (Song et ai., 2000). 
1.5.4 Apoptosis and trophoblast function 
The role of apoptosis in the regulation of trophoblast function is not well defined as 
yet. Apoptosis, assessed by the TUNEL method was noted in the nuclei of both 
cytotrophoblasts and syncytiotrophoblasts, being most abundant in very early 4- to 5-
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weeks placentas, less abundant in early and midterm placentas, and least abundant in 
term placentas (Ishihara et aI., 2000). It was found that Bcl-2 protein, an apoptosis-
inhibiting gene product, was expressed in the cytoplasm of syncytiotrophoblasts, 
being least abundant in very early 4-5 weeks placentas, less abundant in early and 
midterm placentas, and most abundant in term placentas. It is possible that high levels 
of Bcl-2 protein expression in syncytiotrophoblasts in normal term placentas may 
prevent or slow the death of terminally differentiated trophoblasts that progressively 
accumulate during pregnancy (Ishihara et aI., 2000). Recently, it has been suggested 
that Bcl-2 blocks Fas-Fas ligand mediated apoptosis, suggesting that Bcl-2 protein 
and Fas antigen may play important roles in regulating apoptosis of human placental 
trophoblast (Ishihara et aI., 2000). 
Despite expressing both Fas and FasL, villous trophoblasts undergo apoptosis in 
limited numbers during normal pregnancy. However trophoblasts exhibit increased 
apoptosis in pregnancies complicated by fetal growth restriction and preeclampsia 
(Ishihara et aI., 2002; Allaire et aI., 2000). The majority of the apoptotic nuclei in 
these studies were found in the syncytiotrophoblasts of abnormal placentas. 
DiFederico et al, however, reported that apoptosis of the invasive cytotrophoblasts in 
severe preeclampsia was more widespread compared with normal uncomplicated 
placentas (DiFederico et aI., 1999). More recently, Levy et al showed increased 
apoptosis in trophoblast layer of villi from pregnancies complicated by fetal growth 
restriction associated with preeclampsia, which was associated with up-regUlation of 
p53, but not members of the Bcl-2 family of proteins (Levy et aI., 2002). In a previous 
study, the same group showed that hypoxia enhances apoptosis in cultures of human 
trophoblasts, which is associated with increased expression of the proapoptotic 
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proteins p53 and Bax and with a lower expression of the antiapoptotic protein Bcl-2 
(Levy et aI., 2000). These findings implicate the mitochondrial pathway in enhanced 
apoptosis in cultured trophoblasts exposed to low oxygen tension. 
1.5.5 Placental Fas and Fas ligand (FasL) 
Characterisation of the FaslFasL pathway has evolved dramatically since its original 
description as the mechanism controlling the turnover of peripheral activated mature 
T cells (Nagata et aI., 1994). It has become evident that the FaslFasL system plays a 
major role in continuos tissue haemostasis (Song et aI., 2000). Furthermore, 
understanding the FaslFasL interactions has changed the paradigm regarding the 
establishment and maintenance of immune privilege. Once believed to depend on 
physical barriers and anatomical isolation, immune privilege is now viewed as an 
active process by which infiltrating, activated lymphoid cells are eliminated by the 
FaslFasL apoptotic pathway (Bechmann et al., 1999). 
Mor et al. (1998) suggested that placental expression of FasL serves as the key 
component for establishing immune privilege at the maternal-fetal interface. Contrary 
to the old concept of a physical barrier, the trophoblast is now believed to function as 
a dynamic obstacle, averting activated and potentially detrimental T cells. Once they 
recognise placental alloantigens, activated T cells express Fas, which interacts with 
FasL on placental trophoblast cells. Consequently, the activated T cells undergo Fas-
mediated apoptosis. 
Aschkenazi et al. (2002) showed that susceptibility to Fas does not necessarily 
correlate with its trophoblast cell expression, and that cellular inhibitors must exist in 
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the Fas-mediated signalling pathway to prevent apoptosis. In their study, for example, 
IL-I0 treatment increased trophoblast Fas expression, but unexpectedly increased 
trophoblast resistance to apoptosis, suggesting a mechanism of action other than 
regulation of Fas expression. This could be through activation of FLIP, an 
intracellular component of the Fas apoptotic pathway, as IL-I0 treatment increased 
both the expression and activation of FLIP in trophoblast cells. 
Mice with gld mutation are deficient in FasL and have smaller litters with decreased 
viability (Hunt et al., 1997). Studies in these mice suggest that the Fas-FasL pathway 
contributes to preservation of the fetal allograft by preventing the trafficking of 
activated leukocytes between the mother and the fetus during normal gestation, 
observations also supported in humans (Uckan et al., 1997; Jiang & Vacchio, 1998; 
Kauma et al., 1999). These studies suggest that interactions between FasL-positive 
placental trophoblasts and activated maternal lymphocytes that express Fas contribute 
to the induction of tolerance through a clonal deletion mechanism (Guller & 
LaChapelle, 1999). Conversely, alternative mechanisms may be contributory to 
establishing maternal-fetal tolerance during pregnancy as gld mice can reproduce 
(Hunt et al., 1997), and clonotypic maternal T cells that remain after clonal deletion 
are unresponsive to fetal antigen challenge (12-9). This leads us to think that the role 
of Fas and FasL in trophoblast physiology is presumably more complex than 
originally anticipated. Aschkenazi et al (Jiang et al., 1998) showed that despite the 
expression of Fas and FasL by first-trimester trophoblast, it is particularly resistant to 
Fas-mediated apoptosis. They found that susceptibility to Fas does not necessarily 
correlate with its trophoblast cell expression and that cellular inhibitors such as 
Interleukin 10 exist in the Fas-induced signalling pathway to prevent apoptosis. 
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1.5.6 Fas-FasL system and preeclampsia 
As establishment of normal maternal-fetal tolerance appears to involve components of 
the Fas-FasL pathway (Hunt et al., 1997; Uckan et al., 1997; Jiang et al., 1998), 
which also may mediate rejection of transplanted tissues (Griffith et al., 1995; 
Kabelitz, 1998). Thus, it is reasonable to speculate that aberrant function of the Fas-
FasL pathway might also be involved in a maternal rejection of the fetal allograft 
(Kuntz et al., 2002). The contribution of this pathway to the pathogenesis of 
preeclampsia is further suggested by associated maternal and neonatal complications, 
including hepatic inflammation, endothelial injury and neutrophil activation, which 
can be mediated by the Fas-FasL pathway (Kuntz et al., 2002). 
Allaire et al showed that placentas from preeclamptic pregnancies have increased 
apoptosis compared to placentas from normal pregnancIes. Using 
immunohistochemistry, they demonstrated that trophoblastic FasL expression was 
reduced in preeclamptic placentas compared to normal controls, while Fas expression 
was enhanced in these placentas (Allaire et al., 2000). They proposed that the 
combination of reduced FasL expression and enhanced Fas could account for the 
increased placental apoptosis in cases of preeclampsia. On the other hand, increased 
Fas expression could be attributed to placental neutrophil stimulation. High levels of 
neutrophil activation have been described in patients with preeclampsia (Clark et al., 
1998; Greer et al., 1991). It is possible that a dense neutrophil infiltration may alter 
the surrounding environment at the maternal-fetal interface, thereby promoting the up-
regulation of Fas-expression in non-immune cells such as trophoblast and vascular 
endothelium and allowing FasL-induced inflammation and apoptosis (Varani et ai., 
1992). Another study, which evaluated placental Fas and FasL expression in 
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preeclampsia using immunohistochemistry, showed enhanced F asL expression in the 
trophoblasts from preeclamptic placentas, while there was no difference in Fas 
expression between the two groups. 
It seems, however, that the role of FaslFasL in trophoblast apoptosis is far from clear. 
A study by Payne et al demonstrated that Fas expressed by human placental 
cytotrophoblasts does not mediate apoptosis (Payne et al., 1999). A possible 
explanation for this could be the low levels of trophoblast Fas expression 
constitutively (Balkundi et ai., 2003). Recent evidence suggests that cells are more 
sensitive to Fas mediated apoptosis when levels of Fas expression increase (Xiao et 
ai., 2002). A recent study of the regulation of FaslFasL in human trophoblasts in cases 
of chorioamnionitis showed that Fas on trophoblasts is biologically active and by 
specifically blocking FasL receptors, a reduction in TNF-a and IFN-induced apoptosis 
was noticed (Balkundi et al., 2003). In summary, the role of FaslFasL surface proteins 
in the trophoblasts is poorly defined and abnormalities of expression of these proteins 
in cases of abnormal placentation are yet to be defined. Its thought that critical events 
during normal pregnancy, such as immunoprotection are regulated by cytokines 
produced locally at the mother-fetus interface (Norwitz et ai., 2001), and the locally 
produced cytokines may exert their effect via the FaslFasL pathway (Aschkenazi et 
ai., 2002). 
Serum soluble Fas and FasL in preeclampsia 
Soluble Fas, an alternatively spliced product of the Fas gene (see above), protects 
cells from apoptosis by antagonizing the binding between membrane form of the Fas 
and the Fas ligand (Cheng et at., 1994). Elevated serum soluble Fas levels are found 
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in patients with autoimmune disease, malignancy, hepatitis, congestive heart failure 
and infection (Knipping et al., 1995; Shen et at., 1996; Lio et at., 1998; Okuyama et 
at., 1997). A study by Hsu et at. (2001) showed increased serum Fas but not FasL 
levels in preeclampsia compared to normal gestational age matched controls. The 
source for the elevation of serum levels of soluble Fas in-patients with preeclampsia 
was not clear in that study. The activated trophoblast, maternal immune cells, or 
abnormal shedding from the injured vascular endothelium are possible sources of the 
soluble Fas antigen in cases of preeclampsia. 
A study by Harirah et at. (2001) showed elevated serum soluble Fas levels in the 
syndrome of Haemolysis, Elevated Liver Enzymes and Low Platelets (HELLP). 
Serum FasL, however, was not significantly raised in this condition, indicating a 
possible role of Fas but not FasL in the pathogenesis of this disease. Again, several 
explanations for the increased Fas in HELLP syndrome were proposed; this included 
release of Fas from injured hepatocytes, activation of vascular endothelium, or 
abnormal release of Fas by trophoblasts. In vitro studies have documented 
upregulation of Fas expression by endothelial cells when stimulated with tumour 
necrosis factor (TNF) (Sata et at., 2000). In addition, elevated serum Fas could act as 
anti-apoptotic factor in the circulation, which results in delayed maternal neutrophil 
apoptosis. This in tum could result in abnormal systemic inflammatory response 
including endothelial dysfunction and multiple organ affection characteristic of 
preeclampsia (Von Dadelszen et at., 1999). 
The study by Kuntz et al. (2001) challenged the idea of elevated serum soluble Fas in 
preeclampsia and alternatively demonstrated higher soluble FasL levels in paired 
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maternal and cord blood sera of preeclamptic pregnancies compared to normal 
controls. In contrast, soluble Fas levels were similar between the groups. In this study, 
the source of these proteins was unclear, with the trophoblast being a likely candidate. 
A second source of the elevated levels of sFasL might be membrane associated FasL 
released from the surface of activated neutrophils (Liles et aI., 1996). This possibility 
is supported both by the lower neutrophil surface expression of FasL in preeclamptic 
gestations, and by the observation that preeclampsia is associated with neutrophil 
activation (Redman et aI., 1999). 
Elevated serum FasL in preeclampsia in the study by Kuntz et al. (2001) could 
contribute to the clinical presentation of the disease. Serum FasL and the membrane-
bound form associated with microvesicles are bioactive (Martinez-Lorenzo et aI., 
1996; Martinez-Lorenzo et aI., 1999), and can mediate a variety of pathologic 
conditions including cytopenias, hepatic inflammation, autoimmune disorders, and 
rejection syndromes (Liu et aI., 2000; Pinkoski et aI., 2000). So far, however, the 
exact effect of elevated serum soluble Fas or FasL in preeclampsia is far from clear. 
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1.6 Intra-Uterine Growth Restriction (IUGR) 
1.6.1 Aetiology of IUGR 
One of the biggest difficulties in approaching the problem of intrauterine fetal growth 
restriction (IUGR) or the small for gestational age fetus (SGA) fetus is the diverse 
aetiology associated with these conditions (Table 1). Being small does not in itself 
mean that the fetus is growth restricted, although for convenience it is often assumed 
to be so. As birth weight is a simple, universal standard, paediatric studies tend to be 
on patients who are SGA at birth, so in perinatology, being SGA in utero is usually 
the starting point for the investigation of the fetus suspected of IUGR. 
Table 1.1 A list of some of the common causes of being SGA at birth 
Fetal 
Constitutional 
Chromosomal anomaly 
Genetic Dwarfing syndromes 
Infection 
Uteroplacental 
Impaired placental invasion (e.g. preeclampsia) 
Drugs (e.g. smoking, cocaine, etc). 
Placental tumours 
Maternal 
Renal disease 
Cardiovascular disease 
Systemic lupus erythematosus 
Sickle cell disease 
Undernutrition 
The use of ultrasound has enabled us to study the physiology of normal pregnancy, as 
well as diagnosing complications related to structural and chromosomal anomalies. 
One of the most important advances made with ultrasound has been the ability to 
accurately date a pregnancy, especially in the first half. Indeed, apart from ultrasound 
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measurement before 18 weeks (still not available to many around the world), we have 
advanced little from the often uncertain dating by Naegele's rule (Berg & Bracken, 
1992). 
The failure of a fetus to reach its expected growth potential, or to exceed it, can be the 
result of any of a number of complications, acting alone or in combination. Although 
there is some overlap in the following groups, for convenience we divide the causes of 
growth failure into maternal, uteroplacental and intrinsic fetal causes. Animal and 
biochemical studies primarily attempt to understand the effects of 
maternalluteroplacental supply on growth, and to understand the hormonal and 
biochemical changes in the animal fetus that accompany such deprivation. Whatever 
the cause, IUGR has far reaching implications for the developing fetus. In addition to 
the known increase in perinatal morbidity and mortality, epidimiological studies have 
found a correlation between low birth weight, perinatal and neonatal mortality and 
subsequent death from cardiovascular disease up to 70 years later (Barker, 1992). This 
information suggests that we should approach the problem of IUGR on three fronts: 
pre-pregnancy education about diet/drug use, etc., identification of patients at risk 
early in pregnancy, and with ultrasound the early detection and optimum management 
of the compromised fetus. 
In an analysis of a specific group of patients (Abrams & Newman, 1991) found that 
maternal smoking, ethnic minority status and low maternal « 1 Oth centile) booking 
weight were the most significant risk factors for the delivery of a small for gestational 
age fetus. Under nutrition is probably the most common causes of SGA fetuses in the 
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world. In addition, substance abuse such as tobacco, marijuana and alcohol is a well-
known cause of SGA fetuses. 
Fetal structural and/or chromosomal abnormality is recognised as a cause of IUGR. 
Symmetrical IUGR tends to start earlier and require delivery earlier than asymmetric 
IUGR. A ten-year paediatric study (Mili et al., 1991) found that the overall incidence 
of major birth defects was 3.6%; the incidence in babies with a birth weight < 1,500 
gms was 16.2% and with a birth weight >1500<2000 gms was 13.2%. There is a 
strong relationship between low birth weight and cardiac malformations. IUGR can 
also result from intrauterine infection, with rubella being the classical example (Merril 
& Weiner, 1992). The introduction of cordocentesis has allowed in utero assessment 
of infection through analysis of the fetal immune response. 
1.6.2 Diagnosis of the Small for Gestational Age (SGA) fetus 
Clinical suspicion 
Clinical suspicion from abdominal palpation, reduced weight gain or a previous SGA 
baby led to a suspicion of IUGR (less than 10th centile) in 50% of cases and action in 
only one third of those suspected (Rosenberg et al 1982a). Symphysial-fundal height 
(SFH) can be measured easily and predicted low birth weight with a sensitivity and 
specificity of 86% and 90%, respectively in a study that excluded more than half of 
the women entered into it (Belizan et al., 1978). 
In a study of high-risk pregnancies with certain menstrual dates and early ultrasound 
examinations, sensitivity ranged from 79% to 86% and specificity from 79% to 92% 
depending on the type of growth curves used (Cnattingius et ai., 1984). When the use 
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of SFH curves was examined in actual practice with different observers the values fell 
to 56% and 85%, respectively (Rosenberg et ai., 1982b). Recently, the idea of 
customised growth charts was introduced. This means that maternal height; weight 
and race are to be taken into consideration when measuring the SFH, as normograms 
for SFH measurements can be affected by the above factors. 
Ultrasound and biophysical assessment 
The idea that ultrasound can be used to determine fetal size and fetal growth is not 
new (Campbell & Dewhurst, 1971), but because of the inherent errors in the use of 
ultrasound, and our failure to always identify the pregnancies most suitable for 
surveillance, much work continues to be published on this topic (Skorvon et ai., 
1991). There are many difficulties in adopting in-utero growth models from other 
sources because of the differing attributes of a popUlation, the sample size and the 
formulae used among others. However, a study of the accuracy of 20 published 
formulas for predicting birth weight using estimated fetal weight by ultrasound found 
no differences between the different formulae (Medchill et ai., 1991). 
Villar & Belizan (1982) have described three different types of IUGR depending on 
the time of onset of placental insufficiency. The three growth patterns defined were 1. 
Chronic or symmetric IUGR; 2. Subacute or asymmetric IUGR; and 3. Acute IUGR. 
Each is thought to have different aetiologies and prognostic significance. Serial 
ultrasound assessment can identify reduced growth velocity, in which serial fetal 
biometry measurements cross the centiles in the growth charts. These fetuses are more 
likely to suffer from IUGR rather being constitutionally small for age. Serial 
ultrasound, however, cannot always differentiate between the varying types of IUGR. 
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In practice, if an insult occurs before 24 weeks gestation, it is more likely to present as 
symmetric IUGR, whereas if the insult is in the third trimester, the fetus is more likely 
to demonstrate an asymmetric IUGR pattern. 
Manning et al. (1980) described the fetal biophysical score (BPS). The score 
contained five variables: fetal breathing movement, fetal movement, fetal tone, 
quantitative amniotic fluid volume (qAFV) determination, and cardiotocographic fetal 
heart rate testing over a 30 minute observation interval. The BPS may be regarded as 
an acute index of fetal well being, in view of the known association between fetal 
oxygenation and the presence or absence of these biophysical activities (Vintzileos et 
al., 1987). The association between abnormal biophysical activity (low BPS) and 
rising morbidity and mortality is well established (Manning et al., 1985, Vintzileos et 
al., 1987). Gross perinatal mortality ranges from 1.5 per 1000 for a BPS of 8 or 10, 
rising to 17.5 per 1000 for a BPS of 6, and 500 per 1000 for a BPS of zero. In 
practice, the score can be misleading, as the various parameters are not weighted 
correctly for the importance of their presence or absence. 
The two parameters consistently associated with a poor outcome are reduced amniotic 
fluid volume (AFV), clinically known as oligohydramnios, and an abnormal fetal 
heart rate pattern. There are three causes of oligohydramnios, 1. Premature rupture of 
the membranes (PROM), 2. Renal ageneis, and 3. Placenta insufficiency. In the 
absence of PROM and renal disorders, oligohydramnios is the best biophysical 
predictor of a poor perinatal outcome (Manning et al., 1981). Oligohydramnios is 
often a late sign: while useful in confirming a perilous situation for the fetus, it is less 
useful in the early stages of identifying IUGR. 
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The normal fetus has active-inactive cycles of 20-50 minutes, with the cycle length 
generally increasing with gestational age. Normal FHR analysis (Wheeler & Murrils, 
1978), reflects this normal activity, and is an established test of fetal well being. When 
intervention is based on abnormal FHR analysis, perinatal mortality in a high risk 
group can be reduced to <3 per 1000. However, there are a number of problems with 
false positive and false negative results, which limit the use of FHR analysis as a lone 
indicator of fetal well-being. Maternal obesity, drugs, prolonged inactivity cycle, 
excessive activity are but some of the problems that can lead to false positive results. 
The real danger with the use of FHR testing in isolation is the risk of false negative. A 
meta-analysis of all randomised trials using intervention based on FHR findings 
reported that the perinatal mortality in the group with a normal FHR tracing was three 
times that of the abnormal FHR group. This presumably reflects the fact that an 
abnormal FHR trace was acted upon, while a conservative approach was used in the 
group with normal FHR testing. This would suggest that some fetuses with a normal 
FHR trace were compromised, but not to the point of cerebral/cardiac ischaemia. In 
this group of fetuses, a normal pattern was falsely reassuring and occasionally fatal. 
While the assessment of growth and biophysical scoring, in particular AFV and FHR 
testing, are useful tests of fetal well being, there was a need for further understanding 
of the pathophysiological response of the fetus to placental insufficiency. In this 
context, Doppler examination of the fetoplacental circulation was developed to 
critically examine this response (see below). 
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1.6.3 Long-term consequences of IUGR 
If an organ or fetus receives an insult at a critical period of development, the fetus is 
capable of compromising by reprogramming it's potential for development (Lucas, 
1991). This reprogramming appears to be permanent, implying that the true potential 
of the IUGR fetus can never be realised (Law et aI., 1991). This work is supported by 
Hinchcliffe et al. (1991), who found the number of nephrons in kidneys of 
asymmetrically growth retarded fetuses were considerably lower at birth and in the 
first year of life, compared with kidneys from fetuses and infants of normal weight. 
There is also evidence that babies born small for gestational age are physically and 
developmentally behind their appropriate for gestational age (AGA) counterparts 
(Pryor, 1992). In a long term follow up of patients with cerebral palsy (CP) of 
unknown aetiology, the risk of a small (short and thin) baby developing cerebral palsy 
is very much greater than appropriately grown fetus. The risk of CP is even greater if 
the fetus is symmetrically small (small, thin and small head), excluding fetuses with 
chromosomal anomalies (Blair & Stanley, 1992). All this evidence points to the 
primary need for prevention of growth retardation or the early recognition of at risk 
groups so that potential intervention can be utilised at an early stage of the disease. 
1.6.4 Trophoblast apoptosis in IUGR 
Smith et al. (1997) showed that the incidence of apoptosis is significantly higher in 
placentas from pregnancies with intrauterine growth restriction compared to controls. 
This was supported by Ishihara et al. (2002), but showed that increased apoptosis in 
these placentas is mostly localised to the syncytitrophoblast and not the 
cytotrophoblast layer of the placenta. This was also true of placentas in cases of 
severe preeclampsis at term. This, however, was challenged by a study of the 
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morphology of placenta from normal and IUGR pregnancies (Battistelli et aI., 2004). 
This study showed that, although villi in IUGR placentas appeared longer, thinner and 
less vascularized compared to control placentas, they showed no difference in typical 
apoptotic features compared to normal placentas. 
The aetiology of increased apoptosis in IUGR placentas is not entirely clear. Hypoxia 
due to impaired spiral artery remodeling could be implicated. Crocker et al. (2003) 
showed, in an in-vitro model, that both syncytiotrophoblast and cytotrophoblast from 
IUGR pregnancies have increased susceptibility to hypoxia-induced apoptosis 
compared to control placentas. The reason for this was not clear. On the other hand, 
Kilani et al (2003) showed that only extreme hypoxia results in increased trophoblast 
apoptosis in normal trophoblast. 
Other causes of increased trophoblast apoptosis In IUGR include enhanced p53 
expression (Levy et aI., 2002) or reduced Bcl-2 expression (Ishihara et al., 2002). Bcl-
2 protein, an apoptosis inhibiting-gene product, is expressed in the cytoplasm of 
syncytiotrophoblasts and is least abndant in very early 4-5 weeks placentas, less 
abundant in early and midterm placentas, and most abundant in term placentas. 
Apoptosis, on the other hand, was most abundant in very early 4-5 weeks placentas, 
less abundant in early and mid-term placentas, and least abundant in term placentas 
(Ishihara et aI., 2000). This possibly indicates a possible role of Bcl-2 protein in 
preventing apoptosis. In addition, Bcl-2 protein blocks Fas-Fas ligand-mediated 
apoptosis, suggesting that both Bcl-2 protein and Fas antigen may play important 
roles in regulating apoptosis of human trophoblasts. Immunohistochemichal studeis of 
placental Bcl-2 expression in normal term placentas compared to placentas from 
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severe preeclampsia or IUGR at term showed that Bcl-2 protein was abundantly 
immunolocalised in the syncytiotrophoblasts in normal term placentas, but least 
aundant in term placentas in term placentas complicated by severe preeclampsia or 
IUGR (Ishihara et ai., 2002). 
Recent in-vitro study of the role of FaslFasL in spiral artery remodelling suggested 
that apoptotic changes in the endothelial layer of spiral arteries cultured with 
trophoblast in the lumen were detected after 20 hours and were possibly mediated by 
FaslFasL interaction (Ashton et ai., 2005). Allaire et ai. (2000) showed that placental 
FasL is downregulated AND Fas is upregulated in cases of preeclampsia. One third of 
these cases had small for gestational age pregnancies (defined as birth weight <5th 
centile for gestational age). Strictly speaking, this does not mean that all these 
pregnancies had IUGR. The in-vivo role of placental Fas-FasL interaction in spiral 
artey remodelling, placental invasion and the clinical syndrome of IUGR remain to be 
studied. 
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1.7 Placental vasculogenesis 
1.7.1 Stages of placental angiogenesis 
Maternal blood flow into the intervillous space increases 20-fold during pregnancy 
due to vasomotor changes of the distal intramyometrial portions of the uteroplacental 
arteries, and to transformation and dilatation of the decidual segments (Ahmed et aI., 
2000). The latter changes are due to invasion of the vessels by trophoblast cells that 
replace the maternal endothelium and media of the spiral arteries (Benirschke & 
Kaufmann, 1995). Therefore, in contrast with other placental exchange systems, the 
human placenta does not have an endothelium-lined maternal microvascular system 
connecting arteries and veins (Ahmed et aI., 2000). In addition, the core of the 
placental villi is supplied by an endothelium lined fetoplacental system, whose 
development is similar to that of the systemic vascular beds. The only major 
exception to this is the lack of innervation by the autonomic nervous system (Reily & 
Russell, 1977). 
Vascularization of the placental villi starts at day 21 post-conception (Demir et al., 
1989) and is the result of local de novo formation of capillaries rather than protrusion 
of embryonic vessels into the placenta. The villous trees at this stage are made up of 
solid trophoblastic or primary villi and secondary villi, which are characterised by a 
loose mesenchyme (Benirschke & Kaufmann, 1995). There appears to be a paracrine 
role in the initiation of vasculogenesis and mediating trophoblast invasion as 
mesenchymal derived macrophages, maternal decidua and decidual macrophages 
express angiogenic growth factors. 
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1.7.1.1. Branching angiogenesis 
From the stage of primary and secondary villi until the end of fust trimester, the 
villous vasculature increases in number rather than types of vessels (Ahmed et al., 
2000). The number of fetal blood vessels containing capillaries increases, and 
sprouting and branching angiogenesis from the existing capillaries gives rise to a 
primitive capillary network surrounded by an incomplete layer of pericytes 
(Benirschke & Kaufmann, 1995). The villous trees and their vascular bed 
continuously expand from the peripheral ends of the newly differentiated villous 
stems, giving rise to a new capillary network which in turn differentiates into stem 
villi (Castelluci et aI., 1990). 
1.7.1.2 Non-branching angiogenesis 
From 26 weeks of gestation until term the villous vascular growth undergoes a change 
from branching to non-branching angiogenesis due to the formation of a new villous 
type, the mature intermediate villi that specialise in gas exchange. These form at the 
tips of the villous tree and are long (>1000 urn) and slender (80-120 urn diameter) 
containing one or two long, poorly branched, capillary loops. These arise as a result of 
a decrease in trophoblast proliferation and an increase in endothelial proliferation 
along the entire length of the capillary giving a final capillary loop exceeding 4000 
urn in length (Kaufmann et aI., 1985). As these capillaries grow in excess of the villi, 
they coil and bulge through the trophoblastic surface forming the terminal villi. Each 
of these is supplied by one or two capillary coils that are covered by a very thin 
trophoblastic lamella or the vasculosyncytial membrane (Benirschke & Kaufmann, 
1995). These specialised structures are the main site of diffusional gas exchange 
between the maternal and fetal circulations. As gestation increases these terminal 
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capillaries focally dilate to form large sinusoids, this dilatation counterbalances the 
effects of the long poorly branched capillaries on total fetoplacental vascular 
impedance (Kingdom & Kaufmann, 1988). Increasing fetal blood pressure also aids 
this dilatation and fetoplacental blood flow rises throughout gestation to 40 percent of 
fetal cardiac output by term (Hendriks et aI., 1989). 
Placentas from the pathological condition of IUGR display a failure of elongation, 
branching and dilatation of these capillary loops, and failure of terminal villi 
formation (Krebs et aI., 1996; Macara et aI., 1996). Consequently, fetoplacental blood 
flow is severely impaired and transplacental gas exchange is poor, placing the fetus at 
risk of hypoxia and acidosis. 
1.7.2 Placental morphology in IUGR and preeclampsia 
The underlying pathology of increased vascular resistance in IUGR must reside either 
in the stem arteries (increased vasomotor tone) or in the vascular arrangement of the 
capillaries within gas-exchanging villi (Kingdom et aI., 1997). Stereologic two-
dimensional studies of placental structure from cases of IUGR with absent or reversed 
end-diastolic flow (AREDF) in umbilical artery Doppler have indicated a reduction in 
the elaboration of the peripheral gas-exchanging parts of the villous tree in early-onset 
IUGR (Hitschold, 1998; Jackson et aI., 1995). Immunohistochemistry and 
transmission electron microscopy of the placental villous structure in these cases 
showed that the tenninal villi were characterised by reduced numbers of proliferating 
cytotrophoblast, with excess numbers of overlying syncytiotrophoblast nuclei 
(Kingdom & Kaufmann, 1999). Since syncytial fusion is thought to focally retard 
apoptosis in the syncytiotrophoblast (Huppertz et aI., 1998), these findings were 
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interpreted as representing accelerated trophoblast ageing (Kingdom & Kaufmann, 
1999). Villous trophoblasts in these cases is characterised by reduced numbers of non-
branching capillaries (ie predominance of non-branching angiogenesis, see below). 
The combination of arrested trophoblast turnover and failure to evoke an adaptive 
angiogenic response in these placentas suggest that these villi have been exposed to a 
higher than normal oxygen tension- a situation termed placental hyperoxia (Macara et 
aI., 1996). 
Fractional extraction of oxygen from the intervillous space is greatly reduced with 
ARED in the umbilical arteries, such that uteroplacental venous blood has a 30% 
higher oxygen content than under normal circumstances (Pandi et ai., 1992). Severe 
early-onset IUGR with AREDF is very uncommon in un selected pregnancies (Mason 
et aI., 1993). The pathology of AREDF and thus the concept of placental hyperoxia is 
thus the exception to the rule that the placenta adapts to reduced uteroplacental blood 
flow (Kingdom & Kaufmann, 1999). In these cases, hypoxia exists at the level of the 
fetoplacental circulation rather than the intervillous space. This is in contrast to 
placentas in cases of preeclampsia with preserved end diastolic flow (EDF) in the 
umbilical artery, which show villous trophoblast vascular structure characterised by 
predominance of branching angiogenesis. In these cases, hypoxia exists at the level of 
the intervillous space, while the fetoplacental circulation will have significantly higher 
oxygen saturation compared to cases of IUGR with AREDF. 
1.7.4 Oxygen regulation of vascular growth factors 
Successful placentation involves the development of low-impedance uteroplacental 
circulation following trophoblast invasion and transformation of the maternal 
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intramyometrial portion of the spiral arterioles. An oxygen tension gradient exists 
between the maternal decidua and the villous placenta during embryonic 
development. Hypoxia stimulates cytotrophoblast proliferation and inhibits 
trophoblast invasion (Genbacev et at., 1996). At around 12 weeks' gestation, the 
intervillous space switches from relative hypoxia to an enhanced oxygen state. This 
striking rise in oxygen may be the trigger for the trophoblast to change from its 
proliferative state within "hypoxic" cell columns to an invasive extravillous 
trophoblast that is responsible for trophoblast invasion. In preeclampsia and IUGR, 
the uterine blood vessels do not undergo adequate vascular development 
transformation, so the rate of delivery of oxygenated blood to the fetus falls "see 
below". This "uteroplacental insufficiency" has led to the notion of placental hypoxia 
in these two disorders. 
Ultrastructural studies in normal and severe IUGR placentas have challenged the idea 
of placental hypoxia. The terminal villi of IUGR placents showed reduced 
cytotrophoblast proliferation, stromal fibrosis, and poor villous angiogenesis as 
indicated by straight and unbranched capillaries (Krebs et at., 1996; Macara et at., 
1996). There was also congestion of fetal capillaries by erythrocytes, which may 
further limit oxygen transfer from the intervillous space to the fetus. These findings 
were interpreted as evidence of placental hyperoxia, which refers to the oxygen 
tension in the intervillous space being closer to the maternal arterial oxygen level in 
severe IUGR than is the case in normal pregnancy at the same gestation. Since 
hypoxia promotes angiogenesis, the relatively high oxygen levels in the intervillous 
space in contact with IUGR placental villi will limit angiogenesis. Similar changes 
were noticed in placental hyperoxia induced in a primate experimental model (Panigel 
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& Myers, 1972). The observation that oxygen content in uteroplacental venous blood 
in IUGR was significantly higher than in control pregnancies supports the idea of poor 
fetal oxygen extraction in IUGR (Pardi et aI., 1992; Burton et aI., 1996). 
The usual response to uteroplacental ischaemia, or to pregnancy at high altitudes (4-6) 
is for the villous tree to undergo increased capillarization, resulting in increased 
fractional extraction of oxygen to meet the demand of the growing fetus. It seems that 
this adaptive mechanism fails badly in severe IUGR. The molecular regulation of 
villous development and placental angiogenesis must involve the interaction of the 
cellular components of the placenta (trophoblast, stromal cells, and endothelium) and 
the local oxygen gradients established both within each villous and between the 
cellular compartments (Ahmed & Kilby, 1997). The human placenta is richly 
endowed with angiogenic growth factors and their receptors, including VEGF, PIGF 
and Fltl. A study by Ahmed (1997) showed that hypoxia upregulates VEGF and 
downregulates PIGF. Recent studies show that the intensity of immunostaining for 
VEGF and PIGF in severe IUGR placenta was no different from that in normal 
placenta (Ahmed, 1997; Lyall et aI., 1997), supporting the notion that the placenta 
was not hypoxic at delivery. These findings were confirmed by western blotting 
which confirmed the lack of change in VEGF levels in severe IUGR (Ahmed, 1997). 
In preeclampsia, however, levels of PIGF were decreased and those of VEGF 
increased, which may indicate that that in preeclampsia, the intervillous space and 
anchoring villi (source of invading extravillous trophoblast) remain hypoxic. 
Kingdom and Kaufmann identified three types of hypoxia relating to the 
uteroplacental unit; "preplacental hypoxia" as in pregnancy at high altitude and 
maternal anaemia, "uteroplacental hypoxia" as in preeclampsia, and "postplacental 
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hypoxia", as in severe IUGR with absent end-diastolic flow velocity in the umbilical 
artery (Macara et ai., 1996), which indicates elevated fetoplacental vascular resistance 
(Morrow et al., 1989). 
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1.8 Doppler Ultrasound 
Christian Doppler (1843) suggested that the frequency of light and sound could 
change with movement. Experimental proof was provided by Buys Ballot in 1845 
(Jonkman, 1980). Musicians with perfect pitch compared the trumpet note played by a 
stationary horn player and one on a moving train, playing before and after passing a 
station. The musicians scored the notes in eighths of a note and the results compared 
well with those expected on theoretical grounds. 
Doppler ultrasound is now a widely used technique for the investigation of blood 
flow. As equipment has developed, so has the range of applications and the 
confidence in the information obtained. Competent use of Doppler ultrasound 
techniques requires an understanding of three key components: haemodynamics 
within vessels, the capabilities and limitations of Doppler ultrasound, and the different 
parameters, which contribute to the Doppler sonogram. 
1.S.1 The Doppler principle applied to ultrasound 
In medical imaging, the term Doppler ultrasound encompasses continuos wave 
Doppler (CW), pulsed wave Doppler (PW) and colour Doppler imaging (COl). 
Processing for each differs considerably but the underlying principles are similar. 
When ultrasound is reflected from a moving subject, in this case red blood cells, the 
movement of the target causes a frequency shift in the reflected signal and the 
ultrasound receiver detects this frequency shift. The frequency shift, known as the 
Doppler shift frequency or Doppler frequency, can be related to the flow velocity 
within a vessel. The Doppler frequency is substantially altered by three factors: 
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1. The magnitude of the Doppler frequency Increases as blood flow velocity 
Increases. 
2. The Doppler frequency increases as the transmitted ultrasound frequency 
increases. This means that higher frequency probes are more sensitive to low 
velocities. Unfortunately, attenuation of ultrasound in tissue is frequency-
dependent so that high frequency probes (5 MHz and above) may not provide 
adequate penetration when examining deep vessels. Conversely, the use of low 
frequency ultrasound in deep abdominal vessels may lead to low flow velocities 
not being detected. 
3. The Doppler frequency increases as the Doppler ultrasound beam becomes more 
aligned to flow direction (Doppler angle becomes smaller). This is of utmost 
importance in the use of Doppler ultrasound. All Doppler ultrasound equipment 
employ filters to cut out the high amplitude, low frequency Doppler signals 
resulting from tissue movement, for instance due to vessel wall motion. This filter 
frequency limits the minimum flow velocities that can be measured, the actual 
value being dependent on the transmitted frequency and beam/flow angle. 
1.8.2 Continuous Wave Doppler Ultrasound 
Continuous wave (CW) ultrasound is the simplest type of Doppler ultrasound. 
Because CW systems transmit and receive ultrasound continuously, Doppler shifts are 
obtained from all vessels in the path of the ultrasound beam (until ultrasound becomes 
sufficiently attenuated due to depth). Relatively inexpensive Doppler ultrasound 
systems are available which employ CW probes to give Doppler output without the 
addition of B-mode images. One disadvantage of a Doppler only system is that the 
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beam/flow angle may not be known, preventing velocity measurements being derived 
from the Doppler frequency shifts. 
1.8.3 Pulsed Wave Doppler Ultrasound 
A limitation of CW systems is that they are not range-specific, which can make it 
difficult to isolate the Doppler signals from a particular vessel. Pulsed wave (PW) 
systems transmit short pulses of ultrasound, the echoes of which are received after a 
short interval of time. PW systems allow measurement of the depth (or range) at 
which blood flow is observed (by measurement of the time taken for the pulse to be 
transmitted to and reflected back from the blood cells). Additionally, the size of the 
sample volume (or range gate) can be changed by altering the transmitted pulse length 
and the time over which the signal is received. In this way, the region of examination 
of blood flow can be altered to suit specific clinical requirements. 
1.8.4 Colour Doppler Imaging (CDI) and Spectral Doppler 
Colour Doppler imaging (CDI) - also referred to as Doppler flow imaging (CFI) or 
colour Doppler ultrasound (CDU) - produces a colour coded map of Doppler 
frequency shifts superimposed onto a B-mode ultrasound image. Although COl uses 
PW ultrasound, its processing differs from the used to provide the Doppler sonogram. 
The latter employs several long pulses to enable a full spectral analysis of the region 
of interest to be obtained over a small interval of time. This is repeated to generate the 
sonogram in real time. Since COl may have to produce several thousand colour points 
of flow information for each frame superimposed on the B-mode image, analysis is 
simpler. CDI uses fewer, shorter pulses along each colour scan line of the image to 
give a mean frequency shift and a variance at each small area of measurement. This 
frequency shift is converted to a colour pixel. The scanner then repeats this for several 
lines to build up the colour image, which is then superimposed onto the B-mode 
image (Figure 2.1). 
The transducer elements are switched rapidly between B-mode and CDI to give an 
impression of a combined simultaneous image. The pulses used for CDI are typically 
3-4 times longer than those for the B-mode image with a corresponding loss of axial 
resolution. Assignment of colour to frequency shifts is usually based on direction (for 
example red for Doppler shifts towards the ultrasound beam and blue for shifts away 
from it) and magnitude (different colour hues or lighter saturations for higher 
frequency shifts) (Kremkau,1992). The colour Doppler image is dependent on general 
Doppler factors, particularly the need for a good beam/flow angle. Because the beams 
in a linear array transducer are unidirectional, curved vessels can have different colour 
hues and possibly colour reversal throughout the area of investigation. 
Increased sensitivity to low velocity flow can be achieved by decreasing the pulse 
repetition rate (some manufacturers call this altering the scale). Ultimately, sensitivity 
to low velocity flow is limited by the filter frequency used to eliminate noise from 
tissue motion. 
The use of CDI can decrease the available frame rate, because the same transducer 
elements are used for both B-mode and CDI. For each frame, B-mode imaging 
requires only one pulse per scan line, CDI typically requires 5-10. Broadly, the frame 
rate increases with increased pulse repetition frequency, but decreases as the number 
of colour lines increases (e.g. due to a large area of colour flow examination) and 
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decreases as the number of pulses per line is increased (to improve the quality of 
colour signal). The loss of frame rate can be of particular importance in obstetric 
scanning where the fast fetal heart rate results in rapid changes in instantaneous flow. 
Figure 1.2 Colour Doppler image of the Circle of Willis and the Middle Cerebral 
artery superimposed on the B-mode image. 
1.8.5 Blood flow measurement using Doppler ultrasound 
Velocity measurement 
Theoretically, once the beam/flow angle is known, velocities can be calculated from 
the Doppler spectrum as shown in the Doppler equation. However, errors in the 
measured velocity may still occur (Evans et ai., 1989; Gill, 1985). Errors can ari e in 
the measurement of the ultrasound beam/flow velocity angle; u e of high angle (>60) 
may give rise to error, becau e the velocity vector may not be in the direction of the 
vessel axi . In addition, mall change in the angle will re ult in comparatively large 
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changes in the velocity measurement. Other causes of errors include faults in the 
formation of the Doppler spectrum due to causes such as use of filters removing low 
velocity components and the non-uniform insonation of the vessel lumen. 
Furthermore, errors can arise in the calculation packages which the manufacturers 
provide for analysis of the Doppler spectrum 
Flow waveform analysis 
Qualitative analysis of the flow waveform shape and spectrum has proved to be a 
useful technique in the investigation of many vascular beds. It has the advantage that 
derived indices are independent of the beam/flow angle. The flow waveform shape 
arises from the action of a pulsatile pressure waveform acting on a distal impedance. 
Changes in flow waveform shape have been used to investigate both proximal disease 
(e.g in the adult peripheral arterial circulation) and distal changes (in fetal 
circulations). If waveform analysis is to be used to observe changes in one component 
of the proximal or distal vasculature, consideration must be made to ensure that other 
components are not affecting the waveform significantly. 
Resistance Indices 
It is beyond the scope of this introduction to detail all the various indices which have 
been used to describe the shape of slow waveforms. There are variable indices used to 
describe Doppler waveforms in a quantitative way, usually as a guide to some kind of 
classification. The following indices are described briefly because they are commonly 
used in many vascular beds and because the calculations necessary to produce them 
are available on many commercial ultrasound scanners. They are all based on the 
maximum Doppler shift waveform. The heights referred to are of the outline of the 
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waveform, which can be In units of frequency or velocity; all indices are non-
dimensional. 
Pourcelot's resistance index 
Pourcelot's Resistance Index (RI) (1974), also known as Resistance Index is defined 
as; 
(Peak Systolic Height - Minimum Diastolic Height) over (Peak Systolic Height) 
RI=(S-D)/S 
As diastolic flow falls, the value of RI increases, if there is no diastolic flow, RI= 1. RI 
values greater than are possible if there is negative diastolic flow. 
Systolic Idiastolic ration (AlB ratio) 
The systolic diastolic (SID) ratio is calculated by dividing the peak systolic height by 
the minimum diastolic height. As diastolic flow falls, SID increases; when there is no 
diastolic flow, the SID ratio is infinity. 
Pulsatility Index (PI) 
The pulsatility index (PI) (Gosling, 1975) is defined as, 
PI=(Peak Systolic Height-Minimum Diastolic Height)/Mean Waveform Height. 
PI=(S-D)IM 
Because of the need to measure the mean height of the waveform, this takes slightly 
longer to calculate than RI or the SID ratio. It does, however, give a broader range of 
values, for instance describing a range of waveform shapes when there is no end 
diastolic flow. In addition to these indices, the flow waveform may be described or 
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categorised by the presence or absence of a particular feature. Generally, a low 
pulsatility waveform is indicative of low distal resistance and high pulsatility 
waveform occurs in high resistance vascular beds. Care should be taken when trying 
to interpret indices as an absolute measurement of either upstream or downstream 
factors. For example, alterations in heart rate can alter the flow waveform shape in 
vessel and cause significant changes in the value of indices. 
Peak velocity and Time Averaged Velocity 
The angle of insonation is required to calculate velocity measurements. With PW leDI 
systems it is possible to estimate the angle of insonation. The peak velocity is the 
maximum systolic velocity, and time averaged mean velocity (TA V) is calculated by 
averaging velocities throughout the cardiac cycle. 
Qualitative analysis 
The flow velocity waveform can be analysed by qualitative assessment. In particular 
the presence or absence of early diastolic notching (Fig 1.3) and the presence or 
absence of end-diastolic frequencies have been used in the evaluation of the uterine 
and umbilical arteries waveforms, respectively. Although this approach lacks the 
attraction of being able to place a numerical value on a particular waveform, it has 
proven useful in analysis of waveform resistance (see below). 
Figure 1.3 High (A) and low (B) resistance waveforms obtained from the uterine 
artery. 
(A) (B) 
1.9 Screening for placental insufficiency by uterine artery Doppler 
Impaired trophoblastic invasion of the maternal spiral arteries is associated with 
increased risk for subsequent development of intrauterine growth restriction, 
preeclampsia and placental abruption. A series of screening studies involving 
assessment of impedance to flow in the uterine arteries have examined the potential 
value of Doppler in identifying pregnancies at risk of the complications of impaired 
placentation (Fig 1.3 and 1.4). 
Figure 1.4 Qualitative assessment of uterine artery Doppler flow velocity waveforms. 
Good end diastolic flow (A), and early diastolic notching (B). 
(A) (B) 
1.9.1 Studies in selected populations 
Arduini et al. (1987) examined 60 women who had essential hypertension, renal 
disease or a previous pregnancy complicated by pregnancy induced hyperten ion. 
They measured impedance to the flow in arcuate arteries at 18-20 weeks of ge tation 
and defined a resistance index (RI) (see above) more than 0.57 as abnormal. The te t 
had a sensitivity of 64% for the development of pregnancy-induced hyperten ion 
(Pili) (Table 1). 
In a similar study, Jacobson et al. (1990) examined 91 women who had chronic 
hypertension, history of preeclampsia or fetal loss and a variety of other medical 
conditions. They measured impedance to flow in the arcuate arteries at 24 weeks of 
gestation and defined an abnormal result as RI more than 0.57. The sensitivity of the 
test for Pili was 44% (Table 1). Similar study by Zimmerman et al. (1997) examined 
172 women and defined an abnormal result as RI more than 0.68, found a sensitivity 
of increased impedance in the prediction of preeclampsia of 56%. (Table 1). 
Table 1.2 Screening for pregnancy-induced hypertension in high-risk pregnancies be 
measurement of impedance to flow in the arcuate or uterine arteries. * 
Arduini et aI, Jacobson et aI, Zimmerman et 
1987 1990 al1997 
Gestation at Doppler 18-20 weeks 24 weeks 21-24 weeks 
Patients 60 91 172 
Prevalence of preeclampsia 37% 29% 18% 
Sensitivity 64% 44% 56% 
Specificity 94% 73% 83% 
Positive predictive value 70% 330/0 435 
Negative predictive value 80% 81% 89% 
... . e her eds. Placental and Reproduced wIth permIssIon from Nicolatdes, Rizzo and H c ( ) 
fetal Doppler, Parthenon Publishing; 2000, 91. 
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1.9.2 Studies in unselected populations 
Several studies in unselected populations have examined the value of Doppler 
assessment of the uteroplacental circulation in the prediction of preeclampsia and/or 
IUGR. The early studies were limited by the use of continuous wave Doppler, which 
is a blind investigation. Recent studies, however, have used colour Doppler ultrasound 
to assess flow in the uterine artery at the point where it crosses the external iliac 
artery, which is a more reproducible examination. Discrepant results between the 
studies may be the consequence of differences in Doppler technique for sampling and 
the definition of abnormal flow velocity waveform, differences in the populations 
examined (the prevalence of preeclampsia varied from as low as 2% to as high as 
24%), the gestational age at which women were studied, and different criteria for the 
diagnosis of preeclampsia and IUGR. 
One stage screening 
Bewley et al. (1991) calculated the average resistance index from the left and right 
uterine and arcuate arteries in 925 pregnancies at 16-24 weeks gestation. When the RI 
was greater than the 95th centile, there was a la-fold increase in risk for a severe 
adverse outcome, defined by fetal death, placental abruption, IUGR or preeclampsia. 
However, the sensitivity of the test for preeclampsia or IUGR was only 24% and 19% 
respectively with a specificity of of about 95% for both. 
Bower et al. (1993) examined the uterine arteries in 2058 pregnancies at 18-22 weeks. 
An abnormal result, defined by a resistance index above the 95
th 
centile or the 
presence of an early diastolic notch in either of the two uterine arteries, was found in 
160/0 of the pregnancies. The sensitivity of the test was 75% for preeclampsia and 40% 
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for IUGR, and the specificity was 86% for both. This study highlighted the fact that 
abnormal Doppler results provide a better prediction of the more severe types of 
pregnancy complications. Thus, the sensitivity for mild preeclampsia was only 29%, 
but for moderate/severe disease the sensitivity was 82%. Similarly, the sensitivity for 
birth weight below the 10th centile was 38% and, for birth weight below the 5th 
centile, it was 46%. 
Two-stage screening 
Steel et al. (1990) examined the uterine arteries In 1014 nulliparous women by 
continuous wave Doppler at 18 weeks of gestation and, in those with increased 
impedance (RI>0.58), the Doppler studies were repeated at 24 weeks. A screen-
positive result (increased impedance at 24 weeks) was found in 12% of cases, and the 
sensitivity of the test for preeclampsia was 63% and for IUGR was 43% «5th centile). 
Bower et al. (1993) examined the uterine arteries in 2437 unselected pregnancies by 
CW Doppler at 20 weeks gestation. In those with increased impedance to flow 
(R1>95 th centile or early diastolic notch in either of the two uterine arteries), the 
Doppler studies were repeated by colour Doppler at 24 weeks. Persistently increased 
impedance was observed in 5.4% of the patients (compared to 16% at 20 weeks). It 
was reported that increased impedance provides good prediction of preeclampsia (but 
not of non-proteinuric hypertension). Furthermore, in terms of low birth weight, 
abnormal waveforms provide better prediction of severe (below the 3rd centile) rather 
than mild (below the 10th centile) IUGR. 
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Harrington et al. (1996) examined the uterine arteries in 1233 unselected women by 
CW Doppler at 20 weeks gestation. In those with increased impedance (RI>95th 
centile or early diastolic notch in either of the uterine arteries), the Doppler studies 
were repeated by colour Doppler at 24 weeks. Persistently increased impedance was 
observed in 8.9% of the patients. The sensitivity of the test for preeclampsia was 77% 
and for IUGR 32%. Bilateral notching at 24 weeks was observed in 3.9% of patients; 
the sensitivity for preeclampsia was 55%, and for IUGR 22%. The respective 
sensitivities for those complications leading to delivery before 35 weeks were 81 % 
and 58%. Tables 2,3 and 4 summarise the main characteristics and results of the 
different studies used to assess the value of uterine artery Doppler in the prediction of 
preeclampsia and IUGR. 
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Table 1.3 Characteristics of uteroplacental Doppler-screening studies in unselected 
populations *. 
Author N Doppler Vessel Abnormal result Gestational 
aRe (weeks) 
One-stage 
Campbell et 126 PW Arcuate R1>0.58 16-18 
al 
1986 
Hanretty et al 291 CW Arcuate R1>0.52 26-30 
1989 
Bewley et al 925 CW Uterine and Mean RI>951H 16-24 
1991 arcuate centile 
Bower et al 2058 CW Uterine RI>95TH centile or 18-22 
1993 notch 
Valensise et 272 Colour Uterine Mean R1>0.58 22 
al 
1993 
North et al 457 Colour Uterine'" R1>0.57 19-24 
1994 
Chan et al 334 CW Uterine RI>90th centile and 20 
1995 bilateral notches 
Irion et al 1159 Colour Uterine'" Mean R1>0.57 26 
1998 
Kurdi et al 946 Colour Uterine R1>0.55 and 19-21 
1998 bilateral notches 
Two-stage 
Steel et al 1014 CW/CW Uterine R1>0.58 18 & 24 
1990 
Bower et al 2437 CW/Colou Uterine RI>95
th centile or 20&24 
1993 r notches 
Harrington et 1233 CW/Colou Uterine RI>95
th centile or 20&24 
a r notches 
1996 
Frusca et al 419 CW/Colou Uterine Mean R1>0.58 20&24 
r 1997 
'" 
. Reproduced With penrusslon from Nlcolatdes, Rizzo and Hecher (eds.) Placental and 
fetal Doppler, Parthenon Publishing; 2000, 92. 
+Only the uterine artery on the placental side was studied. 
PW, Pulsed wave, CW continuos wave 
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Table 1.4 Results of the uteroplacental Doppler screening studies on unselected 
populations for the prediction of preeclampsia *. 
Author Outcome Prevalence Sensitivity Specificity PPV NPV 
measure (%) (%) (%) (%) (%) 
One-stage 
screeninf{ 
Campbell PET 1 11.9 67 64 20 93 
et al1986 
Hanretty PET 2 24.1 7 94 26 76 
et al1989 
Bewleyet PET 3 4.6 24 95 20 96 
al1991 
Bower et PET 4 2.5 75 86 12 99 
al1993 
Valensise PET 4 3.3 89 93 31 99 
et al1993 
North et PET 4 3.3 27 90 8 97 
al1994 
Chan et al PET 5 6.9 22 97 36 94 
1995 
Irion et al PET 4 4.0 26 88 7 
1998 
Kurdi et PET 3 2.2 62 89 11 99 
al1998 
Two-stage 
screening 
Steel et al PET 4 1.9 63 89 10 99 
1990 
Bower et PET 4 1.8 78 95 22 99 
al1993 
Harringto PET 6 3.6 77 94 31 99 
n et al 
1996 
Frusca et PET 4 1.9 50 92 11 99 
al1997 
'" Reproduced with permission from Nicolaides, Rizzo and Hecher (eds.) Placental and fetal Doppler, 
Parthenon Publishing; 2000, 93. 
Definitions of hypertensive disease (PET) used by different studies 
PET 1 Blood pressure rise (systolic > 30 mmHg or diastolic> 15 mmHg) with proteinurea or 
generalised oedema 
PET 2 Blood pressure> 140/90 mmHg, requiring further investigation or treatment 
PET 3 Blood pressure> 140/90 mmHg and proteinurea (>150 mgl24 h) 
PET 4 Blood pressure> 140/90 mmHg and proteinurea (>300 mgl24 h) 
PET 5 Blood pressure > 140/90 mmhg and proteinurea (>300 mgl24 h) or non-proteinuric 
hypertension before 37 weeks. 
PET 6 Blood pressure rise (systolic> 30 mmHg and diastolic> 25mmHg) with proteinurea (> 500 
mg/24h). PPV Positive Predictive Value, NPV Negative Predictive Value 
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Table 1.5 Results of uteroplacental Doppler screening studies for the prediction of 
IUGR in un selected population 
Author Outcome Prevalence Sensitivity Specificity PPV NPV 
measure (%) (%) (%) (%) (%) 
One-stage 
screening 
Campbell IUGR<10 14.3 67 65 24 92 
et al1986 th 
Centile 
Hanretty IUGR<5 th 5.5 6 93 5 95 
et al1989 Centile 
Bewleyet IUGR<5 th 5.7 19 95 19 95 
al1991 Centile 
Bower et IUGR<5 th 5.2 46 86 15 97 
al1993 Centile 
Valensise IUGR<10 7.7 67 95 54 97 
et al1993 th 
Centile 
North et IUGR<10 6.6 47 91 27 96 
al1994 th 
Centile 
Irion et al IUGR<5 th 11 29 89 25 
1998 Centile 
Kurdi et IUGR<5 th 6.0 37 89 22 95 
al1998 Centile 
Two-stage 
screening 
Steel et al IUGR<5 th 7.2 37 90 23 95 
1990 Centile 
Bower et IUGR<5 th 4.9 30 95 23 96 
al1993 Centile 
Harringto IUGR<10 10.6 32 94 38 92 
et al th n 
1996 Centile 
Frusca et IUGR<10 7.2 43 94 36 96 
al1997 th 
Centile 
'" I ler Reproduced wIth permISSIOn from NIcolaIdes, RIZZO and Hecher (eds.) Placental and feta Dopp , 
Parthenon Publishing; 2000,94. 
PPV Positive Predictive Value 
NPV Negative Predictive Value 
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One -stage screening at 23 weeks 
Albaiges et al. (2000) used colour Doppler to examine the uterine arteries in 1757 
singleton pregnancies attending for routine ultrasound examination at 23 weeks. 
Increased impedance was observed in 7.3% of patients, including 5.1 % with mean PI 
of more than 1.45 and 4.4% with bilateral notches. Increased pulsatility index 
identified 35.3% of women who later developed preeclampsia and 80% with 
preeclampsia requiring delivery before 34 weeks; the respective value for bilateral 
notches were 32.3% and 80%. These findings suggest that a one-stage colour 
Doppler-screening program at 23 weeks identifies most women who subsequently 
develop the serious complication of impaired placentation associated with delivery 
before 34 weeks. The screening results are similar if the high-risk group is defined 
either as those with increased PI or those with bilateral notches. 
More recently, Papageorghio et al. (2001) in a multicentre study assessed the use of 
transvaginal uterine artery Doppler at 23 weeks gestation as screening method for the 
development of preeclampsia and IUGR. They examined 8335 women with singleton 
pregnancies and the presence of an early diastolic notch in the waveform was noted, 
and the mean PI of the two arteries was calculated. Screening characteristics in the 
prediction of preeclampsia and the delivery of a low-birth weight infant were 
calculated. The sensitivity for increased PI above the 95 th centile for preeclampsia 
with fetal growth restriction was 69%, for preeclampsia without fetal growth 
restriction was 24%, for fetal growth restriction without preeclampsia was 130/0, for 
preeclampsia irrespective of fetal growth restriction was 41 % and for fetal growth 
restriction irrespective of preeclampsia was 16%. The sensitivity for fetal growth 
restriction when defined as birth weight less than 5th rather than 10
th 
centile was 
higher (19% vs 16%). The sensitivity for both preeclampsia and fetal growth 
restriction was inversely related to the gestational age at delivery; when delivery 
occurred before 32 weeks, the sensitivity for all cases of preeclampsia with fetal 
growth restriction, preeclampsia without fetal growth restriction and fetal growth 
restriction without preeclampsia increased to 93%, 80% and 56% respectively. The 
sensitivity of bilateral notches in predicting preeclampsia and/or fetal growth 
restriction was similar to that of increased PI but the screen positive rate with notches 
(9.3%) was much higher than that with increased PI (5.1 %). They concluded that a 
one-stage colour Doppler screening program at 23 weeks identifies most women who 
subsequently develop severe preeclampsia and/or fetal growth restriction. 
Comprehensive analysis of uterine artery Doppler flow velocity waveforms for the 
prediction of preeclampsia 
Aquilina et al. (2000) evaluated the performance of different velocimetric indices of 
uterine artery flow velocity waveforms (FVW's) at 20 weeks gestation, alone or in 
combination with qualitative analysis, and established the optimum screening method 
for the prediction of preeclampsia. They studied both uterine arteries at 20 weeks 
gestation in a total of 614 primiparous women, and created receiver operator curves 
(ROC) curves for the AlB ratio, RI and systolic/early diastolic (NC) ratio for 
placental and non-placental uterine arteries, individually or in combination with the 
presence of unilateral or bilateral notches. 
The highest sensitivity (88%) and specificity (830/0) was obtained uSlllg bilateral 
notches/mean RI > or = 0.55 (50th centile) and unilateral notch/mean RI > or = 0.65 
(80th centile). Placental ve10cimetric indices performed better than mean indices but 
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the differences In sensitivity at a set false-positive rate were not statistically 
significant. 
Uterine artery Doppler screening in multiparous women 
Harrington et al. (2004) recently studied the value of second-trimester uterine artery 
Doppler in the prediction of complications resulting from uteroplacental insufficiency 
in low- and high-risk multiparous women. 628 multiparous women were examined at 
20 weeks. 458 had no known risk factors and 170 had clinically identifiable high-risk 
factors at booking. These were history of preeclampsia, small for gestational age 
(SGA) birth weight «5TH centile), placental abruption, stillbirth or early neonatal 
death. The screening efficacy of uterine artery Doppler for adverse perinatal outcome 
in low-risk multiparous women was poor and does not justify routine screening. In 
high-risk mUltiparous women, mid-trimester abnormal uterine artery Doppler 
identifies the vast majority of women who develop complications secondary to 
uteroplacental insufficiency (sensitivity 81.4%, specificity of 89.0%). Normal uterine 
artery Doppler studies in these women confers a risk of adverse outcome similar to 
that of women with an uncomplicated obstetric history. 
A study of the effect of parity on second trimester uterine artery Doppler flow 
velocity and waveforms showed that parity has a significant effect on the resistance 
index and the prevalence of early diastolic notching in the uterine artery flow 
waveforms. These findings suggest that some permanent modification may persist in 
the maternal vessels after a successful pregnancy, altering their impedance in 
subsequent pregnancies. For the prediction of severe early onset preeclampsia, uterine 
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artery Doppler indices showed a trend towards being better predictors of disease in 
nulliparous compared with parous women (Prefumo et aI., 2004). 
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1.10 Haemodynamic response of the growth-restricted fetus to hypoxia 
1.10.1 The fetus in normal pregnancy 
F etoplacental circulation 
The umbilical cord contains two arteries and a vein that branch into chorionic vessels 
that pass through the chorionic plate and are continous with the cotyledonary arteries 
and veins. These branch into villous arteries, veins and capillaries of the fetal 
cotyledons and are situated in the stroma and in the terminal villi (Boyd & Hamilton, 
1970). During pregnancy, there is a progressive change in the type of villi that 
predominate. In the first trimester, they are largely stem villi, in the second, 
intermediate, and in the third, terminal villi budding off from the intermediate villi 
(Kaufmann et aI., 1979). These small terminal villi have a large surface area to 
volume ratio for efficient gas and nutrient exchange. The placenta has an initial 
reparative response to ischaemia. Reduced maternal blood supply leads to a 
proliferation of cytotrophoblastic cells and a thickening of the basement membrane 
(Fox, 1983). 
Fetal Circulation 
The combined output of the fetal heart at 30 weeks is approximately 550 mIs/minute 
(Reed, 1987). About 400 mls/minute passes through the thoracic aorta (Griffin et aI., 
1985), and the remainder supplies the head and neck. About 500/0 of aortic flow is in 
tum directed immediately back to the placenta via the umbilical arteries representing 
approximately 40% of the fetal cardiac output. The well-oxygenated venous return 
from the placenta passes in the umbilical vein. In the liver, umbilical venous blood 
flow is divided, with half the blood passing into the ductus venosus, and the rest 
draining into the portal system and hepatic veins. 
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Fetal oxygenation 
Oxygenation is the process of transporting molecular oxygen from air to the tissues of 
the body. In the fetus, this involves, first, oxygen transfer across the placental, second, 
reversible binding of oxygen to fetal haemoglobin and fetal blood flow, and third, 
oxygen consumption for growth and metabolism. 
In normal fetuses, the blood oxygen tension is much lower than the maternal, and it 
has been suggested that this is due either to incomplete venous equilibration of uterine 
and umbilical circulation and/or high placental oxygen consumption (Soothill et al., 
1986(b); Nicolaides et al., 1989). Studies in a variety of animals have also 
demonstrated that the umbilical venous blood p02 is less than half the maternal 
arterial p02 and this has led to the concept of "Mount Everest in utero". However, the 
high affinity of fetal haemoglobin for oxygen, together with high fetal cardiac output 
in relation to oxygen demand, compensates for the low fetal p02 (Battaglia & 
Meschia, 1986). 
Fetal Hypoxia 
Small-for-gestational age fetuses may be constitutionally small, with no increased 
perinatal death or morbidity, or they may be growth-restricted due to many causes 
(see above). One of which is reduced placental perfusion (i.e. uteroplacental 
insufficiency) . 
Cross sectional studies in pregnancies with growth-restricted fetus have shown that 
increased impedance to flow in the uterine and umbilical arteries is associated with 
fetal hypoxaemia and acidaemia (Soothill et al., 1986(a); Nicolaides et al., 1988). 
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These data support the findings from histoplathological studies that, In some 
pregnancies with small-for-gestational age fetuses, there are: 
Failure of the normal development of maternal placental arteries into low-resistance 
vessels and therefore reduced oxygen and nutrient supply to the intervillous space 
(Brosens et aI., 1972). 
Reduction in the number of placental terminal capillaries and small muscular arteries 
in the tertiary stem villi and therefore impaired maternal-fetal transfer (Giles et aI., 
1985) (see above). 
Animal studies have demonstrated that, in fetal hypoxaemia, there is redistribution in 
blood flow, with increased blood supply to the brain, heart and adrenals and a 
simultaneous reduction in the perfusion of gut and kidneys (Peeters et aI., 1979). 
Doppler ultrasound has enabled the non-invasive assessment of the fetal 
haemodynamic response to hypoxia. 
1.10.2 Doppler assessment of fetal circulation in IUGR 
Arterial circulation 
Pathological studies have demonstrated that increased impedance in the umbilical 
arteries becomes evident only when at least 600/0 of the placental vascular bed is 
obliterated (Giles et al., 1985). In pregnancies with reversed or absent end-diastolic 
frequencies (EDF) in the umbilical artery, compared to those with normal flow, mean 
placental weight is reduced and cross-sectional diameter of terminal villi is smaller 
(Karsdorp et a/., 1996). In pregnancies with fetal growth restriction, those with absent 
EDF, compared to those with normal Doppler, have more fetal stem vessels with 
medial hyperplasia and luminal obliteration, and those with reversed EDF have even 
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more poorly vascularised terminal villi, villous stromal haemorrhages, "haemorrhagic 
endovasculitis" and abnormal thin-walled fetal stem vessels (Salafia et aI., 1997). 
Clinical studies of umbilical arterial flow velocity waveform in IUGR have reported 
progressive increase in impedance to flow until absence and, in extreme cases, 
reversal of EDF (Figure 1.5). The latter represents the extreme end of the spectrum 
and this finding is associated with a high perinatal mortality, as well as an increased 
incidence of lethal fetal structural and chromosomal defects (Todros et aI., 1999; 
Trudinger et aI., 1985). 
In terms of monitoring IUGR pregnancies, abnormal waveforms in the umbilical 
artery are an early sign of fetal impairment. Bekedam et al. (1990) followed up IUGR 
fetuses longitudinally and reported that abnormalities in the umbilical artery preceded 
the occurrence of cardiotocographic signs of fetal hypoxaemia in more than 90% of 
cases. The median time interval between absence of EDF and the onset of 
decelerations was 12 days (range 0-49 days). 
Fetal arterial blood flow redistribution 
In fetal hypoxaemia, there is an increase in the blood supply to the brain, myocardium 
and the fetal adrenal glands and reduction in the perfusion of the kidneys, 
gastrointestinal tract and lower extremities (Figures 1.6 & 1.7) (Harrington et aI., 
1999). Although knowledge of the factors governing circulatory readjustments and 
their mechanism of action is incomplete, it appears that partial pressures of oxygen 
and carbon dioxide play a role, through their action on chemoreceptors. This 
mechanism allows preferential delivery of nutrients and oxygen to vital organs, 
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thereby compensating for diminished placental resources. However, compensation 
through cerebral vasodilatation is limited and a plateau corresponding to a nadir of PI 
in cerebral vessels is reached at least 2 weeks before the development of the fetus is 
jeopardised (Arduini et al., 1992). Vyas et al. (1990) reported that in severe IUGR, 
and concomitant to severe oxygen deficit, there was a sudden rise in middle cerebral 
artery PI; they suggested that vascular dilatation may be suppressed by the 
development of cerebral oedema, or a consequence of alterations in flow due to 
reduced cardiac contractility and a fall in absolute cardiac output. Consequently, 
arterial vessels are unsuitable for longitudinal monitoring of the growth-restricted 
fetus. Venous velocity waveforms give more information regarding fetal well-being or 
comproIllise. 
Fetal arterial Doppler studies are useful in the differential diagnosis of normal small 
for gestational age (SGA) fetuses from growth-restricted ones. In the hypoxaemic 
group, due to impaired placental perfusion, the PI in the umbilical artery is increased, 
in the fetal middle cerebral artery, the PI is decreased; consequently, the ratio in PI 
between the umbilical artery and middle cerebral artery (UAlMCA) is increased 
(Hecher et al., 1992). 
Fetal venous Doppler 
Animal studies have shown that, in severe hypoxaemia, there is redistribution in the 
umbilical venous blood towards the ductus venosus at the expense of hepatic blood 
flow contributing to the fetal cardiac output is increased (Reuss & Rudolph, 1980). 
Under unfavourable conditions, the ductus venosus seems to ensure blood flow 
directly to the fetal heart and, in extreme conditions, umbilical blood may pass 
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exclusively through the ductus venosus. During hypoxaemia and increased cardiac 
afterload, studies in fetal sheep showed an increase in peak systolic forward flow, and 
during atrial contraction retrograde flow occurs. In contrast, reductions in afterload 
are associated with an increase in peak diastolic forward flow, indicating that fetal 
systemic vascular resistance has a major influence on venous return and filling 
patterns of the right heart (Reuss et aI., 1983). This means that increased placental 
resistance and peripheral vasoconstriction, as seen in fetal arterial redistribution, cause 
an increase in right ventricular afterload, and thus ventricular end-diastolic pressure 
increases. This may result in highly pulsatile venous blood flow waveforms and 
umbilical venous pulsations due to transmission of atrial pressure waves through the 
ductus venosus (Kiserud et aI., 1998). The development of these pulsations is close to 
the onset of abnormal fetal heart rate patterns and is frequently associated with 
acidaemia and fetal endocrine changes (Rizzo et ai., 1995). In the ductus venosus on 
the other hand, Colour Doppler examination in the severely hypoxaemic IUGR fetus 
shows abnormal waveforms with absent or reversal of flow during atrial contraction 
and markedly increased pulsatility (Hecher & Hackeloer, 1997) (Figure 1.8). 
Fetal venous Doppler studies are useful in monitoring the IUGR redistributing fetus. 
Normal venous flow suggests continuing fetal compensation, whereas abnormal flow 
indicates the breakdown of haemodynamic compensatory mechanisms. In a study of 
41 fetuses displaying arterial blood flow redistribution, Hecher & Hackeloer (1997) 
showed that, while there were no differences in arterial PI values between fetuses with 
normal and abnormal biophysical profile, venous pulsatility was significantly 
increased in compromised fetuses compared to the non-compromised group. 
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Figure 1.5 Flow velocity waveforms from the umbilical artery in a growth-restricted 
fetus demonstrating progressive deterioration from normal waveform (top) to low but 
positive diastolic flow, absent and finally reversed end-diastolic flow (bottom). 
Figure 1.6 Colour Doppler examination of the circle of Willis (left). Flow velocity 
waveforms from the middle cerebral artery in a normal fetus with low diastolic 
velocities (right, top) and in a growth-restricted fetus with high diastolic velocities 
(right, bottom). 
Figure 1.7 Colour Doppler examination of the descending aorta (left) with normal 
flow velocity waveforms showing positive flow velocities during diastole (right, top) 
and in a growth-restricted fetus with reversed end-diastolic velocities (right, bottom). 
Figure 1.8 Colour Doppler examination of the ductus venosus with normal flow 
velocity waveforms (top). Abnormal waveform with reversal of flow during atrial 
contraction and markedly increased pulsatility in a growth restricted fetus (bottom). 
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1.10.3 Timing of delivery 
In the management of the very preterm (before 33 weeks of gestation) IUGR fetus, 
there is still uncertainty as to whether iatrogenic delivery should be undertaken before 
the development of signs of severe hypoxaemia, with a consequent risk of 
prematurity-related neonatal complications, or whether delivery should be delayed, 
but the risks of prolonged exposure to hypoxia and malnutrition imposed by placental 
insufficiency. Fetuses with severe early-onset growth restriction during the late 
second or early third trimester are capable of tolerating chronic hypoxaemia without 
damage for much longer than a well-nourished late third-trimester fetus with a high-
energy consumption. 
In the growth-restricted hypoxaemic fetus, redistribution of well-oxygenated blood to 
the vital organs, such as the brain, heart and adrenals, represents a compensatory 
mechanism to prevent fetal damage. When the reserve capacities of the circulatory 
redistribution reach their limits, fetal deterioration may occur rapidly. In clinical 
practice, it is necessary to carry out serial Doppler investigations to estimate the 
duration of fetal blood flow redistribution. The onset of abnormal venous Doppler 
results indicates deterioration in the fetal condition and iatrogenic delivery should be 
considered. During the current study, we followed the above general guidance in 
timing the delivery of the preterm fetuses with IUGR with or without preeclampsia. 
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1.11 Summary and aims of current study 
In discussing preeclampsia in 1939, Johnstone concluded that "no completely 
satisfactory explanation of the disease or source of the toxin can as yet be offered" 
and this conclusion is no further advanced today (Johnstone 1939). It is difficult to 
construct a unifying hypothesis. However, the primary event in preeclampsia appears 
to be abnormal trophoblastic invasion early in pregnancy. Maternal genotype and fetal 
phenotype may confer susceptibility and as a result the maternal immunological 
response to fetal antigen is abnormal. The resulting hypoperfused placenta secretes a 
factor into the maternal circulation, which targets the vascular endothelium and gives 
rise to the clinical sequelae of the disease. The nature of this factor( s) remains unclear 
and the effect on endothelial function at cellular level has not been fully elucidated. 
The balance between VEGF and its inhibitors playa fundamental role in maintaining 
vascular endothelial integrity. Disturbance in this balance, such as overexpression of 
sFltl may tip the balance towards generalised endothelial dysfunction such as that 
seen in preeclampsia. Recent evidence suggests that placental expression of molecules 
such as Flt1, PIGF, Fas and FasL is altered in preeclampsia. However, the exact role 
of these molecules in cases of abnormal placentation is far from clear. 
Therefore the aims of the work carried out in this thesis are: 
1. Compare mid-trimester serum levels of sFlt, PIGF, Fas and FasL in pregnancies 
with abnormal mid-trimester uterine artery Doppler that subsequently develop 
preeclampsia, normotensive IUGR and normal outcome. 
2. Establish the correlation between the resistance indices of the uterine arterY 
Doppler and the above serum markers at 24 weeks. 
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3. Compare serum levels of these markers in preeclampsiC4 nonnotensive IUGR and 
controls. 
4. Assess placental expression of FIt!, PIGF, Fas and FasL in cases of preeclampsia, 
normotensive IUGR and control pregnancies. 
1 L~ 
MATERIALS AND METHODS 
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2.1 Ethical approval 
Ethical approval was obtained from East London and the City Research Ethics 
Committee and the Homerton Hospital local research committee prior to 
commencement of the study. Written informed consent was obtained from all women 
participating in the study by the investigator and written patient information sheets 
were given to them. The patients' General Practitioner (GP) was informed of the 
patients' participation in the study. 
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2.2 Patient Selection 
Uterine artery Doppler examination 
553 healthy pregnant women were examined uSIng uterine artery Doppler at 24 
weeks. Among these, there were 395 primiparous and 158 multiparous women. 
Gestational age was determined by means of ultrasound examination at 10-12 weeks. 
All primigravid women and multiparous women with previous pregnancy 
complication (see table) attending for routine anomaly scans at 20 weeks were offered 
uterine artery Doppler examination at 23-24 weeks. 
Table 2.1 Risk factors In mUltiparous women who were offered uterine artery 
Doppler examination 
• History of hypertension in pregnancy, 
• History of delivery of small baby, 
• History of placental abruption, 
• History of stillbirth, 
• History of previous neonatal death. 
Among women who underwent uterine artery Doppler flow examination, 97 women 
had abnormal result defined as above. 63 women were primiparous and 34 were 
multiparous. Eleven women did not attend for follow up (dropped out). The remaining 
86 women were enrolled in the study after obtaining appropriate consent and giving 
them information leaflets. Only women with complete outcome information were 
enrolled in this study. Seven women developed intrauterine growth restriction, 
defined as fetal biometry measures less than the 5th centile for gestational age and 
associated abnormal umbilical artery Doppler or serial fetal growth measurements 
crossing the growth centiles with evidence of redistribution on middle cerebral artery 
Doppler examination. Eight women developed preeclampsia «36 weeks to match the 
IUGR group) defined according to the ISSHP. For each woman with preeclampsia, 
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two normotensive controls with delivery at term of a normally grown infant were 
selected. 
Serial growth scans and Doppler 
Women enrolled in the study were followed up on a fortnightly basis (and more 
frequently if abnormality was detected) until delivery. Uterine artery Doppler flow 
examination and serial fetal biometry growth scans including head circumference 
(HC), abdominal circumference (AC) and femur length (FL) were performed in each 
visit and plotted on fetal growth charts produced by Snijders and Nicolaides (1994). 
Maternal blood pressure (BP) and urine check for protein was done in each visit. If 
there was evidence of proteinurea on urine dipstick examination, then 24-hour urine 
collection for protein was performed. 
Fetal Doppler examination was performed if there is SUspICIon of fetal growth 
restriction. This included umbilical artery, middle cerebral artery and fetal aorta. 
Ductus venosus (DV) Doppler was performed in cases where there is evidence of 
IUGR and fetal arterial redistribution with absent end-diastolic flow (EDF) in 
umbilical artery Doppler examination (see below). 
2.3 Techniques of Doppler examination 
All Doppler studies were done by the investigator USIng ATL 5000 ultrasound 
machine with a 3.5-MHz probe colour flow mapping, and a 100-Hz high-pass filter. 
The quality of the velocity waveforms was maximized by using the smallest possible 
angle of insonation « 30 degrees). At least four consecutive waveforms with clear 
sharp outline were obtained in each Doppler measurement. The RI and PI were 
calculated using built-in calibration in the machine. 553 women were examined using 
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uterine artery Doppler at 24 weeks. They were 395 primiparous and 158 multiparous 
women. 
Uterine arteries 
Uterine artery Doppler examination was performed with the transabdominal approach, 
by placing the transducer in the relevant iliac fossa. After that, the course of the 
uterine artery was followed from the lateral pelvic wall, across the external iliac 
artery. Pulsed Doppler was then applied I-cm medial to the cross over point and with 
a Doppler angle<30 degrees to obtain accurate flow velocity waveforms. In addition 
to PI and RI, the presence or absence of a notch was noted in each of the waveforms 
in both uterine arteries. A notch was considered to be present when there was a clearly 
defined upturn of the flow velocity waveform at the beginning of diastole, which was 
present in all waveforms. Each uterine artery was sampled twice and the same 
operator performed all measurements. Abnormal uterine artery Doppler was defined 
as flow velocity waveforms with bilateral notches and mean RI > 0.55, or unilateral 
notch and mean RI > 0.65 (Aquilina et al2000). 
Umbilical artery 
The umbilical artery waveform was measured from a free-floating loop of cord during 
fetal quiescence. Generally signal was obtained from both the umbilical artery and 
vein, following the above methodology. Three types of flow waveforms were 
identified: 
1. Normal PI and RI and normal end diastolic flow (EDF). 
2. High PI and RI (>90th centile for GA) with positive EDF. 
3. Absent or reversed EDF. All these cases had high PI and RI. 
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Middle cerebral artery (MeA) 
A cross section through the fetal head at the level used for biparietal diameter 
measurement was obtained. The transducer was then moved caudally and the circle of 
Wellis was identified. The course of the MeA was identified using colour flow 
mapping. The course of the vessel allows optimum angles of insonation for obtaining 
accurate flow velocity waveforms. Pulsed Doppler was used and PI and RI were 
measured using, built in calibrations. The evidence of arterial redistribution was noted 
and abnormal MeA Doppler was defined as PI and/or RI less than the 5th centile for 
gestational age. 
Fetal aorta 
Doppler flow waveforms from fetal aorta were obtained using the same principles as 
above. Because of the position of the aorta in fetal body, Doppler measurements 
necessitated angling of the ultrasound probe to maintain the insonation angle less than 
30 degrees. Three types of flow waveforms were identified: 
1. Normal PI and RI and normal end diastolic flow (EDF). 
2. High PI and RI (>90th centile for GA) with positive EDF. 
3. Absent or reversed EDF (AREDF). All these cases had invariably high PI and RI. 
Ductus venosus (DV) Doppler 
The course of the ductus venosus as it courses through the liver between the umhilical 
vein and the right atrium was identified using colour flow mapping. Both cross 
sectional and longitudinal views of the DV were obtained and pulsed Doppkr was 
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obtained when the fetus was quiescent. Presence, absence or reversal of "a wave" was 
noticed in the flow waveforms. DV Doppler was only performed in cases of IUGR 
with evidence of fetal compromise on arterial Doppler examination. 
Doppler measurements from MCA, fetal aorta and ductus venosus were obtained to 
assess fetal well-being and timing of delivery. 
2.4 Blood collection 
Blood was collected from the 86 women with abnormal mid-trimester uterine artery 
Doppler examination during the same visit (24 weeks) after obtaining appropriate 
consent and serum was stored at -80C for further assay (see below). Blood was 
collected again from these women within 24 hours of delivery and serum was stored 
at -80C for further assay. Placental samples were obtained at the time of delivery and 
stored at -80C for further analysis (see below). Serum and placental samples were 
obtained from normotensive gestational age matched controls with appropriately 
grown fetuses delivered by Caesarean Section using similar protocols and stored at -
80C for further analysis. 
5 ml of blood was collected in a sterile vacuum tube and allowed to stay in room 
temperature for 30 minutes to allow clot to form. Serum was separated by 
centrifugation at 1500 g/minute for 10 minutes at 4C and kept in aliquots at -80C until 
further assay. Assays were performed for Fas, Fas Ligand, sFltl and PIGF in the 
samples collected. Specimens were randomly ordered for analysis. and the clinical 
outcome of pregnancy was not known whilst performing the assay. 
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2.5 Placental sample collection 
3-5 cotyledons from the maternal side of the placenta were collected from women 
enrolled in the study. Placental samples were exclusively collected from women who 
underwent Caesarean delivery (both cases and controls) to avoid the potential effect 
labour could have on placental expression of the studied antigens. The samples were 
collected immediately after delivery and washed with normal saline three times. then 
snap frozen in liquid nitrogen. After that, samples were immediately stored at -80C 
for further analysis. Immunohistochmeistry was performed for Fas and FasL. Western 
blotting was performed for Fas, Fas Ligand, FIt 1 and PIGF. 
2.6 Enzyme Linked Immune Sorbent Assay (ELISA) 
2.6.1 Soluble Fas ELISA 
Principle 
We used the sFas ELISA kit (Medical and Biological Laboratories MBL, Nagoya, 
Japan), Code no. 5251, to measure sFas protein by sandwich ELISA. The assay uses 
Fas antibodies against two different epitopes. One of the antibodies is polyclonal and 
recognizes intracellular domain (No. 305-319), and another one is momoclomal 
antibody and recognizes extracellular domain (No. 110-120 a.a.). 
In the wells coated with anti-Fas polyclonal antibody, samples to be measured or 
standards are incubated. After washing, a peroxidase conjugated anti-Fas monoclonal 
antibody is added in the microwell and incubated. After another washing. the 
peroxidase substrate is mixed with the chromagen and allowed to incubate for an 
additional period of time. An acid solution is then added to each well to terminate the 
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enzyme reaction and to stabilize the developing colour. The optical density (0.0.) of 
each well is then measured at 450 nm using a microplate reader. The concentration of 
sFas is calibrated from a dose response curve based on reference standards. 
2.6.2 Soluble FasL ELISA 
Principle 
We used the sFasL ELISA kit (Medical and Biological Laboratories MBL, Nagoya, 
Japan), Code no. 5255, to measure sFasL protein by sandwich ELISA. The assay uses 
FasL antibodies against two different epitopes. In the wells coated with anti-Fas 
ligand monoclonal antibody, 4H9, samples to be measured or standards are incubated. 
After washing, a peroxidase conjugated anti-Fas Ligand monoclonal antibody, 4A5, is 
added in the microwell and incubated. After another washing, the peroxidase substrate 
is mixed with the chromagen and allowed to incubate for an additional period of time. 
An acid solution is then added to each well to terminate the enzyme reaction and to 
stabilize the developing colour. The optical density (O.D.) of each well is then 
measured at 450 nm using a microplate reader. The concentration of sFas Ligand is 
calibrated from a dose response curve based on reference standards. 
2.6.3 Soluble sFltl ELISA 
This assay employs the quantitative sandwich enzyme immunoassay technique. A 
monoclonal antibody specific for VEGF R 1 has been pre-coated onto a microplate. 
Standards and samples are pi petted into the wells and the immobilized antibody binds 
any VEGF R 1 present. After washing away any unbound substances, an enzyme-
linked polyclonal antibody specific for VEGF R 1 is added to the wells. Following a 
wash to remove any unbound antibody-enzyme reagent, a substrate solution is added 
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to the wells and color develops in proportion to the amount of VEOF R 1 bound in the 
initial step. The color development is stopped and the intensity of the color is 
measured. 
2.6.4 Soluble PIGF ELISA 
This assay employs the quantitative sandwich enzyme immunoassay technique. A 
monoclonal antibody specific for PI OF has been pre-coated onto a microplate. 
Standards and samples are pipetted into the wells and the immobilized antibody binds 
any PIOF present. After washing away any unbound substances, an enzyme-linked 
polyclonal antibody specific for PI OF is added to the wells. Following a wash to 
remove any unbound antibody-enzyme reagent, a substrate solution is added to the 
wells and color develops in proportion to the amount of PIOF bound in the initial step. 
The color development is stopped and the intensity of the color is measured. 
2.7 WESTERN BLOTTING 
2.7.1 Homogenisation of placental samples 
Into a 1.5ml microfuge tube, 2.3mg dithiothreitol and 4.6mg ~-glycerophosphate were 
weighed out. 1.5ml Homogenisation Buffer (H.B.) were pipetted into the microfuge tube, 
followed by 75J..LI protease inhibitors (one aliquot). The solution was subsequently vortexed. 
100J..LI of H.B. were applied to clean Duall glass tissue grinders. Approximately 10-15 mg of 
tissue, stored in the -80C freezer, were homogenised in the tissue grinders, on icc. The 
homogenate was pipetted into a labelled 1.5ml microfuge tube, and any excess tissue, in the 
grinder, was ground up in a further 50J..L1. Once complete, approximately 50J.lI of H.B. were 
pipetted down the sides of the grinder, to remove any protein adhered to the glass. The 
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homogenate was removed and pooled with the homogenate from the initial grind. The 
process took 15-20 minutes per sample. 
Each homogenate was centrifuged at 13,000 x g (11,700 rpm in a Herous Biofuge pico) for 
five minutes. The supernatants were decanted into fresh 1.5ml microfuge tubes, and the 
pellets were either discarded or re-suspended in Homogenisation Buffer (H.B.). 
The protein concentration of each sample was estimated by performing a Lowry assay. The 
following standard curve was set up, using 1.5ml microfuge tubes. Standards were 
duplicated, whilst unknowns were repeated a further four times. 
1.5 mg/ml BSA(JlI) dH20 (JlI) H.B. (Jll.) Sample (Jl1.) [Protein] (Ilgl,.ll, 
0 27 3 0 0.00 
2 25 3 0 1.0 
5 22 3 0 2.5 
10 17 3 0 5.0 
15 12 3 0 7.5 
20 7 3 0 10.0 
0 27 3 3 Unknown 
Bio-Rad Dc Protein Assay reagents A, B and S were subsequently added, in the 
following quantiles, to each microfuge tube. (20111. of reagent S were added to each 
ml of reagent A): 
1. 150JlI of reagents AlS per tube+vortexed. 
2. 1200JlI. of reagent B per tube + vortexed immedaitely. 
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The solutions were transferred to cuvettes, and the absorbance read after 5 minutes , 
using a Jenway Genova spectrophotometer, set at a wavelength absorbance of 750nm. 
The protein concentration of each sample was subsequently determined using the 
Graph Pad Prism 3.0 computer software. Following the addition of x2 Laemmli 
Sample buffer (4% SDS, 200/0 glycerol, 10% 2-mercaptoethanol, 0.004% bromphenol 
blue, 0.125M Tris-HCI, pH 6.8) in a 1:1 ratio, the samples were heated at 100C for 10 
minutes and stored at -20C 
2.7.2 SDS·Electrophoresis 
Preparation for Electrophoresis & Western Blotting 
1. Before casting the electrophoresis gel all the apparatus were cleaned with Purite 
Select deiodinised water (dH20) and dried using paper towel. 
600ml of electrode / running buffer were prepared by combining 120 ml of 5X 
electrode / running buffer (see figure 2.1) with 480 ml of deiodinised water. 
Figure 2.1 Preparation of 5X electrode / running buffer, pH 8.3 
Tris base 9g ( 15g1l) 
Glycine 43.2g (72g/l) 
SDS 3g (5g/l) 
The running buffer was stored at 4C (i.e in the fridge). 
2 Blotting buffer was prepared (3.03g Tris-base, 14.4g glycine, 200ml methanol 
per litre, pH 8.3) in advance and stored at 4C (i.e. in the fridge). The pH should 
be -8.3. Neither acid nor base was added to adjust the pH. 
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3 The Bio-Ice cooling unit, full of deionised water, was placed in a -2OC freezer 
overnight. 
Assembling the Glass Plate sandwiches 
SDS-Electrophoresis was performed through the use of the Bio-Rad Mini-Protean II 
electrophoresis system. These instructions were adapted from the Mini-protean II 
Electrophoresis Cell instruction manual. 
1. The gel sandwich was assembled on a clean surface. The longer glass plate 
was laid on the surface first. Two spacers (1.5mm thick) were placed on each 
of the shortest sides of the glass plate. The shorter glass plate was then placed 
on top of the spacers, in alignment with the bottom of the longer glass plate 
and spacers. 
2. The four screws on the clamp assembly were loosened, to allow the insertion 
of the glass plate gel sandwich. The clamp assembly was then stood upright, 
with the screws facing away from the operator. The glass plates were slid 
gently alongside the acrylic pressure plate of the clamp assembly, on the side 
opposing the four screws. 
3. The clamp assembly was placed into the alignment slot of casting stand, so 
that the clamp screws faced away from the operator. The bottom of the two 
glass plates and spacers were then allowed to align along the base of the 
alignment slot. Next, the alignment card was slide between the glass plates 
and spacers to ensure a parallel alignment of spacers. Finally the two pairs of 
clamp screws were gently tightened. 
4. Following the removal of the alignment card, the alignment of the bottoms of 
the glass plate, spacers and clamp assemly was checked by eye. All three 
126 
surfaces were therefore flush. The complete sandwich clamp assembly was 
transferred to the casting slot on the opposite side of the casting stand from the 
alignment slot. The bottom of the clamp assembly/glass plates formed a seal 
with the grey silicon gaskets at the base of the casting slots. 
5. In order to cast a second gel, steps 1-4 were repeated, but the complete 
sandwich clamp assembly was transferred to the casting slot on the same side 
of the alignment slot. 
Casting the Discontinous Polyacrylamide Gels 
A discontinous polyacrylamide ge system was used which consisted of a seperating 
gel (lower gel) and stackingf gel (upper gel). Discontinous gel systems allow better 
resolution of proteins than continous polyacrylamide gels, which employ only one 
continous gel, due to differing acidities of the stacking gel (pH 6.8) and seperating gel 
(pH 8.8). This sudden change in pH causes the proteins of similar molecular masses 
to 'bunch together' , therefore aiding resolution. 
1. A 1.5 mm comb was placed in between the two glass plates of each glass plate 
sandwich. A marker pen was then used to draw a line 0.5 mm below the teeth 
of the comb. The comb was subsequently removed. 
2. A 10% or 7.5% acrylamide separating gel solution was prepared by 
combining the components listed in figure 2.2. 
Figure 2.2 Preparation of 10% and (7.5%) Separating Gel Solutions 
Deiodinized water 8.1 ml (9.7 ml) 
1.5 M Tris-HCI, pH 8.8 5.0 ml (5.0 ml) 
10% (w/v) SDS stock 200 ul (200 ul) 
127 
(stored at room temperature) 
AcrylamidelBis (30% stock) 
Vortexed 
6.6ml 
10% ammonium persulfate (APS) 100 ul 
(i.e. 100mglml, fresh daily) 
TEMED 10ui 
Total volume 20 ml 
Vortexed 
(5.0 ml) 
(100 ul) 
(10 ul) 
(20 ml) 
3. Upon the addition of APS and TEMED the solution sets. To cast the 
separating gel, the separating gel solution was poured between the two glass 
plates of the gel sandwiches, down the side of one of the spacers, using a 
disposable Pasteur pipette. The solution was poured up to the drawn lines. 
This procedure was carried out slowly to prevent mixing the solution with air 
bubbles. 
4. The solution was immediately overlaid with a layer of deionised water. The 
separating gel solution was left to set for 30 minutes. 
5. A 4% stacking gel solution was prepared by combining the components listed 
in Figure 2.3. 
Figure 2.3 Preparation of Stacking Gel Solution 
Deionised water 6.1 ml 
0.5 M tris-HCI, pH 6.8 2.5 ml 
10% (w/v) SDS 
Acrylamidelbis (30% stock) 
Vortexed 
100 ul 
1.33 ml 
100/0 ammonium persulfate (APS) 50 ul 
TEMED 10ul 
Total volume 10 ml 
Vortexed 
6. The layers of deionised water, overlaying the separating gels, were removed 
using absorbent paper towel. Upon the addition of APS and TEMED the 
solution sets. Thus the solution was immediately poured between the glass 
plates, down the side of a spacer, using Pasteur pipette. 
7. A comb (1.5 mm thick) was placed into the top of each stacking gel. The 
stacking gel solutions were then left to set for 20 minutes. The hot block was 
set at 40c, in preparation for the Kaleidoscope markers. 
8. The comb was slowly removed upwards. The areas where the teeth of the 
comb had penetrated the surface of the stacking gel solution later served as 
sample loading wells. 
9. The loading wells were rinsed with deionised water. The gels were then ready 
to clip onto the inner cooling core. 
Assembling the upper buffer chamber 
1. Initially, the cleanliness of the grey U-shaped inner cooling core gaskets was 
inspected, to prevent leakage. 
2. The clamp assemblies/gel sandwiches were then released from the casting 
stand. 
3. With the inner cooling core lying flat on a clean surface, a clamp assembly/gel 
sandwich was clipped into position onto the inner cooling core. This was 
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achieved by sliding the clamp assembly wedges under the locator slots on the 
top of the inner cooling core, with the assembly screws facing outward and the 
glass plates facing the cooling core, until the base of the clamp assembly 
clipped into the cooling core latch. 
4. The inner cooling core was turned over and another clamp assembly/gel 
sandwich was clipped onto this side of the inner cooling core. 
Loading the samples 
1. The inner cooling core, complete with attached clamp assemblies, was 
inserted into the Mini-Protean II cell. The upper buffer was then filled with 
electrode/running buffer. The remainder of the electrode / running buffer was 
poured into the lower buffer chamber, until at least 1 cm of the gel bases were 
covered in buffer. N.B. It was important to ensure that the upper buffer 
chamber was full before loading the samples. If the upper buffer chamber 
leaked, the chamber was only re-filled once the samples had ran into the 
gel, i.e. to avoid displacement of the samples from the wells. The hot block 
was set to 100C and the samples were boiled for 10 minutes. 
2. Set volumes of the homogenised myometrial samples (containing known 
amounts of total protein) were loaded into each sample loading well, at the top 
of the stacking gel, using a 2-20 ul HTL Lab Mate pipette and long, fine 
pipette tips. The volumes of samples to be loaded, for a given total amount of 
protein, was determined by the following equation: 
Volume loaded (ul) = Amount (ug) / Concentration (ug/ul) 
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A solution of standard marker proteins, of known molecular masses, was then 
applied to one of the sample loading wells. A few drops of bromphenol blue 
were also added to the upper buffer chamber. 
3. The lid was placed on top of the Mini-Protean II cell, ensunng that the 
colours of the plugs on the lid matched the colours of the jacks on the inner 
cooling core. 
4. The electrical leads, leading from the lid, were attached to a Bio-Rad Power 
Pac 300. 
5. In order to run the samples into and through the gels, a constant current was 
applied across the gels. The current applied was 30mAlgei (i.e. 60 rnA for two 
gels), which resulted in a voltage of approximately 200V, therefore the 
voltage was set to 300V. Once the samples had ran into the Separating gel, the 
currant was increased to 40mAlgei (i.e. 80 rnA for two gels). The voltage will 
decrease at this step. 
Removing the gel 
1. At the end of the electrophoresis run, the power supply was turned off and the 
electrical cables were disconnected from the power pack. 
2. After the removal of the Mini-Protean II cell lid, the inner cooling core was 
removed from the cell and the lower and upper buffer chambers were 
decanted. 
3. The inner cooling core was laid horizontally and the clamp assemblies 
detached by pushing the cooling core latch downwards and up on the clamp 
assembly. 
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4. The clamp assembly screws were loosened and the glass plate gel sandwiches 
were slid out from the clamp assembly. 
5. To access each gel, one of the spacers was removed and the upper plate was 
gently prised off using a thumb. The gel stuck to one of the glass plates. 
6. The stacking gel was removed with a scalpel blade. The bottom left hand 
comer of the gel was removed to orientate the gel. 
7. The gel was detached from the glass plate by gentle agitation with a thumb, 
either immersed under blotting transfer buffer or in dry conditions. If the 
protein in the gel was to be Western blotted, then the gel was allowed to 
equilibrate for 30 minutes, submerged in blotting buffer, as SDS-gels often 
shrink in blotting buffer (see Section 4.2). 
Gel Staining 
Occasionally it is desirable to visualise the total protein profile, separated in gels 
during electrophoresis. This may be to check protein separation, or it can be 
conducted after Western blotting (see Section 4), to determine the extent of 
protein transfer from a particular gel. One such stain is Coomassie Blue/ Brilliant 
Blue: 
1. Gels were immersed separately in Brilliant Blue R (0.25% (w/v) brilliant blue 
R, 40% (v/v) methanol, 7% (v/v) acetic acid) overnight, with gentle agitation, 
in suitable plastic containers. 
2. The Brilliant Blue R stain was decanted. To increase the contrast between 
stained proteins and gel, i.e. to remove background, the gel was de-stained in 
a solution consisting of 40% methanol and 10% acetic acid, for 1 to 3 hours, 
with several changes of the de-stain solution. 
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2.7.3 Western blotting 
Western blotting was performed through the use of the Bio-Rad Mini Trans-Blot 
Electrophoresis Transfer Cell. All the equipment, including the Mini Trans-Blot 
Cell, gel cassettes and fibre pads were initially rinsed in deionised water. 
Preparation for blotting 
1. PVDF membranes were used, onto which the separated proteins were blotted 
from the gels. PVDF membranes, and filter papers, were cut to the same 
dimensions as fibre pads. The PVDF membrane was 'activated' by immersion 
in methanol, which allows the proteins to bind to the membrane. The PVDF 
membranes were only handled whilst wearing latex gloves and using forceps. 
2. Acrylamide gels shrink in blotting buffer, therefore the gels and membranes 
were soaked in blotting buffer (in a plastic tray) for 30 minutes to allow them 
to equilibrate. 
3. The Bio-Ice cooling unit was inserted into the buffer chamber, a few minutes 
before the blotting procedure began. A magnetic flea was also placed in the 
centre, at the bottom, of the chamber. The blotting chamber was then placed 
on top of a magnetic stirrer. 
Assembly of the Gel Holder Cassette 
1. The fibre pads were submerged in blotting buffer, and any air bubbles were 
removed by compressing the pads, e.g. with a 5ml pipette tip. 
2. The gel holder cassette was opened by sliding and lifting the latch. Once the 
gel holder cassette was immersed in blotting buffer, a bubble-free buffer 
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saturated fibre pad was laid in the centre of the open cassette, followed by a 
piece of filter paper. 
3. A piece of methanol-activated PVDF membrane was then placed on top of the 
filter paper, followed by the gel, another piece of filter paper and the other 
saturated fibre pad. Whilst inserting the different layers, care was taken to 
exclude any possible trapped air bubbles in the blotting sandwich. 
4. The cassette was then closed over and fastened. The cassette was held firmly 
during closure, thereby minimising movement, and subsequent miss-
alignment, of the different sandwich layers. 
5. The buffer tank was half filled with blotting buffer. An electrode module was 
then placed vertically into the buffer tank, followed by the insertion of the 
blotting sandwich into the immersed electrode module. The electrode module 
is colour coded to distinguish the anode from the cathode. The sandwich was 
inserted with the membrane facing the red (+) anode portion of the electrode 
module, whilst the gel faced the black (-) cathode. Thus the negatively 
charged proteins moved out of the gel, towards the anode, and bound to the 
PVDF membrane during the blotting procedure. 
6. The blotting tank was completely filled with blotting buffer. The lid was then 
attached to the top of the tank, so that the red anode pin inserted into the red 
jack on the lid, and the black cathode pin was sheathed by the black jack on 
the lid. 
7. The magnetic stirrer was switched on. The red electrical Wire was then 
plugged into the red socket, and the black electrical wire was plugged into the 
black socket, in the Bio-Rad power pac 300. 
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8. The power pack was set to 100 volts, at constant voltage, which resulted in a 
current of 200-330 mAo The transfer proceeded for 2 hours. N.B. The ice was 
changed every 15 minutes after 1 hour of transfer. 
2.7.4 Protein fixing and staining 
1. Before fixing, a lOx stock solution of Tris Buffered Saline (TBS) (18.2 gil Tris 
base, 87 gil NaCl, made up to 800 ml, pH to 8.0 and then made up to a litre) was 
prepared. 500 ml of Ix tween-20 TBS (Tw-TBS) solution were prepared, 
incorporating 50 ml of 10 x TBS, 0.1 % (0.5 ml) Tween-20 and 1.0% (5g) 
powdered milk. N.B. The tip of the pipette was trimmed before pipetting the 
Tween-20. 
2. Following the completion of the transfer procedure, the PVDF membranes were 
trimmed to the exact size of the gel. The gels were retained for immediate staining 
in a Coomassie Blue R solution. 
3. The trimmed PVDF membranes were incubated in glutaraldehyde solution (100 ul 
of a 25% gluteraldehyde solution in 100ml of deionised water) for 10 minutes. 
Gluteraldehyde helps to cross-link the bound proteins to the PVDF membrane, 
therefore minimising protein loss during the stripping procedure (see below). 
4. The gluteraldehyde solution was decanted and any excess gluteraldehyde was 
removed by washing in deionised water for 15 minutes, with frequent solvent 
changes. 
5. To visualise the loading and banding patterns of bound proteins, the PYDF 
membranes were stained in Ponceau S solution (0.1 % Ponceau S (w/v) in 55 
acetic acid (v/v)) for 20 seconds. The protein standards of known molecular mass 
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were marked onto each membrane, using a ballpoint pen. The PVDF membranee 
were de-stained in Tw-TBS (with several changes). 
2.7.5 Blocking the membrane 
During Western Blotting, a primary antibody that binds to a specific epitope on the 
surface of the protein is used to visualise the protein of interest. However, the 
antibody can also non-specifically bind directly to the PVDF membrane, thereby 
contributing to the background and masking the signal relating to the protein of 
interest. Thus the membranes were first incubated in a blocking solution of Tw-TBS 
incorporating 5% milk powder (i.e. 0.8 g Marvel in 20ml Te-TBS), for at least 30 
minutes on a gyro-rocker at 30 rpm, which coats the membrane with proteins such as 
casein and albumin. It is much less likely that the antibody will bind to the coated or 
'blocked' membrane, compared to the non-coated membrane, therefore minimising the 
background. 
2.7.6 Exposure of the membrane to primary and secondary antibodies 
1. Commercially available primary antibody solutions, which bind to specific 
proteins of interest, were diluted in 10-20 ml Tw-TBS, according to the supplier's 
guidelines. 
2. The PVDF membranes were incubated in primary antibody solution, in a large 
weighing boat, either overnight at 4C, or for 1 hour at room temperature, with 
gentle agitation on a gyro-rocker (25 rpm). 
136 
3. After exposure to the primary antibody, the solution was decanted and frozen for 
re-use (labelled property, including each date that it was used). The membranes 
were transferred to a plastic dish, rinsed in Tw-TBS and washed in Tw-TBS for 
35 minutes with 6 changes of solution and a gyro-rocker speed of 40 rpm. 
4. The PVDF membranes were then incubated in a commercially available 
secondary antibody, diluted in 10-20 ml Tw-TBS, in a large weighing boat, for 1 
hour at room temperature. Secondary antibodies bind to the constant region of the 
primary antibody, and are usually conjugated to a horseradish peroxidase (HRP) 
enzyme, which is utilised during the developing step of the procedure. Different 
types of secondary antibodies are available, which are raised against the constant 
region of antibodies from one particular animal. Thus, if the primary antibody was 
raised in a rabbit, the appropriate secondary antibody, which would bind to the 
primary antibody, should have been raised against rabbit antisera. 
5. After exposure to the secondary antibody, the solution was decanted. The 
membranes were transferred to a plastic dish, rinsed in Tw-TBS, and washed in 
Tw-TBS for 35 minutes with 6 changes of solution. The water bath was also 
switched on, to allow it to heat to 80C. 
2.7.7 Developing-visualising the protein bands 
1. Kodak GBX developer and fixer solutions were prepared by diluting 103 
ml of each stock solution to make 473 ml. Each solution could then be 
stored in dark containers, or poured directly into plastic trays for 
immediate use. 
2. The membranes were transferred to a weighing boat and incuhated 10-
20ml of Pierce Super Signal West Pica Chemilumillcscellt Suhstrate for 5 
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minutes. The substrate is supplied as two solutions, which are active 
when combined in a 1: 1 ratio. The HRP enzyme converts the substrate 
into a chemilumiescent product, which can be visualised using Kodak X-
OMAT AR Scientific Imaging Film. 
3. Excess substrate was removed from the membranes by sliding the 
membranes along the edge of a plastic container. The membranes were 
then placed face up inside an Amersham Pharmacia Biotech 
Hypercassette, under a clear plastic sheet. 
4. In the dark room, sheets of the imaging film were exposed to the 
membranes for various durations of time, e.g. 30 seconds, 1 minute, 5 
minutes by directly placing the film on top of the plastic covered 
membranes and closing the hypercassette lid. 
5. Immediately following each membrane / film exposure period, each 
imaging film was placed into the developer solution, using forceps, until 
dark bands could be easily visualised. N.B. The films were moved around 
a little to prevent stripes from developing on the films. 
6. Each film was immediately rinsed in deionised water and fixed in fixer 
solution for about 60 seconds. The films were hung up to drip dry. 
7. Once dry, the markers on the membrane were drawn into each film. 
8. The density of each band was determined using a densitometry package, 
such as Bio-Rad Molecular Analyst Software package. 
2.7.8 Stripping of the membrane 
To compare the abundance of one protein compared with another, or with a 
phosphorylated form of the same protein. the membranes can be incubated for a 
second time in a different primary antibody. Before the second primary antibody 
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incubation, the first primary antibody must first be stripped from the membrane. This 
can be achieved using the following procedure. 
1. 
2. 
The PVDF membranes were transferred to a plastic dish, containing Tw-
TBS, and washed for 5 minutes. 
A stock of strip buffer (2% SDS, 62.5 mM Tris-HCI, pH 6.8) was 
prepared. 
3. 20 ml of strip buffer were used per membrane. Immediately prior to use. 
140 ul of ~-marcaptoethenol (~-ME) were added per 20 ml of strip buffer, 
in a fume hood. 
4. The Tw-TBS solution was decanted, and the strip buffer, with ~-ME. was 
poured over each membrane. The plastic containers were sealed and placed 
incubated in a water bath, set at 80C, for 45 minutes. 
5. The membranes were rinsed three times in deionised water and 
equilibrated in Tw-TBS for 15 minutes, on a gyro-rocker at 35 rpm, with 
frequent changes of Tw-TBS solution. The antibody incubations were then 
followed as outlined above. The primary antibody used was anti-actin at 
111000 concentration, and the secondary was anti-mouse at 112000 
concentration. 
2.7.9 Naphthol Blue Black membrane staining 
Once the Western blotting procedures was complete, the proteins bound to the PYDF 
membranes were visualised to verify the sample loadings, using the Naphthol Blue 
Black staining system. 
1. A Naphthol Blue Black solution (0.1 % (w/v) aphthol Blue Black, 10<;'c, 
methanol, 20'0 acetic acid) was prepared. 
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2. 
3. 
4. 
5. 
The membranes were incubated for at least 30 minutes, in a plastic dish 
containing the staining solution, on a gyro-rocker set at around 30 rpm. 
The staining solution was decanted and retaind for re-use. 
The membranes were washed in deionised water for 3-5 minutes on a 
gyro-rocker set at 30 rpm. 
To increase the contrast between the protein and the membarne, the 
membranes were incubated in a de-stain solution (20% (v/v) methanol, 7% 
acetic acid) for 5-10 minutes, or until the stained protein bands could be 
visualised clearly, on a gyro-rocker set at 30 rpm. The de-stain removes 
the stain that is not bound to the protein. 
6. The membranes were removed from the de-stain solution and allowed to 
dry. 
2.8 Immunohistochemistry 
Three-micron sections of paraffin-embedded placental tissue were deparaffinized in 
xylene. The avidin-biotin complex method was used for staining using the Vector 
Elite Kit (PK-6200). A positive and negative tissue control was included in each batch 
of staining. A placenta from an uncomplicated pregnancy delivered at term was used 
for this purpose. The negative control was processed identically to the samples, but 
without the addition of the primary antibody. The positive control is treated in the 
same way as the samples, in the presence of the primary antibody. These controls 
allow the specificity of the staining to be monitored so conditions can be altered if 
necessary and allows for any batch-to-batch differences to be accounted for. 
1.+0 
All slides were counter-stained with Mayers Haemalum to facilitate the reco~ition of 
c 
tissue structure and hence make it possible to identify the cells or area of interest. i.e 
the villous trophoblast. Finally, slides were dehydrated in alcohol, cleaned in xylene 
and mounted in Canada Balsam (VWR international, UK). 
An initial optimization study was performed on primary antibodies to achieve optimal 
specific staining with minimal background staining (DAKO Corporation, 200 1). The 
placental control tissue was used for optimization. 
2.9 Statistical analysis 
Statistical analysis was used using Microsoft Statistical Package for Social Sciences 
(SPSS)-lO, Chicago, IL, USA. When comparing means, data was considered non-
parametric and Mann-Whitney u test was used. Correlations between different 
variables were performed using Spearman correlation coefficient. A p value < 0.05 
was considered significant. 
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CHAPTER 1 
Perinatal outcome and umbilical artery Doppler flow in pregnancies with 
abnormal 24-week uterine artery Doppler 
3.1 Introduction 
Uterine artery Doppler examination IS used as a screening tool for pregnancy 
complications related to uteroplacental insufficiency (Harrington et al, 200..+). This 
technique, however, suffers from significant limitations including variable sensitivity 
and positive predictive value (see chapter 1). In addition, its value as screening tool 
for uteroplacental complications in multiparous women is debatable (Harrington et aI, 
2004, Prefumo et al, 2004). Despite these drawbacks, uterine artery Doppler 
examination remains the one screening modality for preeclampsia and IUGR that has 
been most-critically evaluated. 
In this study, uterine artery Doppler examination at 23-24 weeks was used to screen 
for the development of preeclampsia and IUGR. These pregnancies were followed 
until delivery. I compared perinatal outcome in pregnancies that developed 
preeclampsia before 36 weeks, with pregnancies that developed normotensive IUGR. 
I also compared umbilical and uterine artery Doppler flow and resistance indices 
within 24 hours of delivery between the two groups. Umbilical artery Doppler flow 
reflects placental angiogenic response, and differences in umbilical artery Doppler 
flow between the two groups might be due to differences in the quality of 
angiogenesis within placental villi (Ahmed and Kilby, 1997). In addition, I compared 
uterine artery Doppler flow between the two groups to assess the effect of impaired 
trophoblastic invasion on the development of the syndrome of preeclampsia (ie are 
there any differences in uterine artery flow between the two groups (preeclampsia and 
IUGR) at the time of disease?) 
3.2 Methods 
In the uterine artery Doppler screening study at 24 weeks, 86 women attended follow 
up for fortnightly growth scans and uterine artery Doppler flow examination. along 
with BP checks and urine analysis for protein. Fetal Doppler examination was 
performed in cases where there was suspicion of growth restriction on ultrasound 
examination. Using pulsed Doppler, flow velocity waveforms were obtained and 
resistance indices (RI and PD were measured in the umbilical artery, middle cerebral 
artery and fetal aorta (see chapter 2). Doppler of the DV was performed if the IUGR 
was associated with evidence of fetal compromise by arterial Doppler examination. 
Doppler examination was then performed three times per week up to the time of 
delivery. Timing of delivery was decided on clinical grounds, as well as 
cardiotocographic examination, in conjunction with Doppler ultrasound examination 
results. 
Preeclampsia was defined according to the definition by the ISSHP (see chapter one). 
IUGR was defined as fetal weight less than the 5th centile for gestational age along 
with abnormal umbilical artery Doppler examination (see below) or fetal biometry 
measurements crossing the fetal growth centiles over at least two fetal biometry 
examinations 10-14 days apart. This excluded any constitutionally (normal) SGA 
fetuses from the study. Abnormal umbilical artery Doppler was defined as absent or 
reversed EDF and/or resistance indices (PI and RD > 95th centile for gestational age 
(Harrington et aI, 1999). Abnormal uterine artery Doppler was defined as persistence 
of unilaterallbilateral notches with PI and RI > 95 th centile for gestational age. 
S . . rf d Wl·th Microsoft Statistical Package for Social Sciencl" tatlstlcs were pe orme 
(SPSS)-lO, Chicago, IL, USA. Data were considered non-parametric and Mann-
Whitney U test was used for comparisons. 
3.3 Results 
In the study group, 15 pregnancIes delivered before 36 weeks due to pregnancy 
complications related to uteroplacental insufficiency. Eight women developed 
preeclampsia as defined by the ISSHP (see chapter 1). The gestational age of the 
preeclampsia group at delivery ranged between 28-36 weeks (median 32 weeks). 
Birth weight ranged between 720g-2680g (median 1360g). There were two 
intrauterine fetal deaths in this group. One was associated with severe IUGR and 
AREDF in umbilical artery Doppler flow at 28 weeks. The other fetal death was a 
complication of placental abruption at 30 weeks. The fetus was appropriately grown 
with a birth weight of 1250g (loth centile). There were no neonatal deaths in this 
group. Antenatal umbilical artery (UA) Doppler examination 24 hours before delivery 
revealed positive EDF in all cases except one that had AREDF at 28 weeks and 
intrauterine fetal death. 
Seven other pregnancies in the study group were complicated by normotensive IUGR 
«5th centile), which required delivery before 36 weeks for fetal compromise. Four 
pregnancies had AREDF on umbilical artery Doppler examination 24 hours before 
delivery. None of these pregnancies had preeclampsia. The gestational age at delivery 
was not significantly different from the preeclampsia group (range 27-35, median 34 
weeks) (p=0.712). Birth weight ranged from 500-1728g (median 953g). which was 
also not statistically different from the preeclampsia group (p=O.674). Among this 
th & tal death in utero due to severe uteroplacental insufficiency group, ere was one Ie 
and one neonatal death. 
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When comparing uterine artery resistance indices between the preeclampsia and the 
normotensive SGA groups, no significant differences in RI and PI were found at 24 
weeks (p=0.92 for PI and 0.71 for RI). Furthermore, uterine artery Doppler 
examination within 24 hours of delivery in both groups showed persistent bilateral 
notches and PI and RI > 95 th centile in all cases. Again, there were no significant 
differences in uterine artery resistance indices between the two groups at that time 
(p=0.61 for PI and 0.52 for RI). 
When comparing umbilical artery Doppler flow within 24 hours of delivery in both 
groups; PI was significantly lower in preeclamptic pregnancies compared to 
normotensive IUGR [median 1.22, range (0.94-1.40) vs 1.39, (1.25-4.68)]; (p=O.O 1). 
Umbilical artery RI was also significantly less in the preeclampsia group compared to 
IUGR, [median 0.68, range (0.63-0.81) vs 0.83 (0.69-1.00)]; (p=0.007). 
Table 3.1 illustrates the demographic characteristics of both groups, table 3.2 
illustrates the perinatal outcome and table 3.3 summarizes the uterine and umbilical 
artery Doppler findings in both groups 
Table 3.1 Demographic characteristics of the preeclampsia and the IUGR groups 
Preeclampsia (n=8) IUGR (n=7) 
Race 
i 
Afrocarribean 4 3 
White 3 2 
Asian 1 2 
Maternal age 
Median (range) 27 (19-35) 25 (16-34) 
Parity 
Primiparous 7 5 
Multiparous 1 2 
1-l9 
Table 3.2 Perinatal outcomes in preeclamptic and IUGR pregnancies 
Preeclampsia (n=8) IUGR (n=7) P value (Mann-
GA at delivery'" 
Whitney u test) 
Median (range) 32 (28-36) 34 (27-35) (p:-O.712) 0.712 
Birth weight 
Median (range) 1360 (720-2680)g 953 (500-1728)g 
(p~0.674) 0.674 
Fetal death in utero 2 1 
Neonatal death 0 2 
i 
*GA Gestational age 
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Table 3.3 Uterine and umbilical artery Doppler findings in preeclamptic and IUGR 
pregnancIes 
Preeclampsia IUGR P value (Mann-
(n=8) (n=7) Whitney U test) 
Uterine artery Doppler (24 
weeks) 
Bilateral notches Yes Yes 
PI 1.60 (1.22-2.26) 1.49 (1.19-1.87) 0.35 
RI 0.73 (0.64-0.84) 0.72 (0.65-0.78) 0.77 
Uterine artery Doppler 
(within 24hr of delivery) 
Bilateral notches Yes Yes 
PI 1..05 (0.98-1.78) 1.02 (0.96-1.57) 0.61 
RI 0.67 (0.60-0.81) 0.66 (0.59-0.80) 0.52 
I 
! 
- , 
Umbilical artery Doppler 
(within 24hr of delivery) I 
I 
1.22 (0.94-1.4) 1.39 (1.25-4.68) 0.01 
PI 
Umbilical artery Doppler 
(within 24hr of delivery) 
RI 0.68 (0.63-0.81) 0.83 (0.69-1.00) 0.007 
,>0 
Umbilical artery ARED F 1 4 
* AREDF Absent/reversed EDF 
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3.4 Discussion 
In our study, we used uterine artery Doppler flow examination at 24 weeks to screen 
for the development of pregnancy complications related to uteroplacental 
insufficiency, namely preeclampsia and IUGR. The exact pathophysiology underlying 
the difference in outcome between the two groups (development of preeclampsia 
compared to normotensive IUGR) is not clear. We compared perinatal outcome, birth 
weight, umbilical artery Doppler flow and uterine artery Doppler resistance indices in 
the two groups in search for differences that could point to the underlying mechanism 
behind this apparent difference. We found no differences in the gestational age at 
delivery, birth weight or perinatal mortality between the two groups. There were also 
no significant differences in uterine artery resistance and pulsatility indices between 
the two groups at 24 weeks and within 24 hours of delivery. This excludes differences 
in placental invasion between the two groups as a cause for the difference in outcome, 
Umbilical artery Doppler flow, however, was significantly more favourable in the 
preeclampsia group, with significantly lower PI and RI and only one case with 
AREDF in the Doppler flow. This might reflect different placental response in the two 
groups at the micro-vascular level. Despite the significant difference in umbilical 
artery Doppler flow examination between the two groups, this was not reflected in 
differences in perinatal outcome. 
In this study only pregnancies delivered before 36 weeks were included to minimize 
the effect gestational age would have on umbilical artery Doppler examination. All 
normotensive IUGR pregnancies were delivered before 36 weeks: so only 
preeclamptic pregnancies that delivered before 36 weeks were included, Thi.., could 
. ' , d' u' alue (PPV) of uterine artery Doppler examination 
explatn the low posItive pre IC ve v 
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in predicting preeclampsia in my study (10%), compared to other studies that reported 
PPV of up to 36% (Chan et ai., 1995). Other factors that contribute to this difference 
is using different cut off points for uterine artery Doppler flow resistance indices and 
the use of different definitions of preeclampsia. 
Villous vascularization during the first and second trimesters is largely detennined by 
sprouting and branching angiogenesis, which leads to the fonnation of immature 
villous trees, whose vascular core is characterized by continuously growing networks 
of fetal capillaries and their supply vessels (Benirschke & Kaufmann, 1995). At the 
end of the second trimester, there is a switch to non-branching angiogenesis, which 
fonns long, poorly branched terminal capillary loops. As the third trimester 
progresses, these loops form the capillary network of the mature intermediate and 
terminal villi responsible for nutrient and gas exchange between mother and fetus 
(Kaufmann et ai., 1988). The net effect of these angiogenic phases is an exponential 
increase in the volume of fetal capillaries within the placenta, representing about one-
quarter of the feto-placental blood volume by term (Luckhardt et al., 1996). This 
process coincides with the known increase in end-diastolic flow velocities (and a fall 
in the pulsatility index) in the umbilical artery, suggesting that these capillaries are an 
important determinant of fetoplacental vascular impedance in the nonnal placenta 
(Hendricks et aI., 1989). 
Todros et al. (1999) showed that the characteristics of umbilical artery Doppler now 
I . & • IUGR fetuses indicate angiogenesis within placental stem and ve OClty wavelorms In ' . 
gas-exchanging villi. They showed that pregnancies complicated by IUGR in which 
positive EDF was documented in the umbilical artery before delivery had an adaptive 
response in the villous placenta, characterized by enhanced branching angiogenesis. 
This results in greater numbers of highly branched terminal villi (Kingdom & 
Kaufmann, 1997) and compensates, at least in part, for the underlying impairment of 
uteroplacental blood flow indicated by abnormal uterine artery Doppler findings. By 
contrast, they showed that the pattern of villous vascularization in cases of IUGR 
complicated by absent or reversed EDF suggested that this adaptive process failed to 
occur (Macara et ai., 1996; Krebs et ai., 1996), which might be due to an apparent 
lack of placental villous regulation of vascular growth through VEGF and its 
receptors (Todros et ai., 1999). They suggested that hypovascularization of stem villi 
or reduced peripheral villous branching in placentas from fetuses with IUGR and 
AREDF could result from abnormal differentiation of capillary networks in immature 
intermediate villi during early gestation, rather than some obliterative process in the 
third trimester. If the former concept is true, the placental origin of IUGR might begin 
much earlier in gestation than previously thought. 
Roberts & Cooper (2001) suggested that the systemic syndrome of preeclampsia is a 
result of two-stage process. The first starts at the level of the placenta with placental 
hypoxia being the main factor involved. The second stage involves the release of 
cytokines from the placenta to the systemic circulation that triggers the systemic 
manifestations of preeclampsia. According to this theory, placental hypoxia (due to a 
variety of conditions) seems to be a key factor in the development of preeclampsia. In 
this study, I demonstrated that umbilical artery Doppler waveforms from preeclamptic 
. d'ff nt from the normotensive IUGR ones, with significantly lower pregnanCIes are I ere 
resistance indices and nlore favorable blood flow in the preeclamptic group. Thi" 
difference in umbilical artery flow could affect the level of placental oxygen in thc"c 
pregnancies, and in turn affect the maternal systemic response to placental-derived 
factors in the hypoxic group. In other words, pregnancies where umbilical artery 
blood flow is preserved with lower PI and RI tend to have hypoxic placentas 
(Kingdom & Kaufmann, 1997). This might explain the difference in outcome 
(development of preeclampsia) in these two groups. 
It is possible that women in preeclampsia were delivered on clinical grounds for 
maternal reasons before serious deterioration in fetal condition and umbilical artery 
Doppler flow. Hence, the lower umbilical artery Doppler flow resistance indices and 
more favourable flow pattern (one case with AREDF) in the preeclampsia group, 
compared to four in the IUGR group. Larger studies are needed to verify the 
differences between the two groups. In the next chapter, we assess differences in 
placental angiogenic factors both in the serum and placenta in the two groups 
compared to controls. 
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CHAPTER 2 
Serum and placental Fltl and PIGF in high-risk women with abnormal 24-week 
uterine artery Doppler that develop preeclampsia and normotensive IUGR. 
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4.1 Introduction 
Preeclampsia is associated with defective uteroplacental vascularization, along with 
impaired angiogenesis and vascular transformation of the uteroplacental unit. 
Vascular Endothelial Growth Factor-A (VEGF-A) is one of the most important 
growth factors for endothelium, as it induces angiogenesis and endothelial cell 
proliferation (see chapter 1). Placental Growth Factor (PIGF) is a member of the 
VEGF family closely related to VEGF-A. The two main receptors for VEGF-A and 
PIGF, namely VEGFR-I (FIt-I) and VEGFR-2 (KDR), are essential for the 
development of embryonic vasculature (Fong et al., 1995). Flt-l is expressed by 
trophoblast cells and thought to play a physiological function during pregnancy 
(Charnock-Jones et al., 1994). A soluble form ofVEGFR-l (sFlt-l) can be detected in 
peripheral blood. Soluble Flt-I has a strong antagonistic activity and neutralizes the 
effects mediated by VEGF and PIGF effects (Kendall & Thomas, 1993~ Hornig et a/., 
2000; Yamaguchi et al., 2002). Both villous and extravillous trophoblastic cells 
produce sFlt-I (Clark et aI., 1998). Recent evidence suggests that placental 
dysregulation of sFlti and PIGF could be implicated in the pathogenesis of 
preeclampsia through disordered angiogenesis in the trophoblast and hence abnormal 
trophoblast invasion (Maynard et at., 2003; Ahmad & Ahmed, 2004) 
In the last study, I demonstrated significant differences in umbilical artery blood flow 
within 24 hours of delivery between preeclamptic and normotensive IUGR 
pregnancies in women with abnormal uterine artery Doppler. This could be due to 
differences in placental angiogenesis between the two groups. In this chapter. 
placental FItI and PIGF and their soluble serum forms are assessed in cases of 
abnormal uterine artery Doppler that develop preeclampsia and nom10tensive IUGR. 
4.2 Methods 
553 women were examined using uterine artery Doppler at 24 weeks. Among these, 
there were 395 primiparous and 158 mUltiparous women. All primigravid women and 
multiparous women with previous pregnancy complication (see materials and 
methods) attending for routine anomaly scan at 20 weeks were offered uterine artery 
Doppler examination at 24 weeks. Among women who underwent uterine artery 
Doppler flow examination, 97 women had an abnormal result (see materials and 
methods). 63 women were primiparous and 34 were multiparous. Eleven women did 
not attend for follow up (dropped out). The remaining 86 (56 primiparous and 30 
multiparous) women were enrolled in the study after obtaining appropriate consent 
and giving them information leaflets. Blood was collected from the 86 women with 
abnormal 24-week uterine artery Doppler examination during the same visit, after 
obtaining appropriate consent; serum was stored at -80C for further assay (see below). 
Women enrolled in the study were scanned at fortnightly intervals for growth, uterine 
artery Doppler and fetal Doppler examination (if there is evidence of slowing of fetal 
growth). These pregnancies were followed for the development of preeclampsia and 
IUGR. Eight women developed preeclampsia at gestations less than 36 weeks, seven 
women developed normotensive IUGR; four of these had evidence of AREDF in 
umbilical artery Doppler examination, compared to one in the preeclampsia group. 
For details of perinatal outcome, see chapter one. 
Blood was collected from these women within 24 hours of delivery when umbilical 
and uterine artery Doppler examination was performed. Serum was stored at -8OC 
(see materials and methods) for further assay. The control group comprised 16 women 
from the study group with normal pregnancy outcome that delivered at tenn. Blood 
was collected from these pregnancies at 24 weeks (at the ti ft' me 0 u enne artery 
Doppler examination) and at gestations compared to the time of delivery of the 
abnormal outcome group (27-36 weeks). Serum sFltl and PIGF were measured in the 
three groups at 24 weeks and the time of the disease by Enzyme Linked Immune 
Sorbent Assay (ELISA) 
Serum sFIt-l ELISA 
Reagent preparation 
All reagents were brought to room temperature before use. 
Wash Buffer - 20 mL of Wash Buffer Concentrate were diluted into distilled water to 
prepare 500 mL of Wash Buffer. 
Substrate Solution - Color Reagents A and B were mixed together in equal volumes 
within 15 minutes of use and protected from light. 200 uL of the resultant mixture is 
required per well. 
VEGF R 1 Standard - The VEGF R 1 Standard was reconstituted with 1.0 mL of 
distilled water. This reconstitution produced a stock solution of 20 ngimL. The 
standard were mixed to ensure complete reconstitution and allowed to sit for a 
minimum of 15 minutes with gentle agitation prior to making dilutions. 
900 uL of Calibrator Diluent RD6Z were pipetted into the 2000 pglmL tube. 500 ul 
of Calibrator Diluent RD6Z were pipetted into the remaining tubes. The stock solution 
was used to produce a dilution series (seven dilutions were made). Each tube was 
thoroughly mixed before the next transfer. The 2000 pglmL standard serves as the 
high standard. Calibrator Diluent RD6Z serves as the zero standard (0 pglmL). 
Assay procedure 
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All reagents and samples were brought to room temperature before use. All samples, 
controls and standards were assayed in duplicate. 
1. All reagents, working standards and samples were prepared as directed in the 
previous sections. 
2. 100 uL of Assay Diluent RD 1-71 were added to each well. 
3. 100 uL of Standard, control or sample* were added per well and covered with the 
adhesive strip provided. The wells were then incubated for 2 hours at room 
temperature on a horizontal orbital microplate shaker (0.12" orbit) set at 500 rpm 50 
rpm. 
4. Each well was aspirated and washed, repeating the process three times for a total of 
four washes using 400ul of Wash Buffer. 
5. 200 uL of VEGF R1 Conjugate were added to each well and covered with a new 
adhesive strip. The wells were then incubated for 2 hours at room temperature on the 
shaker. 
6. The aspiration/wash was repeated as in step 4. 
8. 200 uL of Substrate Solution were added to each well and incubated for 30 minutes 
at room temperature on the bench top and protected from light. 
9. 50 uL of Stop Solution were added to each well. If color change did not appear 
uniform, the plate was gently tapped to ensure thorough mixing. 
10. The optical density of each well was determined within 30 minutes, usmg a 
microplate reader set to 450 nm. 
Serum PIGF ELISA 
Reagent preparation 
All reagents were brought to roonl temperature before use. 
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Wash Buffer - 20 mL of Wash Buffer Concentrate were diluted into distilled water to 
prepare 500 mL of Wash Buffer. 
Substrate Solution - Color Reagents A and B were mixed together in equal volumes 
within 15 minutes of use and protected from light. 200 uL of the resultant mixture is 
required per well. 
PIGF Standard - The PIGF Standard was reconstituted with 1.0 mL of Calibrator 
Diluent RD6-11. This reconstitution produced a stock solution of 1000 pglmL. The 
standard were mixed to ensure complete reconstitution and allowed to sit for a 
minimum of 15 minutes with gentle agitation prior to making dilutions. 
500 uL of Calibrator Diluent RD6-11 were pipetted into each tube. The stock solution 
was used to produce a dilution series (seven dilutions were made). Each tube was 
thoroughly mixed before the next transfer. The 1000 pglmL standard serves as the 
high standard. Calibrator Diluent RD6-11 serves as the zero standard (0 pglmL). 
Assay procedure 
All reagents and samples were brought to room temperature before use. All samples 
controls and standards were assayed in duplicate. 
1. All reagents, working standards and samples were prepared as directed 10 the 
previous sections. 
2. 100 uL of Assay Diluent RDl-22 were added to each well. 
3. 100 uL of Standard, control or sample* were added per well and covered with the 
dh · t . ·ded The wells were then incubated for 2 hours at room a eSlve s np provl . 
temperature. 
4. Each well was aspirated and washed, repeating the process three times for a total of 
four washes using 400ul of Wash Buffer. 
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5. 200 uL of PIGF Conjugate were added to each well and d'th covere WI a new 
adhesive strip. The wells were then incubated for 2 hours at room temperatur. 
6. The aspiration/wash was repeated as in step 4. 
8. 200 uL of Substrate Solution were added to each well and incubated for 30 minutes 
at room temperature on the bench top and protected from light. 
9. 50 uL of Stop Solution were added to each well. If color change did not appear 
uniform, the plate was gently tapped to ensure thorough mixing. 
10. The optical density of each well was determined within 30 minutes, usmg a 
microplate reader set to 450 nm. 
Western blotting 
Western blotting was used to study placental expression of FItl and PIGF using the 
principles described in chapter two. Four placental samples from pregnancies 
complicated by preeclampsia «36 weeks) with preserved EDF in umbilical artery 
Doppler, four samples from normotensive IUGR with AREDF in umbilical artery 
Doppler and four gestational age matched controls (28-32 weeks) were studied. All 
disease samples had abnormal midtrimester uterine artery Doppler at 24 weeks and at 
the time of delivery while the controls had normally growing fetus with normal 
umbilical and uterine artery Doppler. All cases and controls were delivered by 
Caesarean Section. 
Supernatants of homogenized placental samples were thawed in ice, then heated for 
10 minutes at 90 degrees. Kleidoscope and marker samples were thawed in icc and 
heated for one minutes at 40C and 90C respectively. All samples were centrifuged at 
13G for 40 seconds, then 50 micrograms of each sample was loaded to the wells in the 
1()2 
prepared gel. Using runnIng buffer, separating electrophoresis was started at 60 
Amperes for 10 minutes then at 80 Amperes for 40 minutes, after which the stacking 
gel was removed. The gels were subsequently incubated for 30 minutes in transfer 
buffer. Protein was transferred from the gel to blotting membrane with blot buffer and 
two hours were allowed for protein transfer at 100V under cooling conditions using 
ice. Membranes were then incubated overnight in blocking solution in a cold room. 
Membranes were then incubated in primary antibody solution (FItl and PIOF, R&D 
systems, Abingdon, UK) at a concentration of 1 :500 ugIL for two hours in the shaker. 
Extensive washing was then performed for 30 minutes followed by secondary 
antibody incubation (anti mouse IgO, heavy and light chain specific peroxidase 
conjugate, Calbiochem, USA) at a concentration of 1/2000 for one hour. Membranes 
were then extensively washed for 30 minutes, after which they were incubated for five 
minutes in ECL solution (equal volumes of Supersignal West Pico stable peroxide 
solution and Supersignal West Pi co Luminol enhancer solution (Piercenet, Rockford, 
IL, USA). Films were then developed in a dark room. Protein stripping was then 
performed and actin expression in the three groups was assessed according to the 
technique in chapter two. The intensity of staining for the studied protein and actin 
was assessed using Bio-Rad Molecular Analyst Software package densometer. The 
ratio between the studied protein and actin expression was assessed. Differences in 
protein expression ratios between the three groups were assessed using Mann-
Whitney U test. 
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4.3 Results 
Serial evaluation of serum sFltl and PIGF 
Serum sFltl levels were significantly higher at 24 weeks in women who developed 
preeclampsia (n=8), compared to the normal outcome group (n=16). The median of 
sFltl in the preeclampsia group was 2848 (range: 1022-5243) pglml compared to 
1145 (range: 297-2139) pglml in the normal group; (p=O.OOI). Furthermore, the 
median for PIGF was significantly lower in the preeclampsia group at 24 weeks, 
compared to those with a normal outcome [188 (range: 50-315) versus 532 (range: 
203 -1129) pglml; p=O.OOI]. 
Serum sFltl levels were also elevated at 24 weeks in pregnancies with abnormal 
uterine artery Doppler, which subsequently developed normotensive IUGR (n=7). The 
median (range) for the IUGR group was 2846 (934-3624) pglmL compared to 
controls with a normal outcome (n=16); [median 1145 (range: 297-2139) pglml]; 
p=0.003. On the other hand, serum PIGF levels were significantly lower in the IUGR 
group [median 292., range (50-820) pglmL] compared to the control group (see 
above); p=0.019. At 24 weeks, there were no significant differences in serum sFltl 
(p=0.345) and PIGF (p=0.372) levels between women who subsequently developed 
preeclampsia and those who developed normotensive IUGR. 
The ratio between sFltl and PIGF (sFltlIPIGF) was also assessed in the three groups. 
Women who subsequently developed preeclampsia or normotensive IUGR had 
significantly higher sFlt IIPIGF ratios compared to normal controls. There were no 
significant differences between the preeclampsia and IUGR groups at 24 weeks. 
Using sFlt IIPIGF ratio did not add a significant advantage over the use of sFIt 1 alone 
1M 
m predicting preeclampsia or ruGR. Table 4.1-4.3 summarizes the differences 
between serum level of sFlt! and PIGF at 24 weeks in women who subsequently 
developed preeclampsia, normotensive ruGR and controls. Figures 4.1-4.3 illustrate 
the differences in PIGF and sFlt! and sFltlIPIGF ratio between the three groups at 24 
weeks. 
When following serum sFlt! and PIGF levels longitudinally, there were no significant 
changes in serum sFltl and PIGF in the control group with advancing gestation. There 
was, however, a several fold increase in sFltl levels in cases of preeclampsia (n=8) at 
the time of the disease (in the 24 hours before delivery) [median 41,425 (range: 5000-
300,000) pglml] compared to gestational age matched controls (n=16) [median 1295 
(range: 293-5657) pglml)]; (p<O.OOl). Similar to the control group, PIGF 
concentrations did not change significantly with gestation in women with 
preeclampsia. Serum PIGF, however, was significantly lower in the preeclampsia 
group at the time of the disease (in the 24 hours before delivery) [median 287.5 
(range: 50-425) pg/mL] compared with gestational age matched controls [median 867 
(range: 114-6014) pg/mL] p=0.02. 
In the ruGR group, there were no significant changes in sFltl levels [median 3500 
(range 2255-5243) pglmL] (p=0.63) and PIGF levels [median 200 (range 50-337) 
pglmL] (p=0.37) at the time of disease (in the 24 hours before delivery) compared to 
levels at 24 weeks. When comparing serum sFlt 1 levels in IUGR pregnancies to 
preeclamptic and control pregnancies at the time of the disease. serum sFIt 1 was 
significantly elevated in IUGR compared to controls (p=O.006). and significantly 
. . (-000') In addition there v.'ere lower than that in preeclamptIc pregnancIes p-. _. . 
significant changes in PIGF in the IUGR group compared to gestational age matched 
controls. PIGF was significantly lower in IUGR compared to controls (p=O.OO5), but 
was not different from preeclamptic pregnancies (p=O.118). When comparing 
sFltlIPIGF ratio in the three groups, preeclamptic pregnancies had significantly higher 
ratios compared to IUGR (p=O.021) and control pregnancies (p<O.OOl). The ratios in 
IUGR pregnancies were also significantly higher than controls (p=O.OO 1). 
Tables 4.4-4.6 illustrate sFltl and PIGF levels in preeclamptic, nonnotensive IUGR 
and control pregnancies at the time of the disease (within 24 hours of delivery in the 
preeclampsia and IUGR groups). Figures 4.4 and 4.5 illustrate the differences in sFlt 1 
between the three groups. Figure 4.6 illustrates differences in PIGF between the three 
groups. Figures 4.7 and 4.8 illustrate differences in sFltlIPIGF ratios between the 
three groups at the time of the disease. 
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Table 4.1 Differences in sFltl and PIGF at 24 weeks in women with abnormal uterine 
artery Doppler who subsequently developed preeclampsia and normal controls. 
Preeclampsia (n=8) Controls (n= 16) p 
Median (range) Median (ran~e) 
sFltl 3168 (1022-5243) 1145 (297-2139) 0.001 i 
, 
PIGF 188 (50-315) 532 (203-1129) 0.001 
SFltlIPIGF ratio 18.57 (5.50-60.04) 1.467 (0.88-9.58) 0.001 
J 
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Table 4.2 Differences in sFltl and PIGF at 24 weeks in women with abnormal uterine 
artery Doppler who subsequently developed preeclampsia and normotensive IUGR. 
Preeclampsia (n=8) IUGR (n=7) P 
Median (range) Median (range) 
sFltl 3168 (1022-5243) 2846 (934-3624) 0.345 
PIGF 180 (50-315) 292 (50-820) 0.372 
sFltllPIGF 18.57 (5.50-60.04) 11.15 (3.49-93.40) 0.563 
16S 
Table 4.3 Differences in sPIt! and PIGF at 24 weeks in women with abnormal uterine 
artery Doppler who subsequently developed normotensive IUOR and control 
pregnancIes. 
IUGR (n=7) Controls (n= 16) P I , 
Median (range) Median (range) 
sAtl 2846 (934-3624) 1145 (297-2139) 0.003 
PIOF 292 (50-820) 532 (203-1129) 0.019 
sFlt1 IPIGF 11.15 (3.49-93.40) 1.467 (0.88-9.58) 0.002 II 
~ 
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Figure 4.1 Box and plot comparison between serum sFltl at 24 weeks in women with 
abnormal uterine artery Doppler who subsequently developed nonnoten ive IUGR 
(n=7), preeclampsia (n=8), and normal outcome (n=16). The preeclampsia and IUGR 
groups have significantly higher sFltl levels at 24 weeks compared to the nonnal 
outcome (control) group. Boxes represent interquartile range, where the line 
represents the median. Whiskers at top and bottom represent the highest and lowe t 
values. 
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Figure 4.2 Box and plot comparison between serum PIGF at 24 weeks in women with 
abnormal uterine artery Doppler who subsequently developed normoten ive IUGR 
(n=7), preeclampsia (n=8), and normal outcome (n=16). The preeclampsia and IUGR 
groups have significantly lower PIGF levels at 24 weeks compared to the normal 
outcome (control) group. Boxes represent interquartile range, where the line 
represents the median. Whiskers at top and bottom represent the bighest and lowe t 
values. 
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Figure 4.3 Box and plot comparison between serum sFlt1IPIGF ratio at 24 weeks in 
women with abnormal uterine artery Doppler who subsequently de eloped 
normotensive IUGR (n=7), preeclampsia (n=8), and normal outcome (n=16). The 
preeclampsia and IUGR groups have significantly higher sFlt1IPIGF ratios at 24 
weeks compared to the normal outcome (control) group. Boxes represent interquartile 
range, where the line represents the median. Whiskers at top and bottom repre ent the 
highest and lowest values. 
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Table 4.4 Differences in sFltl and PIGF within 24 hours of delivery in women with 
abnormal uterine artery Doppler who developed preeclampsia and gestational age 
matched controls. 
Preeclampsia (n=8) Controls (n=16) p 
Median (range) Median (range) 
sFltl 41,425 (5,000-300,000) 1295 (293-5,657) <0.001 
PIGF 287.5 (50-425) 867 (114-6,014) 0.02 
sFltlIPIGF ratio 138.1 (72.66-1127.8) 1.344 (0.05-14.02) <0.001 
17 .~ 
Table 4.5 Differences in sFltl and PIGF within 24 hours of delivery in women with 
abnormal uterine artery Doppler who subsequently developed preeclampsia and 
normotensive IUGR. 
Preeclampsia (n=8) IUGR (n=7) P i Median (range) Median (range) 
sFltl 41,425 (5,000-300,000) 3500 (2255-5243) 0.002 
287.5 (50-425) 200 (50-337) 0.118 I PIGF I 
! 
sFltlIPIGF 138.1 (72.66-1127.8) 11.15 (3.49-93.40) 0.021 I 
I 
I 
174 
Table 4.6 Differences in sFltl and PIGF within 24 hours of delivery in women with 
abnormal artery Doppler who developed normotensive IUGR and gestational age 
matched control pregnancies. 
IUGR (n=7) Controls (n=16) P 
Median (range) Median (range) 
sAtl 3500 (2255-5243) 1295 (293-5,657) 0.006 
PIGF 200 (50-337) 867 (114-6,014) 0.005 1 
i 
sFltllPIGF 11.15 (3.49-93.40) 1.344 (0.05-14.02) 0.001 
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Figure 4.4 Box and plot comparison between serum sFlt 1 at the time of the di e e 1D 
women with abnonnal uterine artery Doppler who developed normoten ive nJGR 
(n=7), preeclampsia (n=8), and nonnal outcome (n=16). The preeclamp ia and IUGR 
groups have significantly higher sFlt! levels compared to the normal outcome 
(control) group. Boxes represent interquartile range, where the line repre ent the 
median. Lines at top and bottom represent the highest and lowest value . 
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Figure 4.5 Box and plot comparison between serum sFltl at the time of the di ease in 
women with abnormal uterine artery Doppler who developed normoten ive nJGR 
(n=7), and gestational age matched controls (n=16). The nJGR group ha e 
significantly higher sFltl levels compared to the normal outcome group. Boxe 
represent interquartile range, where the line represents the median. Line at top and 
bottom represent the highest and lowest values. 
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Figure 4.6 Box and plot comparison between serum PIGF at the time of the di ease in 
women with abnormal uterine artery Doppler who developed normotensive IUGR 
(n=7), preeclampsia (n=8), and normal outcome (n=16). The preeclamp ia and IUGR 
groups have significantly lower PIGF levels compared to the normal outcome 
(control) group. Boxes represent interquartile range, where the line repre ent the 
median. Lines at top and bottom represent the highest and lowest value . 
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Figure 4.7 Box and plot comparison between serum sFltlIPIGF ratios at the time of 
the disease in women with abnormal uterine artery Doppler who developed 
normotensive IUGR (n=7), preeclampsia (n=8), and normal outcome (n=16). The 
preeclampsia and IUGR groups have significantly higher sFltlIPIGF ratio compared 
to the normal outcome (control) group. Boxes represent interquartile range, where the 
line represents the median. Lines at top and bottom represent the highest and lowe t 
values. 
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Figure 4.8 Box and plot comparison between serum sFltlIPIGF at the time of the 
disease in women with abnormal uterine artery Doppler who developed normoten ive 
IUGR (n=7), and normal outcome (n=16). The IUGR groups have significantly higher 
sAtl levels compared to the normal outcome (control) group. Boxes repre ent 
interquartile range, where the line represents the median. Lines at top and bottom 
represent the highest and lowest values. 
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Placental expression of sFltl and PIGF 
Placental expression of PIGF and FItl in the three groups was detected using western 
blotting at the corresponding molecular weight of 50 kDa and 180 KDa, respectively. 
There was a significant increase in placental expression of Fit 1 in preeclampsia 
compared to IUGR placentas (p=0.02l) and controls (p=0.043). There were no 
differences in placental expression of FItl between ruGR and control placentas 
(p=0.773). Figure 4.9 illustrates placental Fltl expression in the study groups. 
On the other hand, there were no differences in placental PIGF expression in the three 
study groups (PET vs controls; p=0.773), (PET vs ruGR; p=0.149), (IUGR vs 
controls; p=0.386). Figures 4.10 and 4.11 illustrate trophoblast PIGF and actin 
expression, respectively in the study groups. Table 4.7 summarises Fltl/actin and 
PIGF/actin expression ratios in the studied placentas. Figures 4.12 and 4.13 are a box 
and plot comparison of placental FItl and PIGF expression, respectively between the 
three study groups. 
I Xl 
Figure 4.9 Placental expression of FItl in pregnancies complicated by normoten ive 
IUGR (n (right four lanes), preeclampsia (P) (middle four lanes) and gestational age 
matched controls (C) (left four lanes). 
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Figure 4.10 Placental expression of PIGF in IUGR cn preeclamp ia (P) and control 
(C) pregnancies. No differences were found in placental PIGF expre ion was found 
between the three groups. 
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Figure 4.11 Actin expressIon In the groups studied; I: IUGR pregnancle P: 
preeclampsia, C: control pregnancies. 
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Table 4.7 Fltl/Actin and PIGF/Actin ratios in western blotting from placentas in the 
three study groups. 
Fltl PIGF 
Median (Range) Median (Range) 
IUGR 0.752 (0.347-0.889) 1.266 (0.826-5.893) 
PET 1.498 (0.904-28.618) 2.669 (1.780-20.783) 
CONTROLS 0.83 (0.642-0.953) 2.365 (1.427-4.34) 
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Figure 4.12 Box and plot companson between placental FItl expre IOn ill 
normotensive IUGR (n=4), preeclampsia (PET) (n=4) and control (n=4). 
Preeclamptic placentas have significantly higher FItl expression compared to the 
IUGR (p=O.021) and control groups (p=O.043). No differences were found between 
the IUGR and control groups (p=O.773). Boxes represent interquartile range, where 
the line represents the median. Lines at top and bottom represent the highe t and 
lowest values. 
40-------------------------------------------, 
30 
20 
10 
o 
-10l-__________ --------~~--------~----------
4 N= 4 4 
IUGR PET CONTROLS 
Figure 4.13 Box and plot companson between placental PIGF expre ion 1ll 
normotensive IUGR (n=4), preeclampsia (PET) (n=4) and controls (n=4). 0 
differences were found in placental PIGF expression between the three group. Boxe 
represent interquartile range, where the line represents the median. Line at top and 
bottom represent the highest and lowest values. 
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4.4 Discussion 
My observation of raised sFltl serum concentrations in established pre-eclampsia 
confrrms and extend the recent work of Maynard et ai (2003) and Koga et ai (2003). I 
report here that concentrations of sFlt! increased in the second trimester, before 
evidence of clinical disease and that these are accompanied by a fall in PIGF 
concentrations. The latter observation confirms studies that showed PIGF to be 
reduced in women who subsequently develop pre-eclampsia (Chappell et ai., 2oo2a~ 
Taylor et ai., 2003). These markers of the angiogenic pathway may, alone or in 
combination, be useful in the prediction of the disease. In this study, sFltl was also 
elevated in women with normotensive IUGR from as early as 24 weeks. This suggests 
that sFltl is implicated in impaired trophoblast invasion in these pregnancies (as they 
all had abnormal uterine artery Doppler at 24 weeks). Serum sFltl was also elevated 
within 24 hours of delivery in cases of IUGR despite the absence of preeclampsia. 
This again could be a reflection of impaired placental angiogenesis and invasion, or 
might reflect state of placental hypoxia, which is not as severe as that in cases of 
preeclampsia. 
Recently Thadhani, et ai (2004) have reported no difference between sFltl levels in 
first trimester samples (10.6 week's gestation) of low risk women destined to develop 
pre-eclampsia. The low risk controls (10.6 week's gestation) showed very similar 
concentrations to those of our 'high risk' women with a normal outcome, studied at 24 
weeks. The discrepancy between these studies is most likely to arise from the 
different gestational ages of study, since the placental function only becomes 
obviously abnormal in the second trimester. This is supported by a previous study in 
which placental markers in the maternal serum (e.g. PAI-2, leptin and PIGF) 
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demonstrated abnormal concentrations only from 20 week's gestation onwards 
(Chappell et al., 2002a). Additionally, the women we have studied here were all 
known to have abnormalities of the uteroplacental circulation, and may therefore 
represent a group with particularly severe placental pathology. 
The members of the VEGF family contribute to growth, proliferation and survival of 
endothelial cells and are therefore hypothesized to playa substantive role in placental 
development and growth (Autiero et al., 2003). New developments in our 
understanding of interrelationships between these molecules have shown the 
importance of dynamic intra- and intermolecular cross talk. As an antagonist of 
VEGF-A and PIGF, it has been postulated that sFltl may act as a 'decoy' -receptor, 
through interference with the signals normally leading to the activation of VEGF-R2, 
thereby down regulating the angiogenic activity of VEGF-A and PIGF function. In 
addition, sFltl is able to act in a dominant negative manner to directly inhibit both 
VEGF-Rl and VEGF-R2 signaling (Autiero, et aI2003). PIGF plays a distinct role in 
regulating endothelial cell survival and therefore excess sFltl may inhibit this directly 
(Autiero et al., 2003). 
Maynard et al. (2003) hypothesized that in preeclampsia, excess sFltl causes 
widespread endothelial dysfunction by interfering with the normal physiological 
effects of VEGF and/or PIGF. They demonstrated that both preeclamptic serum and 
normal serum with added sFltl had profound anti-angiogenic effects in vitro and 
resulted in impaired tube formation in the HUVEC (Human Umbilical Vein 
Endothelial Cells) modeL compared to angiogenesis noted when serum from normal 
pregnant women was used. In that study, circulating sFlt 1 at levels obser\'l~d in 
preeclampsia blocked the dose-dependent increase in vasodilatation induced by VEGF 
or PIGF, which suggests that sFltl in preeclamptic patients might oppose 
physiological vasorelaxation, thus contributing to hypertension. Furthermore, 
exogenous sFltl administered to pregnant rats resulted in hypertension and 
proteinurea with renal lesions similar to the ones seen in preeclampsia, mainly 
glomerular enlargement with occlusion of the capillary loops by swelling and 
hypertrophy of endocapillary cells (glomerular endotheliosis), and focal foot-process 
effacement in podocytes. These changes were also observed in non-pregnant rats 
injected with sFltl, which suggests that the systemic effects of sFlt! do not require the 
presence of pregnancy or the placenta to develop. 
In pre-eclampsia the process of decidual spiral arteriole transformation is often 
incomplete and may lead to poor perfusion and episodic hypoxia, which are potent 
stimuli for expression of placental VEGF-A and its receptors, whilst having a 
suppressive effect on PIGF. This could result in increased binding of VEGF-A and 
PIGF to abundant sFlt! and a reduction of free VEGF-A and PIGF. Indeed, such a 
profile was observed in the present study and in the reports of Maynard et al. (2003) 
and Koga et al. (2003). All these data are consistent with PIGF having important 
effects on maternal endothelial cells during pregnancy and when this is inhibited the 
maternal syndrome of pre-eclampsia ensues. Together, this could result in loss of the 
vasodilatory action of free VEGF-A at the level of the maternal endothelium (Autiero 
et al., 2003). 
A study by Mckeeman et al. (2004) showed that serum sFlt 1 concentration III 
preeclampsia was elevated compared to normal controls throughout gestation (starting 
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at 12 weeks). This, however, reached statistical significance at 30 weeks and at pre-
delivery. Another study by Levine et al. (2004) demonstrated that serum sAt 1 
concentration started to increase at 21 to 24 weeks gestation, in women who later 
developed preeclampsia. In this study, serum sFltl concentration increased steeply at 
29 to 32 weeks. In these two studies (Mckeeman et al., 2004; Levine et at., 2004) 
serum sFltl concentration in normal controls remained constant until 33 to 36 weeks 
gestation, when a constant rise started till delivery. In my study, there were no 
differences in serum sFltl and PIGF with advancing gestational age in the control 
group. This could be attributed to that both controls and disease samples were 
collected before 36 weeks (ie. before the expected rise in serum sFlt 1). 
In this study, I have demonstrated that there is significant dysregulation of serum 
levels of sFltl and PIGF at 24 weeks, in pregnancies with abnormal uterine artery 
Doppler who developed severe early onset preeclampsia and normotensive IUGR 
pregnancies, when compared to normal controls. Significant differences in serum 
levels of sFltl between the preeclampsia and IUGR groups were also found at the 
time of the disease, despite similar changes in uterine artery Doppler resistance 
indices at 24 weeks and at the time of disease in these two groups. The control group 
in this study comprised women with abnormal uterine artery Doppler with normal 
pregnancy outcome. There might be an argument that this group is considered a 
"high-risk" group and strictly speaking, not normal controls. On the other hand, 
uterine artery Doppler, used as a screening method in my study, is known to have low 
positive predictive value for abnormal pregnancy outcome. This suggests that more 
than half of pregnancies considered high-risk using this screening method have 
normal pregnancy outcome, without evidence of placental dysfunction. Larger study 
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comparing serum sFltl and PIGF in pregnancies with abnormal uterine artery Doppler 
that develop preeclampsia and/or IUGR with normal uterine artery Doppler controls is 
needed. Elevated level of serum sFltl in normotensive IUGR compared to controls 
suggests that there is an element of placental hypoxia in IUGR cases compared to 
controls. The IUGR group studied comprised of seven cases, four of which had 
AREDF in umbilical artery Doppler. The rest had positive EDF, a factor contributing 
to placental hypoxia in face of reduced uterine artery blood flow due to failed 
modification of spiral arteries. 
The source of elevated sF1tl in preeclampsia is not clear. Trophoblast is a potential 
source as both villous and extra villous trophoblastic cells produce both sFlt 1 and 
PIGF (Tsatsaris et al., 2003). Studies of sF1tl in preeclampsia showed significant drop 
24 hour after delivery. In the study by McKeeman et al. (2004), serum sFltl 
concentrations at 37 weeks in preeclampsia were not significantly higher than 
controls. There was, however, a significant increase at the time of disease in the 
preeclampsia group, which often was not far from 37 weeks. This casts some doubt 
over the role of the placenta as the only source of sFltl, as a significant elevation in 
serum sFltl in the preeclampsia group compared to controls is to be expected at that 
advanced gestation, if the placenta was the major source of sFlt 1. Other potential 
sources include the liver and kidneys; both are affected in preeclampsia (He et ol., 
1999) and could be contributing to the significant increase in sFlt 1 in preeclampsia at 
the time of delivery. 
My observations in this study may have important implications for the prediction and 
thereby prevention of pre-eclampsia. It could be argued that as this study was 
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undertaken using second trimester samples that there would be limited value for 
potential therapeutic intervention. However, in a previous study of vitamin C and E 
supplementation in the second trimester of high-risk pregnancies, a significant 
reduction in the incidence of pre-eclampsia was observed compared to placebo 
(Chappell et aI., 1999). In that study, vitamin supplementation was associated with 
improvement in serum markers of placental function (Chappell et aI., 2002b). Clinical 
trials of antioxidant prophylaxis currently underway will provide an opportunity to 
validate the use of sFltl and PIGF in prediction of pre-eclampsia and to assess 
whether antioxidants reduce sFltl. The current study also has implications for the 
development of a novel prophylactic strategy. Theoretically placental angiogenesis 
and maternal endothelial function could be restored by the administration of PIGF 
and/or VEGF, or by blocking the production or action of sFltl leaving VEGF-A and 
PIGF available for binding to membrane bound VEGF receptors. 
The use of sFltl measurement alone or in combination with PIGF levels as a 
predictive indicator of pre-eclampsia needs to be confirmed in a larger prospective 
study of high-risk women, and in women at lower risk. However, these novel data 
further implicate angiogenic factors and their endogenous regulators in the etiology of 
pre-eclampsia and offer new hope for predictive and preventative strategies. 
In my study, I also demonstrated significant elevation in placental expression of Fit 1 
in preeclampsia compared to normotensive IUGR and controls at the time of delivery. 
All placentas studied were obtained at the time of pre-labour elective Caesarean 
Section, which avoids the confounding effect labour could have on placental 
expression of the studied proteins. My findings supports and extends the findings by 
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Maynard, et al (2003) that showed enhanced expression of Flt1 (using reverse 
transcriptase-polymerase chain reaction (RT-peR» in preeclamptic placentas 
compared to term controls. Another study of sFltl expression in preeclampsia by 
Tsatsaris et al. (2003) showed increased expression of sFlU mRNA in preeclamptic 
placentas compared with uncomplicated pregnancies. This increase was also found in 
placentas from pregnancies complicated by normotensive intrauterine growth 
restriction (IUGR). The authors attributed placental over expression of Fltl and sFltl 
in preeclampsia to the hypoxic state of the placenta. In their study, FItl and sFltl were 
also over expressed in normotensive IUGR placentas. These findings made the 
authors challenge the concept of placental hyperoxia in growth-restricted placentas 
with AREDF in umbilical artery Doppler introduced by Kingdom and Kaufmann 
(1997). In Tsatsaris et al. (2003) study, however, only 20% of their patient's 
population had AREDF in umbilical artery Doppler. In my study, all placentas studied 
in the IUGR group had AREDF in umbilical artery Doppler, whilst all preeclamptic 
placentas had positive EDF in umbilical artery Doppler flow. 
Placental hypoxia seems the major factor triggering the expreSSIOn of Fltl in 
trophoblast. FlU is known to be upregulated by hypoxia, mediated through Hypoxia 
Inducible Factor (HIF-1 a) binding to a hypoxia response element in the FIt 1 gene 
promoter (Gerber et aI., 1997). In addition, hypoxia stimulates alternate splicing of 
the FlU gene and the release of serum sFltl (Kendall & Thomas, 1993). This explains 
the significant increase in placental Flt! and serum sFlt! in cases of preeclampsia in 
my study. The placenta in this condition is known to be hypoxic (all cases had 
preserved EDF in umbilical artery Doppler). On the other hand. Placental expression 
of Fit I in cases of IUGR with AREDF in umbilical artery Doppler was not different 
194 
from gestational-age matched controls. This suggests the absence of placental hypoxia 
in these cases of IUGR compared to preeclampsia. 
I found no differences in PIGF expression between preeclamptic, ruGR and control 
placentas. This supports the findings of the study by Tsatsaris et al. (2003), which 
showed that placental PIGF mRNA expression was not different between 
preeclamptic and normotensive IUGR pregnancies. In my study, western blotting was 
used instead of RT -peR to assess FlU and PIGF expression in placental trophoblast. 
Western blotting detects protein expression at only one point in the tissue studied and 
does not necessarily reflect overall changes in synthesis and expression of that 
protein. In addition, western blotting is more valid in demonstrating the positive 
difference in protein expression between tissues rather than proving the absence of 
differences. Another draw back of this study is that the control group included only 
gestational-age-matched pregnancies, which had other complications such as preterm 
rupture of the membranes and infection. This could potentially influence FIt I and 
PIGF expression in these placentas. 
A study by Ahmad & Ahmed (2004) of the effect of placental sFltl on placental 
angiogenesis showed that levels of sFlt! released from placental villous explants were 
significantly higher in preeclamptic and fetal growth-restricted placentas compared 
with normal term placentas. This, however, was not associated with increase in 
expression of the full-length Fit!. This suggests that sFltl release from preeclamptic 
placenta is triggered without enhanced expression of the parent protein (FIt 1) itself. 
My findings do not support this, as I found a significant increase in placental Fit 1 
expression in preeclamptic placentas compared to both IUGR and controls. 
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Ahmad & Ahmed (2004) also suggested that elevated placental sFltl is implicated in 
impaired placental angiogenesis and trophoblast invasion in pregnancies that develop 
preeclampsia and IUGR. My findings of elevated sFltl in pregnancies with abnormal 
mid-trimester uterine artery Doppler that develop preeclampsia and IUGR suggests 
that sFltl could be a factor involved in impaired trophoblast invasion in these 
pregnancies that persist till the time of delivery. Cases of preeclampsia, however, have 
a several fold increase in serum sFltl just before delivery compared to normotensive 
IUGR. It seems that placental hypoxia at this stage is the main trigger responsible for 
the release of sFlt! in preeclampsia and could be responsible for the widespread 
endothelial dysfunction seen in this condition. 
CHAPTER 3 
196 
The relation between 24-week uterine artery Doppler resistance and 
serum soluble fms-like tyrosine kinase 1 (sPItl) and placental growth 
factor (PIGF) 
5.1 Introduction 
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Development of the feto-placental-uterine unit requires the invasion of the uterus by 
extravillous trophoblast cells, remodelling of the uterine spiral arterioles and 
development of a vast capillary network within the villous core of the placenta. 
Appropriate placental angiogenesis is critical for the successful transfer of oxygen and 
nutrients by the placenta from the maternal circulation into the fetus. Insufficient 
adaptation of the decidual and intramyometrial portions of the spiral arterioles in 
preeclampsia results in reduced utero-placental blood flow, leading to local placental 
hypoxia (Frusca et aI., 1989; Lunell et aI., 1982). Placental oxygen tension is known 
to affect placental production of VEGF-A, PIGF and sFlt!. 
Evidence suggests that major reductions in umbilical artery blood flow (represented 
by absent/reversed EDF and or raised resistance indices) is associated with a pattern 
of villous maldevelopment in the placenta in which the peripheral villi contain 
slender, unbranched and uncoiled capillary loops (Kingdom et al., 1997). In chapter 
one, I reported that pregnancies complicated by preterm preeclampsia had lower 
umbilical artery Doppler resistance indices before delivery, when compared to 
normotensive IUGR pregnancies. This indicates distinct placental response in these 
pregnancies with impaired placental invasion and abnormal uterine artery Doppler 
flow. Todros et al. (1999) suggested that pregnancies complicated by preeclampsia 
(with and without fetal growth restriction) with positive end diastolic frequencies 
(EDF) in umbilical artery Doppler before delivery had an adaptive response in the 
villous placenta, characterized by branching angiogenesis, which compensates for the 
underlying impairment of uteroplacental blood flow. By contrast, this pattern of 
villous vascularization was lacking in the fetal growth restriction group complicated 
by absent or reversed EDF in umbilical artery Doppler. This indicates that umbilical 
198 
artery Doppler flow could indirectly reflect the pattern of placental villous 
development, and consequently oxygen level within the placenta (placentas with 
preserved EDF in umbilical artery Doppler are more hypoxic compared to placentas 
with AREDF in umbilical artery Doppler (Kingdom et ai., 1997». 
In the last study (chapter 2), placental expression of FItI was upregulated in 
preeclampsia, possibly related to placental hypoxia. This also resulted in increased 
serum sFlt! production. The increase in serum sFlU was, however, seen in cases of 
both preeclampsia and normotensive IUGR, despite significantly higher serum levels 
in cases of preeclampsia. This could indicate a more pronounced level of placental 
hypoxia in preeclampsia, compared to IUGR. The increase in serum sFIt 1 in cases of 
preeclampsia and IUGR was noticed from as early as 24 weeks, in pregnancies with 
abnormal uterine artery Doppler. Placental sFItl, through blocking of VEGF-A and 
PIGF, could be implicated in defective angiogenesis and trophoblast invasion in these 
placentas, indirectly seen as abnormal uterine artery Doppler. 
The aim of this study was: 1. To investigate the correlation between uterine artery 
resistance indices (pulsatility index (PI) and resistance index (RI» at 24 weeks and 
serum levels of PIGF and sFItl; 2. To examine the effect of placental hypoxia within 
24 hours of delivery (reflected by umbilical artery PI and RI) on corresponding serum 
levels of sFlt!, in pregnancies complicated by preeclampsia and normotensive IUGR. 
5.2 Methods 
Women enrolled in this study were the same study group with abnonnal uterine artery 
Doppler, that were followed up and enrolled in the previous study (see chapter 2). 
Among the 31 women with abnormal uterine artery Doppler at 24 weeks gestation, 
eight women developed preeclampsia before 36 weeks gestation, seven developed 
nonnotensive IUGR and sixteen were enrolled as controls. Abnonnal uterine artery 
Doppler was defined as bilateral notches with a mean RI>O.55, or unilateral notch 
with a mean RI>O.65. Uterine artery Doppler velocity flow wavefonns were obtained 
via the transabdominal approach, using the technique described in Materials and 
Methods, and the position of the placenta was noticed. Resistance and Pulsatility 
index (RI and PI) in both placental and non-placental side were recorded, along with 
the mean RI and PI, using built in software in the ultrasound machine (ATL-5000). 
Blood was collected from women with abnonnal uterine artery Doppler at the time of 
the examination and serum was stored at -80C, using the technique described in 
chapter 2. Serum assay for sFltl and PIGF, in women with abnormal uterine artery 
Doppler, was performed using sandwich ELISA technique as described in Materials 
and Methods. Data was considered non-parametric and correlation coefficients 
between uterine artery resistance indices [PI, RI (placental and non-placental side), 
and mean PI and RI] and corresponding serum levels of sFlt 1 and PIGF were then 
calculated using Spearman correlation coefficient. 
To investigate the effect of umbilical artery blood flow on serum levels of sFlt 1 and 
PIGF women with abnormal uterine artery Doppler that developed preeclampsia 
, 
(n=8) and normotensive IUGR (n=7) had umbilical artery Doppler examination and 
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blood collected in the same setting within 24 hours of delivery. Serum was stored at -
80C for further assay of sFltl and PlGF. 
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5.3 Results 
Correlation between uterine artery resistance indices and serum sFlt] and PlGF: 
Table 5.1 illustrates the clinical outcome and serum levels of sAtl and PIGF at 24 
weeks in the study and control groups and the corresponding uterine artery Doppler 
resistance indices. Using the Spearman correlation coefficient, significant positive 
correlation was found between sFItl levels and uterine artery PI and RI, in both the 
placental and the non-placental sides and the mean value for RI and PI. Table 5.2 
summarizes the correlation coefficients between uterine artery resistance indices at 24 
weeks and sFlU levels. Figures 5.1-5.6 illustrate the correlations between uterine 
artery resistance indices at 24 weeks and sFItl levels (n=31). 
On the other hand, PIGF was negatively correlated with all uterine artery resistance 
indices at 24 weeks. Table 5.3 illustrates the correlation coefficients between PIGF 
and uterine artery resistance indices (RI, PI (placental and non-placental sides) and 
mean RI and PI) and the corresponding p value. Figures 5.7-5.12 illustrate the 
correlation between PIGF and uterine artery resistance indices at 24 weeks. 
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Table 5.1 Serum sFlt!, PIGF and uterine artery resistance indices at 24 weeks. 
No Outcome sPItl PIGF RI (P) RI (NP) PI(P) PI (NP) Mean Mean 
RI PI 
1 IUGR 1516 292 0.63 0.66 1.11 1.26 0.65 1.19 
2 IUGR 3255 306 0.61 0.76 1.11 1.74 0.69 1.43 
3 IUGR 2846 168 0.70 0.73 1.39 1.50 0.72 1..+5 
4 IUGR 2860 449 0.68 0.79 1.26 1.87 0.74 1 A.+ 
5 IUGR 1393 20 0.74 0.82 1.70 2.04 0.78 1.87 
6 IUGR 3858 820 0.58 0.78 0.98 1.70 0.68 1.34 
7 IUGR 3624 325 0.71 0.79 1.41 1.70 0.75 1.56 
8 PET 1022 186 0.72 0.73 1.59 1.61 0.73 1.60 
9 PET 1472 252 0.59 0.69 1.04 1.40 0.64 1.22 
10 PET 3334 178 0.72 0.77 1.65 1.85 0.73 1.75 
11 PET 2606 315 0.65 0.71 1.25 1.54 0.68 1.40 
12 PET 3002 10 0.57 0.76 0.85 1.70 0.67 1.28 
13 PET 4693 191 0.83 0.85 2.25 2.27 0.84 2.26 
14 PET 5243 284 0.74 0.77 1.52 1.67 0.76 1.60 
15 PET 3943 180 0.79 0.84 1.92 2.15 0.82 2.04 
16 Normal 783 573 0.57 0.58 0.97 0.98 0.58 0.98 
17 Normal 1250 937 0.51 0.70 0.77 1.25 0.60 1.01 
18 Normal 1682 255 0.59 0.65 1.03 1.16 0.62 1.10 
19 Normal 1784 266 0.57 0.75 0.94 1.57 0.66 1.26 
20 Normal 798 730 0.60 0.64 1.06 1.22 0.62 1.14 
21 Normal 928 350 0.40 0.80 1.05 2.03 0.60 1.5.+ 
22 Normal 1482 500 0.65 0.71 1.17 1.40 0.68 1.29 
23 Normal 1376 493 0.56 0.71 0.95 1.50 0.64 1.2"' 
24 Normal 1679 1129 0.40 0.69 0.53 1.37 0.55 0.95 
25 Normal 757 764 0.66 0.66 1.24 1.2tl 0.66 
1.25 
26 Normal 704 564 0.61 0.75 1.07 1.69 0.68 
1.3R 
2( ).~ 
No Outcome sFltl PIGF RI (P) RI (NP) 
27 Normal 2139 203 0.52 0.78 
28 Normal 1519 1025 0.61 0.76 
29 Normal 386 250 0.71 0.73 
30 Normal 735 833 0.60 0.65 
31 Normal 359 255 0.55 0.62 
IUGR:lntrauterine Growth Restriction, PET Preeclampsia 
P: Placental Side, NP: Non-placental side 
PI(P) PI (NP) Mean Mean 
RI PI 
0.79 1.82 0.65 1.31 
1.11 1.24 0.69 0.97 
0.98 1.10 0.72 0.91 
1.02 1.07 0.63 0.85 
0.95 1.15 0.58 0.87 
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Table 5.2 Correlations between uterine artery resistance indices at 24 weeks and 
serum sPltt. Using Spearman correlation coefficient, significant positive correlation 
was found between uterine artery resistance indices and serum sFltl at 24 weeks. 
Spearman Correlation Coefficient p value 
RI (placental side) 0.362 0.045 
RI (non-placental side) 0.632 <0.001 
Mean RI 0.575 0.001 
PI (placental side) 0.391 0.030 
PI (non-placental side) 0.720 <0.001 
Mean PI 0.620 <0.001 
Table 5.3 Correlations between uterine artery resistance indices at 24 weeks and 
serum PIGF. Using Spearman correlation coefficient, significant negative correlation 
was found between uterine artery resistance indices and serum PIGF at 24 weeks. 
Spearman correlation coefficient p value 
RI (placental side) -0.437 0.014 
RI (non-placental side) -0.382 0.034 
Mean RI -0.485 0.006 
PI (placental side) -0.372 0.040 
PI (non-placental side) -0.479 0.006 
Mean PI -0.526 0.002 
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Figure 5.1 Correlation between uterine artery Doppler resistance indice (RI) of the 
placental side at 24 weeks and the corresponding serum sFltl. U ing Spearman 
correlation coefficient, significant positive correlation exists between the two group 
(r=O.362, p=O.045) 
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Figure 5.2 Correlation between uterine artery Doppler resistance indice (RI) in the 
non-placental side at 24 weeks and the corresponding serum sFltl. U ing Spearman 
correlation coefficient, significant positive correlation exists between the two group 
(r=0.632, p<O.OOl) 
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Figure 5.3 Correlation between uterine artery mean resistance indices (mean RI) at 24 
weeks and the corresponding serum sFltl. Using Spearman correlation coefficient, 
significant positive correlation exists between the two groups (r=0.575, p=O.OOl). 
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Figure 5.4 Correlation between uterine artery Doppler pulsatility indice (PD of the 
placental side at 24 weeks and the corresponding serum sFlU. Using Spearman 
correlation coefficient, significant positive correlation exists between the two group 
(r=0.391, p=0.03) 
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Figure 5.5 Correlation between uterine artery Doppler pulsatility indice (PI) of the 
non-placental side at 24 weeks and the corresponding serum sFltl. Using Spearman 
correlation coefficient, significant positive correlation exists between the two group 
(r=0.720, p<O.OOl) 
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Figure 5.6 Correlation between uterine artery Doppler mean pulsatility indice (mean 
pn at 24 weeks and the corresponding serum sFlt!. Using Spearman correlation 
coefficient, significant positive correlation exists between the two groups (r=O.620 
p<O.OOl) 
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Figure 5.7 Correlation between uterine artery Doppler resistance indice (Rr) of the 
placental side at 24 weeks and the corresponding serum PIGF. Using Spearman 
correlation coefficient, significant negative correlation exists between the two group 
(r=-0.437, p=0.014) 
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Figure 5.8 Correlation between uterine artery Doppler resistance indices (Rl) in the 
non-placental side at 24 weeks and the corresponding serum PIGF. Using Spearman 
correlation coefficient, significant negative correlation exists between the two group 
(r=-0.382, p=0.034). 
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Figure 5.9 Correlation between uterine artery mean resistance indices (mean RI) at 24 
weeks and the corresponding serum PIGF. Using Speannan correlation coefficient 
significant negativecorrelation exists between the two groups (r=-0.485, p=0.OO6) 
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Figure 5.10 Correlation between uterine artery Doppler pulsatility indice (PI) of the 
placental side at 24 weeks and the corresponding serum PlOF. U ing Spearman 
correlation coefficient, significant negative correlation exists between the two group 
(r=-0.372, p=O.04). 
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Figure S.ll Correlation between uterine artery Doppler pulsatility index (PD of the 
non-placental side at 24 weeks and the corresponding serum PIGF. U ing Spearman 
correlation coefficient, significant negative correlation exists between the two group 
(r=-0.479, p=0.006). 
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Figure 5.12 Correlation between uterine artery Doppler mean pulsatility indice 
(mean pn at 24 weeks and the corresponding serum PI OF. Using Speannan 
correlation coefficient, significant negative correlation exists between the two group 
(r=-0.526, p=O.002). 
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Correlation between umbilical artery resistance and serum sFlt} within 24 hours of 
delivery 
To investigate the effect of placental blood flow on serum levels of sPIt 1, I used the 
Spearman correlation coefficient to correlate umbilical artery resistance indices (RI 
and PI) within 24 hours of delivery in cases of abnormal pregnancy outcome 
(preeclampsia and normotensive IUGR) (n=15) and the corresponding serum levels of 
sFltl. Significant negative correlation was found between umbilical artery resistance 
indices and corresponding serum sPIti. Table 5.4 summarises the correlation 
coefficients and figures 5.13 and 5.14 illustrate these correlations. 
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Table 5.4 Spearman correlation coefficients between umbilical artery resistance 
indices and corresponding serum sFltl level within 24 hours of delivery in cases of 
preeclampsia and normotensive IUGR (n=15). 
Spearman Correlation p value 
Coefficient 
Umbilical artery RI -0.665 0.007 
Umbilical artery PI -0.674 0.006 
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Figure 5.13 Correlation between umbilical artery Doppler resistance indice (RI) and 
the corresponding serum sFlt! within 24 hr of delivery in preeclampsia and IUGR. 
Using Spearman correlation coefficient, significant negative correlation exi 
between the two groups (r=-0.665, p=0.007). 
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Figure 5.14 Correlation between umbilical artery Doppler pulsatility indice (PI) and 
the corresponding serum sFlt 1 within 24 hours of delivery in cases of preeclamp ia 
and IUGR. Using Spearman correlation coefficient, significant negative correlation 
exists between the two groups (r=-0.674, p=0.006). 
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Discussion 
In this study, the in-vivo effect of varying degrees of impaired placentation and 
angiogenesis at 24 weeks on serum levels of sFltl and PIGF was assessed. This study 
demonstrates positive correlations between uterine artery Doppler resistance indices at 
24 weeks and serum sFltl levels. In addition, negative correlations were found 
between these indices and serum PIGF. I demonstrated in chapter 2 that serum sFlt 1 
and PIGF levels were abnormal in pregnancies with abnormal uterine artery Doppler 
at 24 weeks. Serum values were abnormal in pregnancies that developed preeclampsia 
or normotensive IUGR, without major differences between the two groups. The 
positive correlation between serum sFltl and uterine artery resistance indices and the 
negative correlation between PIGF and those resistance indices provides further 
evidence of the effect of placental sFItI and PIGF on impaired placental angiogenesis 
and trophoblast invasion. 
The pathogenesis of preeclampsia is thought to act at three levels: defective 
placentation, placental ischaemia, and endothelial cell dysfunction (Chung et al., 
2004). Vascular endothelial growth factor is a critical regulator for vascular growth 
and function. VEGF actions are mediated via binding to its receptors, which include 
VEGFR-I (Fltl) and VEGFR-2 (FlkllKDR). VEGFR-2 is the major signal transducer 
of VEGF in endothelial cells and mediates most known VEGF bioactivities. In 
contrast, FItI has been implicated in the inhibition of VEGF-dependent endothelial 
function (Giles et aI., 2000; Zeng et aI., 2001). 
d h I t d sFlt I in patients with Recently Ahmad and Ahmed (2004) showe t at e eva e . 
preeclampsia has anti-angiogenic effects during placental development. They showed 
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that conditioned media from preeclamptic placentas attenuated endothelial cell 
migration and in vitro tube formation, two key markers of angiogenesis. This suggests 
that raised levels of sFltl in those placentas may explain the poorly developed feto-
placental vasculature associated with this disorder. In normal pregnancy, the rapid 
growth of the placenta and the associated vascularization occurs from the second 
trimester on wards. In preeclampsia, during this period, circulating levels of sAt 1 are 
elevated. The study by Ahmad and Ahmed (2004) showed that in preeclampsia there 
is loss of >70% of PIGF activity in the placenta. This strongly supports the premise 
that the VEGFIPIGFaxis is dysregulated in this disorder. They showed that removal 
of sAtl by immunoprecipitation from preeclamptic controlled medium significantly 
restored angiogenesis. This further suggests that the elevated sAt 1 in preeclampsia is 
likely to be responsible for the poorly developed feto-placental vasculature associated 
with this disorder. 
My study is the first to assess the in vivo relation between uterine artery resistance 
indices and serum sFltl and PIGF in mid trimester. My findings support and extend 
the study by Ahmad and Ahmed (2004), that suggested that sFlt 1 is a major factor 
responsible for impaired placental angiogenesis and development in midtrimester in 
complicated pregnancies. The increase in serum sAtl was associated with a 
concomitant drop in free PIGF, which suggests bindings of PIGF by its antagonist 
sFlt 1. 
A study of placental bed expression of Fltl in preeclampsia and intrauterine growth 
. . al I h d significant reduction in Fit 1 mRNA 
restnctlon compared to norm contro s s owe 
b d d to controls Fit 1 expression was expression in preeclamptic placental e s compare ' . 
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also reduced in placental beds from IUGR pregnancies but this did not reach statistical 
significance (Tsatsaris et aI., 2003). In this study, it was not possible to determine 
whether this modification was a cause or a consequence of the pathologic status of 
pregnancy. The authors suggested that low levels of Atl in placental beds might 
explain the defective uterine vascularization associated with early-onset preeclampsia. 
In my study, the association between uterine artery resistance indices and serum levels 
of sAU and PIGF indicates a role for these markers, both at placental and serum level, 
in modulating trophoblast invasion of the spiral arteries and the physiological changes 
in uterine artery resistance seen in normal pregnancies. On the other hand, 
upregulation of sFltl expression at 24 weeks in cases of abnormal uterine artery 
Doppler could represent a response to placental hypoxia due to defective trophoblast 
invasion. Hypoxia has been shown to increase sFltl production by placental 
cytotrophoblasts (Hornig et aI., 2000). This provides evidence that placental hypoxia 
is an early event in these pregnancies. 
Disordered placentation is responsible for a wide range of pregnancy complications, 
ranging from miscarriage through second trimester fetal death and the classic third 
trimester complications of preeclampsia, intrauterine growth restriction and placental 
abruption. Placentation begins with implantation of the blastocyst beneath the uterine 
epithelium and differentiation into embryonic and extraembryonic tissues (Cross, 
1998). A maternal uteroplacental circulation is gradually established in tandem with a 
fetoplacental circulation. Close co-ordination of the development of these circulations 
is essential to Ineet the rising fetal demands for oxygen. Any disturbance of the 
balance between these circulations will alter intra-placental oxygen content. An 
increasing body of evidence supports the concept that villous development depends 
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upon local oxygen conditions, and in tum that disturbed placental oxygenation is a 
feature of many pathological conditions (Kingdom and Kaufmann, 1999) including 
preeclampsia. 
The data on FItl expression in normal and preeclamptic placentas is controversial. I 
demonstrated in the last chapter that there is upregulation of FIt 1 expression in 
preeclamptic placentas, compared to placentas from IUGR and control pregnancies at 
the time of delivery. This might be a result of a lowered placental oxygen level within 
the placenta in preeclampsia with abnormal uterine artery Doppler. Placentas from 
pregnancies with AREDF in umbilical artery Doppler are known to have impaired 
branching angiogenesis, characteristic of normal third trimester placentas. The cause 
of this is not entirely clear but the reduced number and maldevelopment of peripheral 
villi result in a marked impairment of oxygen extraction from the intervillous space 
(Krebs et aI., 1996). This results in a raised placental oxygen level that potentially 
offsets impaired oxygenation, resulting from impaired trophoblast invasion. In 
contrast, placentas from preeclamptic pregnancies with positive end-diastolic 
frequencies have a normal pattern of stem artery development, increased capillary 
angiogenesis and development of terminal villi, as signs of an adaptive mechanism 
(Todros et aI., 1999). This causes local placental hypoxia and possibly upregulation of 
FItl and its soluble form sFItl (Hornig et aI., 2000). 
In this study, I have demonstrated that there is an inverse correlation between 
umbilical artery resistance indices and serum sFltl levels within 24 hours of delivery. 
This provides further evidence of the role of placental hypoxia in preeclampsia. 
Preeclamptic pregnancies had significantly lower umbilical artery Doppler resistance 
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indices that resulted in increased placental blood flow from the fetal side and 
consequently placental hypoxia in the face of diminished uteroplacental blood supply. 
Hypoxia is known to up regulate placental sFltl production, which could be 
responsible for the widespread endothelial dysfunction seen in the disease (Maynard 
et aI., 2003). In contrast, normotensive IUGR pregnancies with raised umbilical artery 
resistance indices and lower umbilical artery blood flow had significantly lower serum 
sFltl levels, possibly due to relatively higher oxygen level within the placenta. This is 
due to lowered placental blood flow from the fetal side rather than higher 
uteroplacental blood flow. 
In summary, this study reports that there is significant dysregulation of expression of 
sFltl and PIGF in pregnancies with abnormal uterine artery Doppler resistance indices 
from as early as 24 weeks. This dysregulation correlated with the severity of 
uteroplacental dysfunction. Abnormalities in PIGF and sF1tl expression could be a 
contributing factor to impaired placental angiogenesis and trophoblast invasion in 
these pregnancies. On the other hand, this dysregulation could represent a response of 
the placenta to hypoxia caused by impaired spiral artery invasion by trophoblast. 
Further research in this area is needed to accurately describe the role of these 
molecules in pregnancies with abnormal uterine artery Doppler. These findings 
provide potential therapeutic approaches for the prevention and treatment of 
preeclampsia and suggest that pharmacological intervention to inhibit sFlt 1 may be 
worthy of investigation. 
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CHAPTER 4 
Serum and placental Fas and Fas ligand in high-risk women with 
abnormal 24-week uterine artery Doppler 
6.1 Introduction 
Apoptosis, or controlled cell death, is an important feature of placental cell 
management in normal pregnancy (Smith et al., 1997). There is evidence that 
placentas of pregnancies complicated by pre-eclampsia or IUGR show enhanced 
apoptosis when compared with placentas of normal pregnancies (DiFederico et al., 
1999; Allaire et al., 2000; Ishihara et al., 2002). Furthermore, physiological changes 
in the spiral arteries are absent in pregnancies complicated by preterm pre-eclampsia 
and intrauterine growth restriction, which, in tum, causes placental hypoxia 
(Harrington et aI., 1997). It is not clear whether increased placental apoptosis in these 
pregnancies is the cause of impaired placental invasion or is a direct result of 
placental hypoxia. The cause of impaired trophoblast invasion in pregnancies with 
abnormal mid-trimester uterine artery Doppler that subsequently develop 
preeclampsia and/or intrauterine growth restriction (IUGR) is far from clear. I showed 
in chapters 2 and 3 important dysregulation of the VEGF system and its receptors in 
these pregnancies. This affects placental angiogenesis and possibly trophoblast 
growth and invasion, but does not provide explanation of the increased apoptosis in 
these placentas. 
The placenta has always been viewed as an immune-privileged site. The factors 
behind this immune privilege are not entirely clear yet. Breaking of this immune 
privilege was viewed responsible for inadequate placental function and hence 
development of conditions such as preeclampsia and intrauterine growth restriction 
(Allaire et aI., 2000). The Fas-Fas ligand system is believed to affect the death of 
inflammatory cells in immune-privileged sites such as the cornea of the eye and the 
testis. Many tissues express Fas membrane protein, whereas Fas ligand is expressed 
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only by circulating lymphocytes and in cells in immune-privileged sites. At those 
privileged sites, Fas-expressing peripheral T cells bind to Fas ligand in tissues 
expressing it. Fas-Fas ligand interaction delivers a signal to induce apoptosis in 
peripheral lymphocytes (Griffith et at., 1995). Prior research has suggested that Fas 
ligand is normally expressed in human trophoblast throughout pregnancy and induces 
apoptosis in circulating activated T cells (Bamberger et ai., 1997). The expression of 
Fas ligand by the placenta might affect survival of the fetal allograft through the 
induction of apoptosis of circulating maternal leukocytes, allowing cytotrophobalsts 
to invade into the myometrium while escaping immune recognition. Alterations in the 
balance of mutual induction of apoptosis might affect diseases associated with 
abnormal placentation (eg pre-eclampsia, IUGR, placenta acretaJpercreta, 
choriocarcinoma) (Allaire et at., 2000). Recent studies have shown that membrane 
Fas activation may transduce dual apoptosis and non-apoptosis pathways. The non-
apoptotic functions of Fas include proliferation, fibrosis, inflammation and 
angiogenesis (Hohlbaum et at., 2002). 
This study evaluates serum and placental levels of Fas and FasL in pregnancies with 
abnormal 24 week uterine artery Doppler that develop pregnancy complications due 
to uteroplacental insufficiency, namely pre-eclampsia and IUGR pregnancies, 
compared to normal controls. 
230 
6.3 Methods 
Serum Fas and FasL assay in pregnancies with abnormal mid-trimester uterine 
artery Doppler. 
In the uterine artery Doppler screening study at 23-24 weeks, 86 women attended 
follow up for fortnightly growth scans and uterine artery Doppler flow examination, 
along with BP checks and urine analysis for protein. Fetal Doppler examination was 
performed in cases where there was suspicion of growth restriction on ultrasound 
examination. Using pulsed Doppler, flow velocity waveforms were obtained and 
resistance indices (RI and PI) were measured in the umbilical artery, middle cerebral 
artery and fetal aorta (see chapter 2). Doppler of the DV was performed if the IUGR 
was associated with evidence of fetal compromise by arterial Doppler examination. 
Doppler examination was then performed three times per week up to the time of 
delivery. Timing of delivery was decided on clinical grounds, as well as 
cardiotocographic examination, in conjunction with Doppler ultrasound examination 
results. 
Preeclampsia was defined according to the definition by the ISSHP (see chapter one). 
IUGR was defined as fetal weight less than the 5th centile for gestational age along 
with abnormal umbilical artery Doppler examination (see below) or fetal biometry 
measurements crossing the fetal growth centiles over at least two fetal biometry 
examinations 10-14 days apart. This excluded any constitutionally (normal) SGA 
fetuses from the study. Abnormal umbilical artery Doppler was defined as absent or 
reversed EDF and/or resistance indices (PI and RI) > 95 th centile for gestational age 
(Harrington et al, 1999). Abnormal uterine artery Doppler was defined as persistence 
of unilaterallbilateral notches with PI and RI > 95th centile for gestational age. 
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Statistics were performed with Microsoft Statistical Package for Social Sciences 
(SPSS)-10, Chicago, IL, USA. Data were considered non-parametric and Mann-
Whitney U test was used for comparisons. 
In this cohort, 15 pregnancies delivered before 36 weeks due to pregnancy 
complications related to uteroplacental insufficiency. Eight women developed 
preeclampsia. The gestational age of the preeclampsia group at delivery ranged 
between 28-36 weeks (median 32 weeks). Birth weight ranged between 720g-2680g 
(median 1360g). There were two intrauterine fetal deaths in this group. One was 
associated with severe IUGR and AREDF in umbilical artery Doppler flow at 28 
weeks. The other fetal death complicated placental abruption at 30 weeks. The fetus 
was normally grown with a birth weight of 1250g (loth centile). There were no 
neonatal deaths in this group. Antenatal umbilical artery (UA) Doppler examination 
24 hours before delivery revealed positive EDF in all cases except one that had 
AREDF at 28 weeks and intrauterine fetal death. 
Seven other pregnancies in the study group were complicated by normotensive IUGR 
«5th centile) that needed delivery before 36 weeks due to fetal compromise. Four 
pregnancies had AREDF in umbilical artery Doppler examination 24 hours before 
delivery. None of these pregnancies had preeclampsia. The gestational age at delivery 
was not different from the preeclampsia group (range 27-35, median 34 weeks) 
(p=O.712). Birth weight ranged from 500-1728g (median 953g), which was not 
different from the preeclampsia group (p=0.674). Among this group, there was one 
fetal death in utero due to severe uteroplacental insufficiency and one neonatal death. 
Blood was collected from pregnancies enrolled in the study at 24 weeks (the time of 
uterine artery Doppler examination) and within 24 hours of delivery. Serum was 
stored at -80C for further assay. Serum Fas and FasL was measured in the 
preeclampsia, IUGR and gestational age matched control (n=16) groups both at 24 
weeks and at the time of disease using Enzyme Linked Immune Sorbent Assay (ELISA) 
Enzyme Linked Immune Sorbent Assay (ELISA) 
I.Serum Fas ELISA 
Procedure 
• Preparation of Reagents 
1. Wash solution 
100 ml of Wash concentrate was diluted with 900 ml of distilled water. 
2. Conjugate solution 
Peroxidase conjugated anti-Fas monoclonal antibody 1: 101 was diluted with 
conjugate diluent by adding 10ul of the Peroxidase conjugated anti-Fas 
monoclonal antibody to 1000ul of the conjugate diluent. 
3. Standards 
a) sFas calibrator was reconstituted with 100ul of distilled water. 
b) The reconstituted calibrator 1: 100 was diluted with Assay diluent accurately to 
make the first standard by adding 10ul of the reconstituted Calibrator to 990ul 
of Assay diluent. 
c) The first standard was serially diluted with Assay diluent to make 7 standards. 
Assay diluent was used for 0 ng/ml standard. 
• Preparation of samples 
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1. Serum was used for sFas ELISA assay after thawing in room temperature for 
60 minutes. 
2. Dilution: each sample was diluted 1:5 with Assay diluent by adding SOul of 
sample to 200ul sample diluent. 
• Sample incubation 
Duplicate assays were used. 
1. 150ul of prepared samples and standards were added to 96-well polyvinyl 
plate as the same order of assay run. After that, 100ul of each sample were 
transferred to the antibody-coated microwell simultaneously usmg 
multichannel pipette. Pipetting was completed as quickly as possible 
2. The plate was incubated for 60 minutes at room temperature (22C) with 
shaking at 200 rpm. 
• Washing 
The well contents were discarded and the wells were washed with wash solution 
and the contents were discarded. The wells were washed four times using wash 
bottles. Washing buffer was used at room temperature (23C). 
• Conjugate incubation 
1. Conjugate solution was poured into the vessel. After removing wash solution 
that remained completely, 100ul of conjugate solution were pi petted to each 
well with multichannel pipette. 
2. The conjugate solution in the wells was incubated for 60 minutes at room 
temperature with shaking at 200 rpm. 
• Washing 
The well contents were discarded and the wells were washed with wash solution 
and the contents were discarded. The wells were washed four times using wash 
bottles. Washing buffer was used at room temperature (23C). 
• Substrate incubation 
1. Substrate reagent was pored into the vessel by adding 100ul of prepared 
Substrate reagent to each well. Substrate reagent was used at room 
temperature and the vessel used was different from the one used for pouring 
Conjugate solution. 
2. The substrate was incubated at room temperature for 30 minutes with shaking 
at 200 rpm. 
• Stopping reaction 
Stop solution was poured into the vessel. 100ul of stop solution was pipetted to 
each well with multichannel pipette. 
• Reading 
The absorbance of each well was read at 450 nm. Reading was done promptly 
after stopping reaction. 
• Calculation 
The mean absorbance value of each standard was calculated, and was plotted and 
was plotted to construct a standard curve (Absorbance on the vertical axis, 
concentration (ng/ml) on the horizontal axis. The concentration of samples was 
calculated by multiplying the value read from the standard curve by dilution factor 
(X 5). 
Serum FasL ELISA 
Procedure 
• Preparation of Reagents 
1. Wash solution 
100 ml of Wash concentrate was diluted with 900 ml of distilled water. 
2. Conjugate solution 
Peroxidase conjugated anti-Pas Ligand monoclonal antibody 1: 101 was diluted 
with conjugate diluent by adding 10ui of the Peroxidase conjugated anti-Fas 
monoclonal antibody to 1000ui of the conjugate diluent. 
3. Standards 
d) sPas Ligand calibrator was reconstituted with 100ul of distilled water 
(250nglml). 
e) The reconstituted calibrator (250nglml) 1 :50 was diluted with Assay diluent 
accurately to make the first standard by adding 20ul of the reconstituted 
Calibrator to 980ul of Assay diluent. 
f) The first standard was serially diluted with Assay diluent to make 6 standards. 
Assay diluent was used for a nglml standard. 
4. Substrate solution 
Just prior to colour development, equal volumes of substrate A and substrate B. 
The solution was used as soon as possible using disposable new pipette and 
vessel, as the substrate solution is easy to oxidized by metal ion. 
• Preparation of samples 
1. Serum was used for sPas ELISA assay after thawing in room temperature for 
60 minutes. 
2. Dilution: each sample was diluted 1:5 with Assay diluent by adding Saul of 
sample to 200ul sample diluent. 
3. Dilution 
Each sample was diluted 1:2 with assay diluent by adding 100ul of sample to 
100ul Assay diluent. 
• Sample incubation 
Duplicate assays were used. 
1. 150ul of prepared samples and standards were added to 96-well polyvinyl 
plate as the same order of assay run. After that, 100ul of each sample were 
transferred to the antibody-coated microwell simultaneously usmg 
multichannel pipette. Pipetting was completed as quickly as possible 
2. The plate was incubated for 60 minutes at room temperature. 
3. Washing 
The well contents were discarded and the wells were washed with wash solution 
and the contents were discarded. The wells were washed four times using wash 
bottles. Washing buffer was used at room temperature (23C). 
• Conjugate incubation 
3. Conjugate solution was poured into the vessel. After removing wash solution 
that remained completely, 100ul of conjugate solution were pipetted to each 
well with multichannel pipette. 
4. The conjugate solution in the wells was incubated for 60 minutes at room 
temperature. 
• Washing 
The well contents were discarded and the wells were washed with wash solution 
and the contents were discarded. The wells were washed four times using: wash 
bottles. Washing buffer was used at room temperature. 
• Substrate incubation 
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4. Substrate reagent was pored into the vessel by adding l00u1 of prepared 
Substrate reagent to each well. Substrate reagent was used at room 
temperature and the vessel used was different from the one used for pouring 
Conjugate solution. 
5. The substrate was incubated at room temperature for 30 minutes. 
• Stopping reaction 
Stop solution was poured into the vessel. 100ul of stop solution were pipetted to 
each well with multichannel pipette. 
• Reading 
The absorbance of each well was read at 450 nm. Reading was done promptly 
after stopping reaction. 
• Calculation 
The mean absorbance value of each standard was calculated, and was plotted and 
was plotted to construct a standard curve (Absorbance on the vertical axis, 
concentration (ng/ml) on the horizontal axis. The concentration of samples was 
calculated by multiplying the value read from the standard curve by dilution factor 
(X 2). 
Placental expreSSlon of Fas and FasL in preeclamptic, normotensive IUGR and 
control pregnancies. 
Western blotting 
Western blotting was used to study placental expression of Fas and FasL using the 
principles described in chapter two. Four placental samples from pregnancies 
complicated by preeclampsia with preserved EDF in umbilical artery Doppler, four 
samples from normotensive IUGR with AREDF in umbilical artery Doppler and four 
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gestational age matched controls were studied. The gestational age of the placentas 
studied (disease and control groups) ranged from 28-32 weeks. All disease samples 
had abnormal midtrimester uterine artery Doppler at 24 weeks. 
In summary, supernatants of homogenized placental samples were thawed in ice, and 
then heated for 10 minutes at 90 degrees. Kleidoscope and marker samples were 
thawed in ice and heated for one minutes at 40C and 90C respectively. All samples 
were centrifuged at 13G for 40 seconds, and then 50 micrograms of each sample was 
loaded to the wells in the prepared gel. Using running buffer, separating 
electrophoresis was started at 60 Amperes for 10 minutes then at 80 Amperes for 40 
minutes, after which the stacking gel was removed. The gels were subsequently 
incubated for 30 minutes in transfer buffer. Protein was transferred from the gel to 
blotting membrane with blot buffer and two hours were allowed for protein transfer at 
100V under cooling conditions using ice. Membranes were then incubated overnight 
in blocking solution in a cold room. 
Membranes were then incubated in primary antibody solution (Fas and FasL, R&D 
systems, Abingdon, UK) at a concentration of 1: 500 ug/L for two hours in the shaker. 
Extensive washing was then performed for 30 minutes followed by secondary 
antibody incubation (anti mouse IgG (for Fas) and anti goat IgG (for FasL), heavy and 
light chain specific peroxidase conjugate, Calbiochem, USA) at a concentration of 
112000 for one hour. Membranes were then extensively washed for 30 minutes, aftn 
which they were incubated for five minutes in ECL solution (equal volumes of 
Supersignal West Pico stable peroxide solution and Supersignal West Pica Luminal 
enhancer solution (Piercenet, Rockford, IL, USA). Films were then developed in a 
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dark room and membrane stripping was then performed to assess actin expression 
according to the technique in chapter 2. The intensity of staining for the studied 
protein and actin was then assessed using Bio-Rad Molecular Analyst Software 
package densometer. Fas/actin ratio was used to assess level of Fas protein expression 
in the three study groups. 
Immunohistochemistry 
Three-micron sections of paraffin-embedded placental tissue were deparaffinized in 
xylene. The avidin-biotin complex method was used for staining using the Vector 
Elite Kit (PK-6200). The primary antibodies used were polyclonal rabbit Fas L (N-20) 
antibodies (Santa-Cruz Biotechnology, Santa Cruz, California). A positive and 
negative tissue control was included in each batch of staining. A placenta from an 
uncomplicated pregnancy delivered at term was used for this purpose. The negative 
control was processed identically to the samples, but without the addition of the 
primary antibody. The positive control is treated in the same way as the samples, in 
the presence of the primary antibody. These controls allow the specificity of the 
staining to be monitored so conditions can be altered if necessary and allows for any 
batch-to-batch differences to be accounted for. 
All slides were counter-stained with Mayers Haemalum to facilitate the recognition of 
tissue structure and hence make it possible to identify the cells or area of interest, i.e 
the villous trophoblast. Finally, slides were dehydrated in alcohol, cleaned in xylene 
and mounted in Canada Balsam (VWR international, UK). 
An initial optimization study was perfonned on Fas L antibodies to achieve optimal 
specific staining with minimal background staining (DAKO Corporation, 200 1). The 
placental control tissue was used for optimization, and a primary antibody dilution of 
1 :80 was used for Fas L. Two observers who were blinded to clinical conditions 
examined the specimens using the intensity of staining of the trophoblast. The 
differences in Fas ligand expression were assessed in the trophoblast from the three 
groups. 
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6.3 Results 
Serum Fas and FasL levels at 24 weeks In women with abnormal uterine artery 
Doppler 
FasL level was below the kits detection level in all cases at 24 weeks. There \\'ere no 
differences in serum Fas level at 24 weeks in women with abnormal uterine artery 
Doppler that subsequently developed preeclampsia, normotensive IUGR or normal 
outcome. 
Serum Fas and FasL levels at the time of the disease in women with abnormal uterine 
artery Doppler 
FasL levels were below the kits detection level in all cases at the time of the disease. 
When following serum Fas longitudinally in the three study groups, no significant 
changes in Fas level with gestational age were found. In addition, there were no 
significant differences in serum Fas between pregnancies that developed 
preeclampsia, normotensive IUGR (within 24 hr of delivery) and normal outcome. 
Tables 6.1-6.3 summarize serum Fas values in the three study groups at 24 weeks and 
at the time of the disease. Figures 6.1 and 6.2 show a box and plot presentation of 
serum Fas levels in the three study groups at 24 weeks and at the time of the disease, 
respectively. 
Table 6.1 Serum Fas values at 24 weeks and at the time of the disease in women who 
developed preeclampsia (n=8), compared to control pregnancies (n=16). No 
significant differences were found between the two groups at 24 weeks and at the time 
of the disease. 
Preeclampsia Control P value+ 
Median (range) Median (range) 
(nglml) (nglml) 
24 weeks 12.23 (3.05-16.05) 11.56 (4.93-23.12) 0.976 
Disease 12.71 (2.66-22.59) 9.15 (1.92-23.12) 0.372 
+ Mann Whitney U Test 
Table 6.2 Serum Fas values at 24 weeks and at the time of disease in women who 
developed normotensive IUGR (n=7), compared to control pregnancies (n=16). No 
significant differences were found between the two groups at 24 weeks and at the time 
of the disease. 
IUGR Control P value + 
Median (range) Median (range) 
(ng/ml) (ng/ml) 
24 weeks 7.47 (1.67-9.86) 11.56 (4.93-23.12) 0.061 
Disease 7.71 (4.34-12.20) 9.15 (1.92-23.12) 0.423 
+ Mann Whitney Test 
Table 6.3 Serum Fas values at 24 weeks and at the time of disease in women who 
developed preeclampsia (n=8), compared to normotensive IUGR pregnancies (n=7). 
No significant differences were found between the two groups at 24 weeks and at the 
time of the disease. 
Preeclampsia IUGR P value + 
Median (range) Median (range) I I 
! 
(ng/ml) (ng/rol) 
24 weeks 12.23 (3.05-16.05) 7.47 (1.67-9.86) 0.165 
Disease 12.71 (2.66-22.59) 7.71 (4.34-12.20) 0.132 
+ Mann Whitney Test 
Figure 6.1 Box and plot diagram showing serum Fas levels at 24 weeks in women 
who subsequently developed preeclampsia (n=8), normotensive IUGR (n=7) and 
normal outcome (n=16). No significant differences were found in the three group at 
24 weeks. Boxes represent interquartile range, where the line represent the median. 
Whiskers at top and bottom represent the highest and lowest values. 
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Figure 6.2 Box and plot diagram showing serum Fas levels at the time of the di e e 
in women with abnormal uterine artery Doppler who developed preeclamp ia (n= , 
normotensive IUGR (n=7) and normal outcome (n=16). No significant difference 
were found in the three groups at the time of the disease. Boxes repre ent interquartile 
range, where the line represents the median. Whiskers at top and bottom repre ent the 
highest and lowest values. 
CIJ 
as 
LL 
30--------------------------------------------1 
20 
10 
N= 16 
Controls 
oL-------~----------~--------~7------~ 
8 
Preeclampsia IUGR 
_ 7 
Placental expression 0+ F as and F asL in women wl'th l . 
'J preec ampslG, nonnotensive 
IUGR and gestational-age matched controls. 
Western blotting for Fas demonstrated clear bands at a molecular weight of 45kDa 
corresponding to the Fas protein. Figures 6.3 and 6.4 illustrate placental expression of 
Fas and actin in the three study groups, respectively. Table 6.4 shows densometer 
values for Fas/actin ratio in the placentas studied from the three groups. No differences 
in placental expression of Fas between preeclamptic, normotensive IUGR and control 
placentas were found [(preeclampsia, IUGR; p=0.564), (preeclampsia, controls; 
p=0.564), (IUGR, controls; p=0.564)]. 
Western blotting for FasL failed to produce any visible banding despite changing 
protein loading (to 100 micrograms), incubation conditions and reaction times. 
Different antibody for FasL (anti-FasL, Santa-Cruz biotechnology, California, USA) 
was tried and no banding could be demonstrated corresponding to FasL. 
Immunohistochemistry was then used to assess trophoblast FasL expression in the 
three groups according to the procedure outlined above. No differences in the 
intensity of staining for FasL could be seen in the three study groups. Figures 6.5 and 
6.7 demonstrate placental expression of FasL in the three groups using 
immunohistochemistry . 
Figure 6.3 Western blotting for trophoblast expression of Fas in placentas from 
normotensive IUGR (n, preeclamsia (P) and control (C) pregnancies with abnormal 
uterine artery Doppler. No significant differences in placental expression of the e 
proteins were found between the three study groups. 
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Figure 6.4 Actin expressIon In the groups studied; I: IUGR pregnancie P: 
preeclampsia, C: control pregnancies. 
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Table 6.4 Fas/actin ratio in placentas from the study groups (normotensive IUGR, 
preeclampsia, and controls). No significant differences in placental Fas expression 
were found between the groups (see text). 
Case Condition Fasl Actin ration 
1 IUGR 1.333 
2 IUGR 1.077 
3 IUGR 5.532 
4 IUGR 1.354 
5 PET 0.609 
6 PET 14.038 
7 PET 1.943 
8 PET 2.741 
9 Control 3.969 
10 Control 0.88 
11 Control 0.80 
12 Control 1.462 
Figure 6.5 Box and plot presentation of placental Fas expression. Western blotting 
showed no significant differences in placental Fas expression between IUGR, 
preeclampsia and control placentas. 
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Figure 6.6 Representative samples of immunohistochemistry for trophoblast F L 
expression in placentas from preeclampsia (A), normotensive ruGR (B), and normal 
controls (C). FasL is a membrane surface protein. No significant difference in 
staining intensity of trophoblast cell membranes were found between the three group . 
(A) Preeclampsia: 
(B) Normotensive IUGR with AREDF in umbilical artery Doppler 
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(C) Control 
6.4 Discussion 
Fas (CD95, APO-1) is a ubiquitously expressed member of the tumour necrosis factor 
receptor superfamily, which mediates diverse cellular responses, including 
proliferation, inflammation, angiogenesis, and apoptosis (Jarad et aI., 2002). Among 
receptor-mediated apoptosis pathways, signals transduced by Fas stimulation have 
been so extensively characterized that Fas is viewed as the prototypical death receptor 
in susceptible cells (Nagata, 1997). However, in some cell types, Fas may mediate 
apoptosis-independent processes such as proliferation, angiogenesis, fibrosis, and 
inflammation (Hohlbaum et aI., 2002). 
My study on serum level of Fas in the three groups (preeclampsia, normotensive 
IUGR and controls) did not show any significant differences at 24 weeks (with 
abnormal uterine artery Doppler) or at the time of the disease. I used kits for 
measuring Fas and FasL produced by MBL international (Nagoya, Japan). A study of 
serum soluble Fas levels in preeclampsia by Hsu et al (2001) showed that pregnant 
women with preeclampsia had significantly higher serum soluble Fas levels than 
normotensive controls. Another study by the same group of serum soluble Fas levels 
in the syndrome of hemolysis, elevated liver enzymes and low platelets (HELLP) 
showed elevated serum soluble Fas but not FasL in HELLP pregnancies compared to 
gestational age matched controls (Harirah et al., 2001). These findings were later 
challenged by Kuntz et al (2001), who showed that serum soluble Fas levels were 
similar in both preeclamptic and control pregnancies. Serum soluble FasL, on the 
other hand, was significantly elevated in preeclamptic gestations, both in serum and 
umbilical cord blood. The differences in the findings of these groups could be 
attributed to using different manufacturing kits. The first group used ELISA kits for 
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the detection of Fas and FasL by Oncogene Research Products (Cambridge, MA, 
USA), while the second group used kits manufactured by MBL international (Nagoya, 
Japan). In summary, the findings in my study do not support a role for Fas in the 
pathogenesis of preeclampsia or normotensive IUGR. 
In this study, I evaluated trophoblast Fas and FasL expression 10 pregnancIes 
complicated by pre-eclampsia and normotensive IUGR with abnormal uterine artery 
Doppler, compared with control pregnancies. No differences were found in Fas and 
FasL expression in placentas from preterm pre-eclampsia and IUGR compared to 
gestational-age matched controls. This supports and extends previous findings by 
Ishihara et al (2002) regarding placental Fas expression in preeclampsia. 
The immune factors responsible for maintenance of the fetal and placental semI-
allogenic graft appear to lie at the uterus-placenta interface. Expression of FasL and 
complement regulatory proteins, along with failure to express MHC class I and II 
molecules in the placenta were thought to be crucial factors for the maintenance of 
pregnancy (Weetman, 1999). This is the first study to evaluate Fas and Fas ligand 
expression in placentas from pregnancies complicated by preeclampsia and IUGR 
with abnormal uterine artery Doppler. All pregnancies in the study groups delivered at 
a preterm gestational age «36 weeks). This, in comparison to the study by Ishihara et 
al (2002) of the placental expression of Fas antigen in severe pre-eclampsia or IUGR 
at term, which showed no difference in Fas expression in placentas from normal 
pregnancies and those complicated by pre-eclampsia and IUGR. They, however, 
confirmed the earlier finding of increased apoptosis in syncytiotrophoblast of these 
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placentas. Reduced expression of Bcl-2, a survival factor, in the diseased trophoblast 
was found, which could probably contribute to enhance apoptosis in these placentas. 
Mor et al (1998) illustrated that placental expression of FaslFas ligand is vital for the 
survival of invading trophoblast and seems to be involved in regulation of placental 
growth in first trimester normal pregnancies. In their study, Fas and FasL expression 
was confirmed by immunohistochemistry and double immunoflouresence in villous 
trophoblast cells from normal first trimester placentas and seems to be important in 
maintaining homeostasis during the process of normal trophoblast growth and 
invasion (Runic et al., 1996). Acshkenazi et al (2002) showed that Fas expression in 
early pregnancy trophoblast is affected by cytokines secreted by T helper and T 
suppresser lymphocytes. This balance affects Fas expression, activation, and in tum 
may affect the ability of invading trophoblast to survive. A recent study of the 
function of Fas membrane proteins in renal tubular cells demonstrated a relation 
between membrane Fas induction and ~ integrin expression and function in the 
absence of apoptosis. It was found that ~ integrin induction is an additional pathway 
that is regulated by constitutively expressed Fas. ~ Integrins play an important role in 
the endometrial phenotype change that occurs during the secretory phase and the first 
stage of implantation, and has a clear role in trophoblast invasion during the early 
stages of pregnancy (Merviel et al., 2001). In an in-vitro model of extra villous 
trophoblast invasion of uterine spiral arteries, Ashton et al. (2005) showed that 
endothelial apoptosis, induced by extravillous trophoblast, is a possible mechanism by 
which the endothelium in spiral arteries is removed, and consequently vascular 
remodeling may occur. Apoptosis was blocked by caspase inhibition and FasL 
blocking antibody, providing evidence that FaslFasL interactions have an important 
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role in trophoblast-induced endothelial apoptosis. This study used extravillous 
trophoblast to induce apoptosis in spiral artery endothelium. My study, on the other 
hand, assessed placental trophoblast expression of Fas and FasL. This could be a 
factor causing the difference between these two studies. 
The aetiology of increased apoptosis in human trophoblast in preeclampsia and IUGR 
is not entirely clear. The study by Allaire et al (2000) showed reduced Fas ligand and 
enhanced Fas expression in trophoblast from pregnancies complicated by 
preeclampsia. They concluded that reduced Fas ligand expression in the placental 
trophoblast could account for the increased apoptosis given the role of Fas ligand in 
evading immune detection of the placenta by maternal cytotoxic T lymphocytes and 
Natural Killer (NK) cells. Koenig and Chegini (2000), on the other hand, found 
increased Fas ligand expression in the syncytiotrophoblast from pregnanCIes 
complicated by pre-eclampsia. Both studies, however, relied solely on 
immunohistochemistry for the assessment of FaslFasL expreSSIOn. 
Immunohistochemistry has limitations in evaluating tissue protein expreSSIOn, 
attributed to the technique-related variability and section-dependent staining intensity. 
Other factors that could contribute to apoptosis in human trophoblasts is hypoxia. 
Levy et al (2000) demonstrated that hypoxia up-regulated p53 and Bax expression in 
cultured trophoblasts; both enhance apoptosis at a cellular level through the 
mitochondrial pathway. Hypoxia also reduced the expression of Bcl-2, a cellular 
survival factor that protects against apoptosis (Levy et al .. 2000). These findings 
implicate the mitochondrial pathway in enhanced apoptosis in cultured trophoblasts 
exposed to low oxygen tension. A recent study by Levy et al (2002) showed a two-
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fold increase in p53 expression in placental villi from placentas of fetuses with IUGR 
compared with placentas from normal pregnancies. 
Studies on the role of Fas ligand as the enforcer of immune privilege does not fit the 
established paradigm of this role. When Allison et al (1997) used transgenic mice 
expressing FasL on their islet ~ cells for transplantation, they found that rather than 
being the solution to the transplantation immunologist's rejection problem, expression 
of FasL caused a more rapid rejection of islet cells accompanied by a "granulocyte 
infiltration". Kang et al (1998) used an entirely different approach to test the same 
question, using adenoviruses to confer FasL expression on islet cells. They also found 
accelerated rejection accompanied by "massive neutrophilic infiltrates". 
In summary, although the FaslFasL system seems important for early pregnancy 
implantation and trophoblast survival, the findings in this study do not support a role 
for Fas or Fas ligand in abnormal placentation in pregnancies complicated by preterm 
pre-eclampsia and IUGR. Further research is needed to the etiology of impaired 
trophoblast invasion and reduced trophoblast mass available to regulate maternal-fetal 
exchange in these conditions. 
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GENERAL DISCUSSION 
261 
The work carried out in this thesis characterises abnormalities within the serum and 
the placenta of women with abnormal midtrimester uterine artery Doppler, that 
develop preeclampsia, compared to normotensive IUGR and controls. This provides 
an insight into the mechanisms and consequences of abnormal placentation. 
Preeclampsia has been sometimes termed the "disease of theories," as several models 
for its pathogenesis have been proposed. But, as of today, no satisfactory unifying 
hypothesis has emerged (Roberts & Cooper, 2001). For the fetus to develop normally, 
it must receive sufficient oxygen and nutrients. These are supplied via the maternal 
spiral arteries in the uterus. During normal pregnancy, cytotrophoblasts convert from 
an epithelial to an endothelial phenotype (a process termed pseudo-vasculogenesis) 
and invade maternal spiral arteries. By the end of the first trimester, this vascular 
remodelling increases the bulk flow and the supply of nutrients and oxygen to the 
fetus (Goldman-Wohl & Yagel, 2002; Zhou et aI., 2002). In preeclampsia, pseudo-
vasculogenesis is defective, and the resultant placental ischaemia has been proposed 
as a trigger for the release of unknown-placenta derived factors. The latter would 
induce systemic endothelial dysfunction and therefore contribute to the renal, 
cardiovascular, and neurological manifestations of preeclampsia. Despite intensive 
efforts, the precise nature of the placenta-derived factors has remained enigmatic for 
years. 
The research in this thesis looked at differences in the serum and placenta between 
preeclamptic and normotensive IUGR pregnancies with abnormal uterine artery 
Doppler. Strict criteria were employed and pregnancies included had regular growth 
. d b'l' I artery Doppler examination and clinical assessment for 
scans, utenne an urn I Ica 
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preeclampsia. Strict definitions were used for inclusion in the IUGR group, so as to 
avoid including normal but "small for gestational age" pregnancies. This, in a way, 
limited the number of patients enrolled in the study, as only patients who were 
followed from 24 weeks were eligible. I also compared pregnancies that were 
matched for gestational age, to limit the potential confounding effect of gestational 
age on sFltl and PIGF. Pregnancies with abnormal mid-trimester uterine artery that 
developed preeclampsia after 36 weeks were not included as the upper gestational-age 
in the normotensive IUGR group was 35 weeks. This explains the relatively low 
positive predictive value of uterine artery Doppler in predicting abnormal pregnancy 
outcome in my study, compared to other studies. 
Uterine artery Doppler examination at 24 weeks showed no difference in uterine 
artery resistance indices between pregnancies that developed preeclampsia compared 
to normotensive IUGR. This provided evidence that shallow trophoblast invasion was 
the basic pathology behind both conditions, but there was no difference in the degree 
of impairment of trophoblast invasion between the two groups, which could explain 
the difference in clinical outcome. Uterine artery Doppler resistance was measured in 
the 24 hour period prior to delivery, in pregnancies enrolled in the study, expecting a 
difference in trophoblast invasion between the two groups (preeclampsia and IUGR), 
which could account for the difference in clinical outcome. Again, no differences 
could be found between the two groups in uterine artery Doppler resistance before 
delivery. As uterine artery resistance indirectly reflects depth of trophoblast invasion, 
my findings rule out differences in trophoblast invasion as the underlying cause for 
the difference in clinical outcome between preeclampsia and normotensive IUGR. 
The unexpected finding in my study, however, was the significant differences in 
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umbilical artery resistance between the two groups in the 24-hour period prior to 
delivery. This reflects different angiogenic responses within the placenta in the two 
groups and indirectly a reflection of the placental oxygen level, which could be 
contributing to the systemic manifestations of preeclampsia. 
Recent work by Maynard et al (2003) and Ahmad & Ahmed (2004) report the novel 
insight that circulating levels of two angiogenic growth factors, soluble fms-like 
tyrosine kinase 1 (sFltl) receptor and Placental Growth Factor (PIGF), may playa 
more important role than previously believed. Their study revealed that in pregnant 
women with preeclampsia, the placenta produces elevated levels of sFlt 1, which 
captures free VEGF and PIGF. As a result, the normal vasculature in the kidney, 
brain, lungs, and other organs is deprived of essential survival and maintenance 
signals and becomes dysfunctional. In this thesis, I report a novel insight into 
differences in serum sFltl and PIGF between preeclamptic and normotensive IUGR 
pregnancies with abnormal uterine artery Doppler, compared with controls that had a 
normal pregnancy outcome. It appears that sFltl plays a central role in the systemic 
manifestations of preeclampsia through antagonism of VEGF. Whereas dynamic 
surges of high VEGF levels mediate angiogenesis in the embryo and in the adult 
during disease, continuous low levels of VEGF are required for endothelial cells to 
survive prolonged periods and function properly (Luttun & Carmeliet, 2003). Thus, 
when sFltl plasma levels rise, they may reduce the circulating VEGF and PIGF levels 
below a critical threshold required for maintenance of the established vasculature in 
the adult. The resultant endothelial dysfunction may disrupt the blood brain barrier 
and cause intracranial hypertension, oedema in the liver, and affect glomerular 
function. 
The finding of significant differences in umbilical artery Doppler between the 
preeclampsia and normotensive IUGR groups provides further evidence that placental 
hypoxia could be the centre piece in the development of preeclampsia. Absent end 
diastolic flow in umbilical artery Doppler reflects predominance of non-branching 
angiogenesis within the placenta, a factor that results in higher placental oxygen 
levels. That this situation could arise in the face of uteroplacental ischaemia is 
superficially hard to understand until one appreciates that the catabolic severely-
IUGR fetus (with reduced activity) is surviving with minimal oxygen consumption 
(Pardi et ai., 1993). Fractional extraction of oxygen from the intervillous space is 
greatly reduced with AREDF in the umbilical arteries, such that uteroplacental venous 
blood has 30% higher oxygen content than under normal circumstances (Pardi et al., 
1992). Early-onset IUGR and abnormal umbilical artery Doppler is very uncommon 
in unselected pregnancies (Mason at al., 1993), while between 5-10% of such 
pregnancies are often conveniently assigned as IUGR based on birth weight centiles 
(the correct term for the latter is small-for-gestational age). The pathology of AREDF 
in umbilical artery Doppler, and thus the phenomenon of placental hyperoxia, is thus 
the exception to the rule that the placenta adapts to reduced uteroplacental blood flow 
(Kingdom et ai., 1998). 
My findings of increased placental Fltl and serum sFltl in preeclampsia supports the 
notion of appropriate placental adaptation to reduced uteroplacental placental blood 
flow in these pregnancies. This, in tum, resulted in placental hypoxia and upregulated 
sFlt1 expression and consequently the syndrome of preeclampsia. This sequence of 
. of normotensive IUGR (especiallv with AREDF in 
events does not start In cases -
umbilical artery) due to much lower degree of placental hypoxia. rvly data, however. 
demonstrated that serum sFltl, in the 24 hours before delivery, in cases of 
normotensive IUGR, was significantly higher than controls. This could be due to a 
degree of placental hypoxia in these cases, albeit not as severe as that in cases of 
preeclampsia. This degree of placental hypoxia is to be expected since three out of the 
seven cases of normotensive IUGR had preserved end-diastolic flow in umbilical 
artery Doppler. This, in the face of impaired uteroplacental blood flow, would result 
in a degree of placental hypoxia that upregulates serum sFltl. In addition, the level of 
sFltl needed to trigger widespread endothelial dysfunction could be different between 
different pregnancies, depending on the baseline degree of endothelial susceptibility 
in the maternal vasculature. My findings of inverse correlations between serum sFlt I 
and umbilical artery resistance indices at the time of delivery in affected pregnancies, 
provides further evidence of the apparent effect of umbilical artery blood flow on 
placental hypoxia and consequently serum sFltl. 
The cause of impaired trophoblast invasion and spiral artery remodelling in 
preeclampsia and IUGR is not clear. Abnormal uterine artery Doppler provides 
indirect in-vivo evidence of impaired trophoblast invasion. Ahmad & Ahmed (2004), 
showed that sFltl inhibits in-vitro placental angiogenesis and endothelial cell 
migration. In this thesis, I provided further evidence of the role of sFlt I on impaired 
trophoblast invasion and placental angiogenesis, as positive correlations were found 
between uterine artery resistance indices at 24 weeks and the corresponding serum 
sFltl. This sheds unprecedented light on the pathogenesis of impaired vascular 
remodeling in pregnancies with abnormal uterine artery Doppler that de\l~lop 
preeclampsia and IUGR. 
There are a few limitations to the research in this thesis. First, serum values for sFlt 1 
and PIGF were used to reflect placental expression of these markers in the mid-
trimester. Whether this association between placental and serum expression of these 
markers remains valid needs further evaluation. Furthermore, placental expression of 
FItl and PIGF was assessed in villous, but not the extra villous trophoblast. This 
makes it difficult to draw conclusions on the role of placental FIt 1 and PIGF in 
trophoblast invasion and spiral artery remodeling, a function of extra-villous 
cytotrophoblasts. However, it could be reliably concluded that differences in placental 
expression of FItl between preeclampsia and IUGR do exist, and most likely a result 
of differences in placental hypoxia between the two groups. 
Increased trophoblast apoptosis occurs in placentas from pregnancies complicated by 
IUGR and preeclampsia. The potential effect of apoptosis on impaired trophoblast 
invasion and spiral artery remodelling is not clear. I studied trophoblast expression of 
Fas and FasL in placentas from pregnancies with abnormal uterine artery Doppler. No 
differences in Fas and FasL expression were found between the groups studied. 
Furthermore, levels of serum soluble Fas were not different between the preeclampsia, 
normotensive IUGR and control groups at 24 weeks and at the time of the disease. 
This is in contrast to previous reports that showed conflicting evidence about serum 
Fas levels in preeclampsia. My findings do not support a role for the FaslFasL system 
in the pathogenesis or the clinical manifestations of preeclampsia or IOGR. In my 
study, however, placental expression of Fas and FasL was evaluated in villous rather 
than extravillous trophoblast. Therefore, no conclusion could be made about the role 
of these surface proteins in impaired placentation. Recent evidence suggests that 
d th I, It' 'nduced by extra-\'illolls FaslFasL interaction is involved in en 0 e la apop OSlS 1 -
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trophoblast during spiral artery remodeling in vitro (Ashton et at., 2005). The in-vivo 
role of Fas and FasL in impaired placentation needs to be investigated in a study of 
expression of these surface markers in extra-villous trophoblasts in cases of abnormal 
uterine artery Doppler that develop preeclampsia and IUGR. 
In summary, the clinical syndrome of preeclampsia and IUGR is the concluding 
episode of a story of failed physiological modification of the uterine circulation by the 
developing placenta. The work described in this thesis demonstrates that: 
1. Serum sFltl correlates positively with uterine artery resistance indices at 24 
weeks and provides further evidence of the role sFlt 1 in failed pseudo-
vasculogenesis and maternal spiral artery remodeling in preeclampsia and 
IUGR. 
2. Placental Fltl and serum sFltl is upregulated in preeclampsia compared to 
normotensive IUGR and controls. This is due to placental hypoxia in 
preeclampsia and, through capturing free VEGF and PIGF; serum sFltl 
contributes to the widespread endothelial dysfunction in this condition. 
3. Placental and serum Fas is not changed in pregnancies with preeclampsia or 
IUGR, and consequently the role of this protein in the pathogenesis of these 
conditions is doubtful. 
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